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A B S T R A C T
Background
It has been proposed that antioxidants may prevent cellular damage in the retina by reacting with free radicals that are produced in the
process of light absorption. Higher dietary levels of antioxidant vitamins and minerals may reduce the risk of progression of age-related
macular degeneration (AMD).
Objectives
The objective of this review was to assess the effects of antioxidant vitamin or mineral supplementation on the progression of AMD in
people with AMD.
Search methods
We searched CENTRAL (2017, Issue 2), MEDLINE Ovid (1946 to March 2017), Embase Ovid (1947 to March 2017), AMED
(1985 to March 2017), OpenGrey (System for Information on Grey Literature in Europe, the ISRCTN registry (www.isrctn.com/
editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and theWHOInternational Clinical Trials Registry Platform (ICTRP)
(www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched
the electronic databases on 29 March 2017.
Selection criteria
We included randomised controlled trials (RCTs) that compared antioxidant vitamin or mineral supplementation (alone or in combi-
nation) to placebo or no intervention, in people with AMD.
Data collection and analysis
Both review authors independently assessed risk of bias in the included studies and extracted data. One author entered data into
RevMan 5; the other author checked the data entry. We graded the certainty of the evidence using GRADE.
Main results
We included 19 studies conducted in USA, Europe, China, and Australia. We judged the trials that contributed data to the review to
be at low or unclear risk of bias.
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Nine studies compared multivitamins with placebo (7 studies) or no treatment (2 studies) in people with early and moderate AMD.
The duration of supplementation and follow-up ranged from nine months to six years; one trial followed up beyond two years. Most
evidence came from the Age-Related Eye Disease Study (AREDS) in the USA. People taking antioxidant vitamins were less likely
to progress to late AMD (odds ratio (OR) 0.72, 95% confidence interval (CI) 0.58 to 0.90; 2445 participants; 3 RCTs; moderate-
certainty evidence). In people with very early signs of AMD, who are at low risk of progression, this would mean that there would be
approximately 4 fewer cases of progression to late AMD for every 1000 people taking vitamins (1 fewer to 6 fewer cases). In people
at high risk of progression (i.e. people with moderate AMD) this would correspond to approximately 8 fewer cases of progression for
every 100 people taking vitamins (3 fewer to 13 fewer). In one study of 1206 people, there was a lower risk of progression for both
neovascular AMD (OR 0.62, 95% CI 0.47 to 0.82; moderate-certainty evidence) and geographic atrophy (OR 0.75, 95% CI 0.51
to 1.10; moderate-certainty evidence) and a lower risk of losing 3 or more lines of visual acuity (OR 0.77, 95% CI 0.62 to 0.96;
1791 participants; moderate-certainty evidence). Low-certainty evidence from one study of 110 people suggested higher quality of life
scores (National Eye Institute Visual Function Questionnaire) in treated compared with the non-treated people after 24 months (mean
difference (MD) 12.30, 95% CI 4.24 to 20.36).
Six studies compared lutein (with or without zeaxanthin) with placebo. The duration of supplementation and follow-up ranged from six
months to five years. Most evidence came from the AREDS2 study in the USA. People taking lutein or zeaxanthin may have similar or
slightly reduced risk of progression to late AMD (RR 0.94, 95% CI 0.87 to 1.01; 6891 eyes; low-certainty evidence), neovascular AMD
(RR 0.92, 95% CI 0.84 to 1.02; 6891 eyes; low-certainty evidence), and geographic atrophy (RR 0.92, 95% CI 0.80 to 1.05; 6891
eyes; low-certainty evidence). A similar risk of progression to visual loss of 15 or more letters was seen in the lutein and control groups
(RR 0.98, 95% CI 0.91 to 1.05; 6656 eyes; low-certainty evidence). Quality of life (measured with Visual Function Questionnaire)
was similar between groups in one study of 108 participants (MD 1.48, 95% -5.53 to 8.49, moderate-certainty evidence).
One study, conducted in Australia, compared vitamin E with placebo. This study randomised 1204 people to vitamin E or placebo,
and followed up for four years. Participants were enrolled from the general population; 19% had AMD. The number of late AMD
events was low (N = 7) and the estimate of effect was uncertain (RR 1.36, 95% CI 0.31 to 6.05, very low-certainty evidence). There
were no data on neovascular AMD or geographic atrophy.There was no evidence of any effect of treatment on visual loss (RR 1.04,
95% CI 0.74 to 1.47, low-certainty evidence). There were no data on quality of life.
Five studies compared zinc with placebo. The duration of supplementation and follow-up ranged from six months to seven years.
People taking zinc supplements may be less likely to progress to late AMD (OR 0.83, 95% CI 0.70 to 0.98; 3790 participants; 3 RCTs;
low-certainty evidence), neovascular AMD (OR 0.76, 95% CI 0.62 to 0.93; 2442 participants; 1 RCT; moderate-certainty evidence),
geographic atrophy (OR 0.84, 95% CI 0.64 to 1.10; 2442 participants; 1 RCT; moderate-certainty evidence), or visual loss (OR 0.87,
95% CI 0.75 to 1.00; 3791 participants; 2 RCTs; moderate-certainty evidence). There were no data reported on quality of life.
Very low-certainty evidence was available on adverse effects because the included studies were underpowered and adverse effects
inconsistently reported.
Authors’ conclusions
People with AMD may experience some delay in progression of the disease with multivitamin antioxidant vitamin and mineral
supplementation. This finding was largely drawn from one large trial, conducted in a relatively well-nourished American population.
We do not know the generalisability of these findings to other populations. Although generally regarded as safe, vitamin supplements
may have harmful effects. A systematic review of the evidence on harms of vitamin supplements is needed. Supplements containing
lutein and zeaxanthin are heavily marketed for people with age-related macular degeneration but our review shows they may have little
or no effect on the progression of AMD.
P L A I N L A N G U A G E S U M M A R Y
Antioxidant vitamin and mineral supplements to slow down the progression of age-related macular degeneration (AMD)
What is the aim of this review?
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The aim of this Cochrane Review was to find out whether taking antioxidant vitamin and mineral supplements slows down the
progression of AMD and prevents visual loss. Cochrane researchers collected and analysed all relevant studies to answer this question
and found 19 studies.
Key messages
Taking an antioxidant multivitamin supplement may slow down the progression of AMD. Most benefit will be seen in people who
have a higher chance of progression. Although vitamin supplements are generally regarded as safe, the studies included in this review
did not provide good evidence as to safety as they were generally too small.
What was studied in the review?
AMD is a condition of the central area (macula) of the back of the eye (retina). The macula degenerates with age. In some people,
this deterioration happens more quickly, and is associated with a particular appearance at the back of the eye. In its earliest stage (early
AMD), yellow spots (drusen) can be seen under the retina by an eye health professional on examining the eye. The affected person
will probably be unaware that they a problem. As AMD progresses, it can lead to the loss of the cells in the back of the eye, which
are needed for vision. This is known as geographic atrophy. Sometimes, new (harmful) blood vessels grow in the macula. These new
blood vessels may bleed and cause scarring. This is known as neovascular or wet AMD. Any damage to the macula can affect vision,
particularly central vision. Neovascular AMD and geographic atrophy are known as late AMD.
It is possible that antioxidant vitamins may help to protect the macula against this deterioration and loss of vision. Vitamin C, E, beta-
carotene, lutein, zeaxanthin, and zinc are examples of antioxidant vitamins commonly found in vitamin supplements.
The Cochrane researchers only looked at the effects of these supplements in people with AMD. There is another Cochrane Review on
the effects of these supplements in people who do not already have AMD.
What are the main results of the review?
The Cochrane researchers found 19 relevant studies. Ten studies were from Europe, six from USA, two from China, and one from
Australia. These studies compared multivitamin supplements, zinc, vitamin E and lutein and zeaxanthin with placebo.
•Taking antioxidant vitamins plus zinc probably slows down the progression to late AMD and vision loss (moderate-certainty evidence).
This may result in a small improvement in quality of life (low-certainty evidence).
•Taking lutein alone (or combined with zeaxanthin) may have little or no effect on progression to late AMD and vision loss (low-
certainty evidence).
•Taking vitamin E alone may have little or no effect on the progression to late AMD and vision loss (low-certainty evidence).
Although vitamin supplements are generally regarded as safe, the studies included in this review did not provide good evidence as to
safety as they were generally too small and adverse effects were reported inconsistently.
How up-to-date is this review?
The Cochrane researchers searched for studies that had been published up to 29th March 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antioxidant mult ivitamin and mineral supplement versus placebo or no treatment
Patient or population: people with AMD
Setting: community
Intervention: ant ioxidant mult ivitamin and mineral supplement*
Comparison: placebo or no treatment
Outcomes Anticipated absolute effects∗∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with M ultivitamin
antioxidant vitamin or
mineral supplement
Progression to
late AMD (neovascular
AMD, geographic atro-
phy or both)
Low OR 0.72
(0.58 to 0.90)
2445
(3 RCTs)
⊕⊕⊕©
MODERATE1
Average follow-up in
study contribut ing most
of the events was 6
years
15 per 1000 11 per 1000
(9 to 14)
High
430 per 1000 352 per 1000
(304 to 404)
Progression to neovas-
cular AMD
Low OR 0.62
(0.47 to 0.82)
1206
(1 RCT)
⊕⊕⊕©
MODERATE1
Average follow-up 6
years. Est imate of ef -
fect f rom study popula-
t ion including AMD cat-
egory 3 & 4 only
10 per 1000 6 per 1000
(5 to 8)
High
300 per 1000 210 per 1000
(168 to 260)
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Progression to geo-
graphic atrophy
Low OR 0.75
(0.51 to 1.10)
1206
(1 RCT)
⊕⊕⊕©
MODERATE1
Average follow-up 6
years. Est imate of ef -
fect f rom study popula-
t ion including AMD cat-
egory 3 & 4 only
10 per 1000 8 per 1000
(5 to 11)
High
300 per 1000 243 per 1000
(179 to 320)
Progression to visual
loss (loss of 3 or more
lines on logMAR chart)
Low OR 0.77
(0.62 to 0.96)
1791
(1 RCT)
⊕⊕⊕©
MODERATE1
Average follow-up 6
years
15 per 1000 12 per 1000
(9 to 14)
High
430 per 1000 367 per 1000
(319 to 420)
Quality of lif e
assessed with: change
in National Eye Inst itute
Visual
Funct ion Quest ionnaire
(NEI-VFQ) score (higher
scores better)
The mean change in
NEI-VFQ score in the
control group was -8.7
The mean NEI-VFQ
quality of lif e score in
the intervent ion group
was 12.3 higher (4.24
higher to 20.36 higher)
- 110
(1 RCT)
⊕⊕©©
LOW 2,3
Follow-up 24 months
Adverse ef fects Data f rom AREDS suggested no serious adverse ef fects associated with mult ivitamin use (hazard
rat io for mortality 0.87, 95%CI 0.60 to 1.25) but part icipants in the ant ioxidant arms more f requent ly
reported yellow skin (8.3% versus 6.0%, P = 0.008).
⊕©©©
VERY LOW 4
-
Resource use and costs - - - - - Not reported
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* Most of the evidence in this table is drawn f rom the AREDS study which studied ant ioxidants (vitamin C 500 mg, vitamin E 400 IU, beta-carotene 15 mg daily) plus zinc 80
mg as zinc oxide, copper 2 mg as cupric oxide (daily)
* * The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and
its 95% CI). The assumed risk in the comparison group is est imated using data f rom AREDS: low risk = AREDS category 2; high risk = AREDS category 4
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate-certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for imprecision because upper conf idence interval crosses line of m inimum important dif f erence (0.8
to 1.25)
2 Downgraded one level for risk of bias because study was not placebo-controlled and at high risk of performance and
detect ion bias
3 Downgraded one level for imprecision because conf idence intervals included clinically insignif icant ef fect
4 Downgraded for one level for imprecision (as included studies were underpowered to look at adverse ef fects), one level for
risk of bias (adverse ef fects were inconsistent ly reported) and one level for inconsistency (inconsistent results reported).
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B A C K G R O U N D
Description of the condition
Age-relatedmacular degeneration (AMD) is a disease affecting the
central area of the retina (macula). In the early stages of the dis-
ease, lipid material accumulates in deposits underneath the retinal
pigment epithelium. These deposits are known as drusen, and can
be seen as pale yellow spots on the retina. The pigment of the reti-
nal pigment epithelium may become disturbed, with areas of hy-
perpigmentation and hypopigmentation. In the later stages of the
disease, the retinal pigment epithelium may atrophy completely.
This loss can occur in small focal areas, or can be widespread (ge-
ographic). In some cases, new blood vessels grow under the reti-
nal pigment epithelium and occasionally, into the subretinal space
(exudative or neovascular AMD). Haemorrhage can occur, which
often results in increased scarring of the retina.
In general, the early stages of the disease are asymptomatic. In
the later stages, there may be considerable distortion of vision and
complete loss of visual function, particularly in the central area of
vision. Population-based studies suggest that in older people (80
years and above), approximately one in three people have early
signs of the disease (Klein 1992). The estimated prevalence of late
AMD is 1.4% (95% Credible Interval (CrI), 1.0% to 2.0%) at
70 years of age, 5.6% (95% CrI, 3.9% to 7.7%) at age 80, and
20% (95% CrI, 14% to 27%) at age 90 (Rudnicka 2012). It is
the most common cause of blindness and visual impairment in
industrialised countries (Bunce 2010).
Description of the intervention
Photoreceptors in the retina are subject to oxidative stress through-
out life, due to combined exposures to light and oxygen. It has
been proposed that antioxidants may prevent cellular damage in
the retina by reacting with free radicals produced in the process
of light absorption (Christen 1996). Antioxidants are any vitamin
or mineral that is known to have antioxidant properties in vivo,
or that has been shown to be an important component of an an-
tioxidant enzyme present in the retina. The following vitamins
and minerals are usually considered to be ’antioxidant’: vitamin
C, vitamin E, carotenoids, selenium, and zinc.
There are a number of non-experimental studies that have exam-
ined the possible association between antioxidant micronutrients
and AMD, although few studies have examined supplementation
specifically. Data on vitamin intake in observational studies should
be considered cautiously, as people who have a diet rich in antiox-
idant vitamins and minerals, or who choose to take supplements
regularly, are different in many ways from those who do not; these
differencesmay not be adequately controlled by statistical analysis.
The results of these observational studies have been inconclusive.
How the intervention might work
Photoreceptors in the retina are subject to oxidative stress through-
out life, due to combined exposures to light and oxygen. It has
been proposed that antioxidants may prevent cellular damage in
the retina by limiting the damaging effects of free radicals pro-
duced in the process of light absorption (for a review see Christen
1996). Antioxidant vitamin and mineral supplements are increas-
ingly being marketed for use in age-related eye disease, including
AMD.
Why it is important to do this review
People with AMD need to have reliable information, in order to
decide whether or not to take vitamin supplements.
O B J E C T I V E S
The objective of this review was to assess the effects of antioxidant
vitamin or mineral supplementation on the progression of AMD
in people with AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This review included randomised controlled trials.
Types of participants
Participants in the trials were people with AMD in one or both
eyes.
Types of interventions
We included trials inwhich antioxidant vitamin ormineral supple-
mentation, alone or in combination, was compared with placebo
or no intervention. Antioxidants were defined as any vitamin or
mineral that was known to have antioxidant properties in vivo, or
that was known to be an important component of an antioxidant
enzyme present in the retina. The following were considered: vi-
tamin C, vitamin E, carotenoids (including the macular pigment
carotenoids lutein and zeaxanthin), selenium, and zinc.
The overall objective of the review was to assess the impact of
antioxidant vitamin and mineral supplements on the progression
of AMD. Trials in this area fall into two broad categories: those
evaluating a single vitamin or mineral (for example, vitamin E
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or zinc), and those investigating a multivitamin formulation (for
example, Ocuguard). The following comparisons were considered
in this review.
1. Multivitamin formulation versus placebo. All the
formulations which include two or more antioxidant vitamins or
minerals fall into this category.
2. Single-component formulations versus placebo. Currently,
only vitamin E, zinc and lutein have been studied as single
formulations, however, in principle any of the antioxidant
vitamins or minerals could be assessed as individual components.
Types of outcome measures
We modified our protocol for the current update (2017) to in-
clude outcomes specified by the UK NICE macular degeneration
guideline panel (NICE 2016); see Differences between protocol
and review.
We considered the following outcomes:
• Progression to late AMD (neovascular AMD, geographic
atrophy, or both);
• Progression to neovascular AMD;
• Progression to geographic atrophy;
• Progression to visual loss (loss of 3 or more lines on
logMAR chart)*;
• Quality of life;
• Resource use and costs.
*As visual acuity is also commonly reported as a ’mean score’ we
also include mean visual acuity as a continuous outcome.
Follow-up:
We considered the maximum follow-up identified in the studies
at any point in time.
Adverse effects
We considered any adverse effects reported by the included studies.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist conducted
systematic searches in the following databases for randomised con-
trolled trials and controlled clinical trials. There were no language
or publication year restrictions. The date of the search was 29
March 2017.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 2) (which contains the Cochrane Eyes
and Vision Trials Register) in the Cochrane Library (searched 29
March 2017) (Appendix 1);
• MEDLINE Ovid (1946 to 29 March 2017) (Appendix 2);
• Embase Ovid (1980 to 29 March 2017) (Appendix 3);
• AMED (Allied and Complementary Medicine Database)
(1985 to 29 March 2017) (Appendix 4);
• OpenGrey (System for Information on Grey Literature in
Europe) (www.opengrey.eu/; searched 29 March 2017)
(Appendix 5);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch;
searched 29 March 2017) (Appendix 6);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; searched 29 March
2017) (Appendix 7);
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/ictrp; searched 29 March 2017)
(Appendix 8).
For the 2012 and 2017 updates, we specifically looked for ad-
verse effects, using a simple search aimed to identify systematic
reviews of adverse effects of vitamin supplements, see Appendix 9
for search strategy.
Searching other resources
We searched the reference lists of identified trial reports to find
additional trials. We used the Science Citation Index to find stud-
ies that cited the identified trials. We contacted investigators of
included studies to identify additional published and unpublished
studies.
Data collection and analysis
Selection of studies
Both authors independently assessed the titles and abstracts of all
reports of trials identified by the electronic searches. We obtained
the full texts of possibly relevant trials.We selected relevant studies
according to the definitions in the Criteria for considering studies
for this review.
Data extraction and management
We extracted data using a standardised form, developed by
Cochrane Eyes and Vision. For the initial review, we sent these
data for verification to the trial investigators of all studies included
in the review. In the 2012 and current updates, data were inde-
pendently extracted by both authors, compared, disagreements re-
solved by discussion, and data cut and pasted into Review Man-
ager (Review Manager 5 2014) by one author and checked by the
other. In the current update, citations were screened and dupli-
cate data extracted using web-based review management software
(Covidence).
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Assessment of risk of bias in included studies
We assessed risk of bias using Cochrane’s tool for assessing the risk
of bias as described in Chapter 8 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
Measures of treatment effect
We used the risk ratio (RR) for dichotomous outcomes where pos-
sible. As one of the main large trials reported odds ratios (OR) and
their confidence intervals only (derived from repeated measures
logistic regression), we used the OR as the measure of effect for
analyses that included this trial (AREDS 2001).
For continuous outcomes, we used the mean difference (MD)
where possible, and the standardisedmeandifference (SMD)when
visual acuity was measured on different scales. In this case, we cor-
rected for differences in direction between Snellen and logMAR
scales by multiplying the Snellen decimal values by -1. Where pos-
sible, we checked for skewness using methods outlined in Chapter
9 of the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011).
Unit of analysis issues
The main study design method in this area is the parallel-group
randomised controlled trial. Cluster-randomised trials are un-
likely, but would still be considered. Cross-over studies would not
be appropriate in this area because of the uncertain and complex
natural history of AMD. Currently, no such studies have been
identified, but if they are in the future, we will only use data from
the first phase.
As the intervention is applied to the individual, the unit of ran-
domisation is the individual person. As people have two eyes, it is
possible for there to be a unit of analysis issue if eyes are reported,
rather than results for the person. For each included trial we doc-
umented whether the unit of analysis was the same as the unit of
randomisation and noted any implications for the analysis. For
studies reporting right and left eyes separately, we extracted data
for the right eye.
Dealing with missing data
The data included in the review represent an ’available case analy-
sis’. The majority of the data in the current review came from two
large trials with high (over 95%) follow-up.
Two studies specifically excluded people who experienced a neo-
vascular event (one component of late-stage AMD) from the anal-
yses (CARMA 2013; Stur 1996). The published reports did not
give enough information to include these people in the analyses.
Assessment of heterogeneity
We assessed heterogeneity by looking at the forest plots to see
whether the effect measures for the different studies were in the
same direction and of a similar order of effect. An I² statistic value
of 50% or more was taken to indicate considerable inconsistency
of results, such that a pooled result may be inaccurate and should
not be reported.
The main clinical heterogeneity was the type of supplement. This
was incorporated into the analysis strategy by considering the for-
mulations by type.
Assessment of reporting biases
In future versions of this review, when sufficient trials are included
in the meta-analyses (10 or more), we plan to examine the funnel
plot to assess whether there is any evidence that smaller studies are
reporting larger effects, which may indicate publication bias.
Data synthesis
We planned to pool data using a random-effects model (because
it was likely that the effects of antioxidant vitamin and mineral
supplementation may vary in different population groups) but
with the proviso that if there were three or fewer trials we would
use the fixed-effects model. In the event most of our analyses fell
into the latter category and sowe largely used a fixed-effectsmodel.
Subgroup analysis and investigation of heterogeneity
Currently, there are not enough studies to performuseful subgroup
analyses, and these are not proposed for this version of the review.
Characteristics that may be important are the type and severity
of AMD. Subgroup analyses on type or severity of AMD may be
considered in future.
Sensitivity analysis
A sensitivity analysis was not planned.
Summary of findings tables
Weprepared separate ’Summary of findings’ tables for the different
types of vitamin supplement.
We assessed the certainty of the evidence (GRADE) for each out-
come using customised software (GRADEpro 2014). JE did the
initial assessment, which was checked by JL.We considered risk of
bias, inconsistency, indirectness, imprecision, and publication bias
when judging the certainty of the evidence (Schünemann 2011).
The ’Summary of findings’ tables include an estimate of the risk
of each outcome in the general population. We used data from
AREDS to estimate the risk in the control group in low risk
(AREDS category 2) and high risk (AREDS category 4) popula-
tions.
R E S U L T S
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Description of studies
Results of the search
Summary of searches for previous versions of this review
Date review
published
Date searches
up to date
Newly included
trials
Total number of
trials included
in the review
Total number of
excluded trials
Trials awaiting
assessment
Ongoing trials
November 1997 August 1997 AMDSG 1996;
Newsome 1988;
Stur 1996
3 1 Holz 1993 (in-
cluded February
2002)
AREDS 2001;
VECAT 2002
November 1998 October 1998 Kaiser 1995 4 1 France 1998
(un-
published but in-
cluded in current
update)
-
February 2002 November 2001 AREDS 2001;
Holz 1993;
VECAT 2002
7 1 - -
February 2006 January 2006 Veterans LAST
study 2004
8 1 Wang 2004 (in-
cluded Novem-
ber 2007)
-
November 2007 August 2007 Wang 2004 9 25 - -
October 2012 August 2012 Bartlett 2007;
CARMIS 2011;
LISA 2011;
Newsome 2008
13 41 CARMA
2013 (included
current update)
LUTEGA 2013
and Falsini 2010
(both excluded
current update)
AREDS2 2013
and
NCT91948476
(Ma 2012) (both
included current
update):
NCT00879671
(this is the same
trial as LISA
2011 included in
October 2012)
NCT00893724
(excluded
current update)
June 2017 (cur-
rent update)
March 2017 AREDS2 2013;
Berrow 2013;
CARMA 2013;
19 55 - NCT01694680;
NCT02625376
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(Continued)
CLEAR 2013;
France 1998*;
Ma 2012
* This is an unpublished trial for which we are unlikely to
be able to obtain the data. We originally excluded this, but
following more recent guidelines (see MECIR standard C12;
methods.cochrane.org/mecir), we are including this study in the
current review.
Searches for current update (2017)
Update searches run in March 2017 yielded a further 872 records
(Figure 1). After 157 duplicate were removed, the Cochrane Infor-
mation Specialist (CIS; formerly the Trial Search Co-ordinator)
screened the remaining 715 records and removed 562 references
that were not relevant to the scope of the review. We screened the
remaining 153 references and obtained 38 full-text reports for fur-
ther assessment.We identified 18 reports of six new studies for fur-
ther details; see Characteristics of included studies. France 1998,
which had previously been excluded, has now been reassessed and
added to the review as an included study. We excluded 18 re-
ports of 15 studies and identified two new ongoing studies; see
Characteristics of excluded studies. In the previous version of this
review, there were five reports of studies awaiting classification.
For this update, we assessed these reports; two have now been
included and three were excluded. The previous ongoing studies
were reassessed and those studies that had been completed were
either included or excluded in this update.
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Figure 1. Study flow diagram.
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Included studies
Below is a summary of the 19 trials included in this review. See
Characteristics of included studies for detailed information on
individual trials.
Multivitamin supplements
Seven studies compared multivitamin supplements with placebo
(AMDSG 1996; AREDS 2001; Bartlett 2007; CARMA 2013;
Kaiser 1995; Veterans LAST study 2004; Wang 2004), and two
studies compared multivitamin supplements with no treatment
(Berrow 2013; CARMIS 2011). Table 1 summarises the daily
dose of key antioxidant vitamin and mineral supplements con-
sidered. These studies were conducted in USA (AMDSG 1996;
AREDS 2001; Veterans LAST study 2004), Europe (Bartlett
2007; CARMA 2013; Kaiser 1995), and China (Wang 2004).
AMDSG 1996, Bartlett 2007, Berrow 2013, CARMIS 2011, and
Veterans LAST study 2004 only enrolled people with early AMD.
Wang 2004 recruited people with both early and late-stage disease.
In AREDS 2001, participants had a range of disease, frommild or
borderline features to late AMD. CARMA 2013 enrolled people
with either late AMD in one eye and any AMD in the other, or
people with AMD features of “sufficient severity” in both eyes, i.e.
either more than 20 drusen, or a combination of drusen and pig-
mentary abnormalities. Kaiser 1995 recruited people with “non-
serous” AMD.
People taking part in the trials were identified by referral from
local ophthalmologists (Kaiser 1995), from people attending De-
partment of Veterans Medical Centers (AMDSG 1996; Veterans
LAST study 2004), from retinal specialty clinics and general pop-
ulation volunteers (AREDS 2001), from an eye outpatient clinic
(Berrow 2013; Wang 2004), and from regional tertiary referral
centres (CARMA 2013). Bartlett 2007 recruited participants by
sending letters to “local optometrists, ophthalmologists, and a spe-
cialist centre for rehabilitation of people with sight loss”; partici-
pants were then seen at theUniversity research centre. InCARMIS
2011, it was not clear how they identified participants.
The number of participants enrolled ranged from 14 (Berrow
2013), to 3640 (AREDS 2001). Apart from AREDS 2001, all
these trials recruited fewer than 500 people; the median number
randomised was 90. The average age of participants ranged from
66 to 75 years; the median percentage of women was 55%, two
trials recruited mainly men (AMDSG 1996; Veterans LAST study
2004).
The duration of supplementation and follow-up ranged from nine
months (Bartlett 2007), to six years (AREDS 2001). Only one
trial followed up beyond two years (AREDS 2001).
Lutein and zeaxanthin supplements
Five studies compared lutein supplements with placebo (AREDS2
2013; CLEAR 2013; LISA 2011; Ma 2012; Veterans LAST study
2004). In AREDS2 2013, all participants also took the AREDS
formula (Table 1).
The daily dose of lutein used in all these studies was 10 mg; two
studies considered additional doses of 20 mg (LISA 2011; Ma
2012). Two studies combined lutein with zeaxanthin, either a dose
of 2mg (AREDS2 2013), or 10mg (Ma 2012). These studies were
conducted in USA (AREDS2 2013; Veterans LAST study 2004),
Europe (CLEAR 2013; LISA 2011), and China (Ma 2012).
CLEAR 2013,Ma 2012, andVeterans LAST study 2004 only con-
sidered people with early macular degeneration. AREDS2 2013
enrolled people “at risk for progression to advanced AMD, with
bilateral large drusen, or large drusen in one eye and advanced
AMD in the fellow eye”. LISA 2011 recruited individuals in cat-
egories 2, 3, and 4 according to AREDS criteria (similar to the
participants in AREDS 2001).
People taking part in the trials were identified from people at-
tending Department of VeteransMedical Centers (Veterans LAST
study 2004), from “clinical centers” (AREDS2 2013), and “local
communities” (Ma 2012). In CLEAR 2013, “An advertising cam-
paign was conducted within the universities and in local newspa-
pers”. In LISA 2011, it was not clear how they identified partici-
pants.
The number of participants enrolled ranged from 84 (CLEAR
2013), to 4203 (AREDS2 2013). Apart from AREDS2 2013, all
of these trials recruited fewer than 150 people; themedian number
randomised was 110. The average age of participants ranged from
69 to 75 years; the median percentage of women was 57%; one
trial recruited mainly men (Veterans LAST study 2004).
The duration of supplementation and follow-up ranged from six
months (LISA 2011), to five years (AREDS2 2013). The majority
of trials followed up to 12 months, only one trial followed up to
two years (Ma 2012).
Vitamin E
One study, conducted in Australia, compared vitamin E with
placebo (VECAT 2002). This study randomised 1204 people to
vitamin E 400 IU daily or placebo, and followed up for four years.
Participants were enrolled from the general population and only
19% had AMD, mainly early AMD. Average age was 66 years,
and 56% were women.
Zinc
Six studies compared zinc with placebo (AREDS 2001; France
1998; Holz 1993; Newsome 1988; Newsome 2008; Stur 1996).
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In France 1998, 170 people with neovascular AMD in one eye
and drusen in the other were randomised to receive zinc 30 mg
or placebo. This study was unpublished and we have no further
information.
Three studies considered zinc sulfate 200 mg daily (Holz 1993;
Newsome 2008; Stur 1996), one study investigated zinc oxide 80
mg daily (AREDS 2001), and one study used zinc monocysteine
50 mg daily (Newsome 2008).
Holz 1993 and Newsome 2008 only enrolled people with early
macular degeneration; in AREDS 2001, participants had a range
of disease, frommild or borderline features to late AMD;Newsome
1988 recruited people with both early and late-stage disease; Stur
1996 only enrolled people with late-stage disease in one eye.
The number of participants enrolled ranged from 58 (Holz 1993),
to 3640 (AREDS 2001). Apart from AREDS2 2013, all of these
trials recruited fewer than 500 people; the median number ran-
domised was 141. The average age of people participating in the
trials ranged from 65 to 74 years; median percentage of women
was 57%.
People taking part in the trials were identified by referral from local
ophthalmologists (Newsome 1988), eye outpatient clinics (Stur
1996), and from retinal specialty clinics and general population
volunteers (AREDS 2001). In Holz 1993 and Newsome 2008, it
was not clear how they identified participants.
The duration of supplementation and follow-up in these trials
ranged from six months to seven years.
Excluded studies
Details of excluded studies are provided in ’Characteristics of
excluded studies’.
Risk of bias in included studies
Figure 2 and Figure 3 summarise the ’Risk of bias’ assessment.
Overall, we considered the trials to be at low risk of bias for the
main types of bias, in particular, selection bias (allocation sequence
generation and concealment) and performance and detection bias.
This is because all trials, except Berrow 2013 and CARMIS 2011,
had a placebo control. Three trials were not well reported (Holz
1993; LISA 2011; Wang 2004), and one trial was unpublished
(France 1998).
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Inmost trials randomisation appeared to have been executed prop-
erly, that is, an unpredictable sequence of treatment allocation was
adequately concealed from people recruiting participants into the
trial. As Holz 1993 had only been published in abstract form to
date, the details of randomisation were not clear.
Blinding
Two trials had a ’no treatment’ control group so were considered to
be at high risk for performance and detection bias (Berrow 2013;
CARMIS 2011).
In general, there was not a lot of information to judge the success
of themasking. In AREDS 2001, four people were documented as
being unmasked to study group. More people in the antioxidant
group (8.3%) reported changes in skin colour (yellowing) than in
the placebo group (6.0%, P < 0.01), and more people in the zinc
groups reported difficulty swallowing the study tablets (17.8%
versus 15.3%, P = 0.04). However, there was little evidence of
unmasking when participants were asked to guess their treatment
assignment at the end of the study. The percentages of participants
who guessed correctly, by treatment assignment, were: placebo
17%, antioxidants alone 16%, zinc alone 18%, and antioxidants
plus zinc 16%. In the Veterans LAST study 2004, the tablets were
apparently identical in appearance, but it was not clear whether
taste or systemic effects differed between the different groups.
Incomplete outcome data
Information on attrition bias was not so clearly reported, and it
was difficult to assess how likely this bias was. Three studies were
considered to be at high risk of attrition bias.
In CARMIS 2011, 19% of the treated group and 38% of the
untreated group were excluded from the final analysis.
In Veterans LAST study 2004,members of the placebo group were
removed from analysis, due to the fact that they had taken lutein.
In Stur 1996, analysis of the main outcome measures (visual func-
tion and progression of disease) was not done on a strictly in-
tention-to-treat basis, as anyone experiencing the study end point
of late-stage AMD (neovascularisation) was withdrawn from the
study. Contact with the trial investigator revealed that all of these
participants ended up with visual acuity of 20/200 (6/60) or less,
and that these participants were excluded because the investigators
wished to detect functional changes caused by degeneration of the
retinal pigment epithelium and the sensory retina, and not vision
losses caused by choroidal neovascularisation. Similarly, CARMA
2013 excluded people with CNV from analyses of visual acuity.
Selective reporting
There was some evidence of selective reporting in six studies, but
this was generally difficult to assess, and we could not be confident
that selective reporting did not occur in other included studies.
Effects of interventions
See: Summary of findings for the main comparison
Multivitamin versus placebo; Summary of findings 2 Lutein or
zeaxanthin versus placebo; Summary of findings 3 Vitamin E
versus placebo; Summary of findings 4 Zinc versus placebo
Table 2 provides more information on the outcomes and follow-
up times relating to the data included in these analyses.
Multivitamin and mineral supplement versus placebo
See Summary of findings for the main comparison.
Nine studies investigated multivitamin supplements (Table 1).
Only three trials reported data on our primary outcome of pro-
gression to late AMD (AREDS 2001; CARMA 2013; CARMIS
2011), and only one of these trials reported data separately on neo-
vascular AMD and geographic atrophy (AREDS 2001). Mean vi-
sual acuity was more commonly reported, but there was consider-
able variability in themeasurement and reporting of this outcome.
AMDSG 1996 and Veterans LAST study 2004 measured visual
acuity using a Snellen chart and converted the score into logMAR
units. AREDS 2001, CARMIS 2011 and Bartlett 2007 used the
logMAR visual acuity chart developed as part of the Early Treat-
ment of Diabetic Retinopathy Study (ETDRS 1980). No useable
data could be extracted for Berrow 2013, Kaiser 1995 and Wang
2004.
Only one trial reported on quality of life (CARMIS 2011) using
the Italian version of the National Eye Institute Visual function
questionnaire (NEI-VFQ).
There were several different strategies for dealing with eyes. Some
studies reported AMD for the person which means that the unit
of analysis was the person and they were counted as having AMD
if it was present in one or both eyes (AREDS 2001). Some studies
reported findings on right eyes and left eyes separately (AMDSG
1996; Veterans LAST study 2004), selected a trial eye (Bartlett
2007; Kaiser 1995; Wang 2004) or averaged the data for the two
eyes in participants where both eyes were included (CARMA
2013).
Data from AREDS 2001 were reported as adjusted odds ratios
only. The odds ratios were calculated using repeated-measures lo-
gistic regression and were adjusted for baseline co-variates age, sex,
race, AMD category and smoking status.
People taking antioxidant vitamins were probably less likely to
progress to late AMD (odds ratio (OR) 0.72, 95% confidence in-
terval (CI) 0.58 to 0.90; 2445 participants; 3 studies; moderate-
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certainty evidence; Analysis 1.1), neovascular AMD (OR 0.62,
95% CI 0.47 to 0.82; 1206 participants; 1 study; moderate-cer-
tainty evidence; Analysis 1.2) and geographic atrophy (OR 0.75,
95% CI 0.51 to 1.10; 1206 participants; 1 study; moderate-cer-
tainty evidence; Analysis 1.3), and probably less likely to lose 3 or
more lines of visual acuity (OR 0.77, 95% CI 0.62 to 0.96; 1791
participants; 1 study; moderate-certainty evidence; Analysis 1.4).
Trials reporting mean visual acuity in continuous format were
smaller and had shorter treatment and follow-up durations (six
months to 18 months; AMDSG 1996; Bartlett 2007, ; Veterans
LAST study 2004). No effect of treatment on visual acuity was
seen from these analyses. The pooled mean difference (MD) was
0.04 logMAR, 95% CI -0.01 to 0.09; participants = 485 (Analysis
1.5). Data on mean visual acuity in CARMIS 2011 were also not
available in a form suitable to include in the analyses in this review,
but we have requested them from the study investigators; the trial
publication reported stabilisation of visual acuity in the treated
group compared with the non-treated group.
CARMIS 2011 reported higher quality of life (NEI VFQ-25)
scores in the treated compared with the non-treated group after 24
months. Themean change in overall score at 24 months follow-up
was 3.6 (95% CI 0.50 to 6.81) in the treated group and -8.7 (95%
CI -16.54 to -0.97) in the non-treated group (mean difference
(MD) 12.30, 95% CI 4.24 to 20.36; 110 participants; 1 study;
low-certainty evidence).
Table 3 summarises information available on adverse effects.
Very low-certainty evidence was available on adverse effects from
these Included studies. Theywere underpowered to look at adverse
effects and these were inconsistently reported. Data from AREDS
2001 suggested no important effect on mortality associated with
multivitamin use (hazard ratio for mortality 0.87, 95% CI 0.60 to
1.25). In AREDS 2001 participants in the antioxidant arms more
frequently reported yellow skin (8.3% versus 6.0%, P = 0.008).
None of the trials reported resource use and costs.
Lutein and/or zeaxanthin versus placebo
See Summary of findings 2.
Five studies compared lutein supplements (10 or 20 mg) with
placebo and followed up for six months to five years (AREDS2
2013; CLEAR 2013; LISA 2011; Ma 2012; Veterans LAST study
2004). In AREDS2 2013, all participants also took the AREDS
formula (Table 1).
Only one trial reported data on progression to late AMD, neovas-
cular AMD, and geographic atrophy (AREDS2 2013). CLEAR
2013, LISA 2011, and Ma 2012 reported mean logMAR visual
acuity measured on an ETDRS chart. Veterans LAST study 2004
measured visual acuity using a Snellen chart and converted the
score into logMAR units. LISA 2011 did not report any data in a
form that could be used in this review.
Only one trial reported on quality of life, using theChinese version
of the NEI-VFQ (Ma 2012).
There were several different strategies for dealing with eyes.
AREDS2 2013 reported by eye. The study reports hazard ratios
adjusted for one or two eyes per person. We have extracted data
on eyes only. The confidence intervals for effect estimates from
this study, as reported in this review, are therefore narrower than
they should be as they do not take into account within-person cor-
relation. As all confidence intervals around effect estimates from
this study include 1 (no effect), this lack of adjustment does not
make any difference to the conclusions of the review. Some studies
reported findings on right eyes and left eyes separately (Veterans
LAST study 2004) or selected a trial eye (CLEAR 2013; LISA
2011). In some studies there was not enough information to tell
(Ma 2012).
People taking lutein or zeaxanthin may have similar or slightly
reduced risk of progression to late AMD (risk ratio (RR) 0.94,
95% CI 0.87 to 1.01; 6891 eyes; 1 study; low-certainty evidence;
Analysis 2.1), neovascular AMD (RR 0.92, 95% CI 0.84 to 1.02;
6891 eyes; 1 study; low-certainty evidence; Analysis 2.2), and ge-
ographic atrophy (RR 0.92, 95% CI 0.80 to 1.05; 6891 eyes; 1
study; low-certainty evidence; Analysis 2.3). Similar risk of pro-
gression to visual loss of 15 or more letters was seen in lutein and
control group (RR 0.98, 95%CI 0.91 to 1.05; 6656 eyes; 1 study;
low-certainty evidence; Analysis 2.4).
Three studies reported mean logMAR visual acuity; there was no
evidence of any difference between treatment and control groups
(MD 0.00 logMAR, 95% CI -0.05 to 0.05; 231 participants; I2
= 0%).
Ma 2012 observed similar changes in quality of life scores between
supplement and placebo groups (MD 1.48 score, 95% CI -5.53
to 8.49; 108 participants; 1 study; low-certainty evidence).
Table 3 summarises information available on adverse effects.
Very low-certainty evidence was available on adverse effects from
these Included studies. Theywere underpowered to look at adverse
effects and these were inconsistently reported.Data fromAREDS2
2013 suggested no serious adverse effects associated with lutein
and zeaxanthin use. Hazard ratio for mortality comparing lutein/
zeaxanthin to no lutein/zeaxanthin was 1.06 (95% CI 0.87 to
1.31).
None of the trials reported resource use and costs.
Vitamin E versus placebo
See Summary of findings 3.
There was only one trial investigating vitamin E alone (VECAT
2002). This trial randomised 587 participants to vitamin E sup-
plementation and 592 to placebo, and followed them up for an
average of four years. Over 80% of the participants in this trial
had no signs of AMD. One eye per person was included in the
trial.
The number of late AMD events was low (4/494 in vitamin E and
3/504 in placebo group) and therefore, the estimate of effect was
very uncertain (RR 1.36, 0.31 to 6.05). We judged this to be very
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low-certainty evidence as there were only 7 events (downgraded
two levels for imprecision) and only 19% of the study population
had AMD (downgraded one level for indirectness). There were no
data on neovascular AMD or geographic atrophy.
There was no evidence of any effect of treatment on visual acuity;
59 people in the vitamin E group and 57 people in the placebo
group lost more than nine letters of acuity (equivalent to 2 or
more lines) on the Bailey-Lovie chart (RR 1.04, 95% CI 0.74
to 1.47). We downgraded for imprecision and indirectness giving
low-certainty evidence.
No serious adverse effects were seen. Similar numbers of people in
the vitamin E and placebo groups withdrew due to adverse effects
(four versus seven), reported any adverse effect (91 versus 83), or
ocular adverse effect (105 versus 90).
There were no data on quality of life or resource use and costs.
Zinc versus placebo
See Summary of findings 4.
Four trials investigated the effect of zinc supplementation (AREDS
2001; Holz 1993 (published in abstract form only); Newsome
1988; Stur 1996). In addition, we are aware of one unpublished
study for which we have no data (France 1998). One further trial
investigated zinc-monocysteine (Newsome 2008).
Three trials reported data on our primary outcome of progression
to late AMD (AREDS 2001; Holz 1993; Stur 1996); only one
of these trials reported data separately for neovascular AMD and
geographic atrophy (AREDS 2001). Two studies reported mean
visual acuity (Newsome 1988; Stur 1996).
There were several different strategies for dealing with eyes. Some
studies reported AMD for the person which means that the unit
of analysis was the person and they were counted as having AMD
if it was present in one or both eyes (AREDS 2001). Some studies
reported findings on right eyes and left eyes separately (Newsome
2008), selected a trial eye (Stur 1996) or averaged the data for the
two eyes in participants where both eyes were included (CARMA
2013; Newsome 1988). In some studies there was not enough
information to tell how eyes had been dealt with (France 1998;
Holz 1993).
Data from AREDS 2001 were reported as adjusted odds ratios
only. The odds ratios were calculated using repeated-measures lo-
gistic regression and were adjusted for baseline co-variates age, sex,
race, AMD category and smoking status.
People taking zinc supplements may be less likely to progress to
late AMD (OR 0.83, 95% CI 0.70 to 0.98; 3790 participants; 3
studies; low-certainty evidence; Analysis 4.1), neovascular AMD
(OR 0.76, 95% CI 0.62 to 0.93; 2442 participants; 1 study; mod-
erate-certainty evidence; Analysis 4.2), geographic atrophy (OR
0.84, 95% CI 0.64 to 1.10; 2442 participants; 1 study; moderate-
certainty evidence; Analysis 4.3), and visual loss (OR 0.87, 95%
CI 0.75 to 1.00; 3791 participants; 2 studies; moderate-certainty
evidence; Analysis 4.4).
Only one trial has investigated zinc-monocysteine (Newsome
2008). At six months, people taking zinc-monocysteine read more
letters (distance visual acuity). In people treated with zinc-mono-
cysteine, the mean (SD) number of letters read correctly on an
EDTRS charts with best correction was 39 (0.672) at baseline
and 43 (0.784) at six months in their right eyes. In people taking
placebo, the values were 40 (0.649) at baseline and 39 (0.921) in
their right eyes. Differences between the groups were statistically
significant. Similar findings were seen for the left eye.
In Stur 1996, the primary outcome was incidence of choroidal
neovascularisation (CNV) in all participants. During the treat-
ment period, a CNV developed in the study eye in 14 participants
(nine in the treatment group, five in the placebo group). People
who experienced a CNV were not included in the analyses of vi-
sual acuity.
Table 3 summarises information available on adverse effects.
Very low-certainty evidence was available on adverse effects from
these Included studies. Theywere underpowered to look at adverse
effects and these were inconsistently reported.
The main reported adverse effect leading to withdrawal from the
studies was gastrointestinal symptoms. Of 286 people randomised
into trials of zinc sulfate supplementation compared with placebo
(excluding AREDS 2001), 5/146 zinc-treated people withdrew
due to gastrointestinal symptoms compared with 2/140 controls.
No one developed copper-deficiency anaemia (high zinc intakes
can inhibit copper absorption). In AREDS 2001 participants in
the zinc arms reported more anaemia (13.2% versus 10.2%, P =
0.004), however, serum haematocrit levels were the same. Later
follow-up of the cohort of people taking part in the AREDS study
found that there was a significant increase in hospital admissions
due to genitourinary diseases in people taking zinc supplements
(11.1% versus 7.6%, P = 0.0003). In AREDS2 2013 reported
gastrointestinal disorders and hospitalizations for genitourinary
diseases were similar comparing high-dose and low-dose zinc.
There were no data reported on quality of life and resource use
and costs.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Lutein and/ or zeaxanthin versus placebo
Patient or population: people with AMD
Setting: community
Intervention: lutein and zeaxanthin*
Comparison: placebo
Outcomes Anticipated absolute effects∗∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with Lutein and
zeaxanthin
Progression to
late AMD (neovascular
AMD, geographic atro-
phy, or both)
Low RR 0.94
(0.87 to 1.01)
6891 eyes
(1 RCT)
⊕⊕©©
LOW 1,2
Average follow-up 5
years
15 per 1000 14 per 1000
(13 to 15)
High
430 per 1000 404 per 1000
(374 to 434)
Progression to neovas-
cular AMD
Low RR 0.92
(0.84 to 1.02)
6891 eyes
(1 RCT)
⊕⊕©©
LOW 1,2
Average follow-up 5
years
10 per 1000 9 per 1000
(8 to 10)
High
300 per 1000 276 per 1000
(252 to 306)
Progression to geo-
graphic atrophy
Low RR 0.92
(0.80 to 1.05)
6891 eyes
(1 study)
⊕⊕©©
LOW 1,2
Average follow-up 5
years
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10 per 1000 9 per 1000
(8 to 11)
High
300 per 1000 276 per 1000
(240 to 315)
Progression to visual
loss (loss of 3 or more
lines on logMAR chart)
Low RR 0.98
(0.91 to 1.05)
6656 eyes
(1 RCT)
⊕⊕©©
LOW 1,2
Average follow-up 5
years
15 per 1000 15 per 1000
(14 to 16)
High
430 per 1000 421 per 1000
(391 to 452)
Quality of lif e as-
sessed with Visual
Funct ion Quest ionnaire
(VFQ) (higher scores
better)
The mean VFQ quality
of lif e score in the con-
trol group was 77.3
The mean VFQ quality
of lif e score in the inter-
vent ion group was 1.48
higher (5.53 lower to 8.
49 higher)
- 108
(1 RCT)
⊕⊕⊕©
MODERATE 2
Follow-up 12 months.
Adverse ef fects Data f rom AREDS2 suggested no serious adverse ef fects associated with lutein and zeaxanthin
use (hazard rat io for mortality was 1.06 (95% CI 0.87 to 1.31)
⊕©©©
VERY LOW 3
-
Resource use and costs - - - - - Not reported
* Most of the evidence in this table is drawn f rom the AREDS2 study in which part icipants too a daily dose of lutein 10mg and zeaxanthin 2mg or placebo. All part icipants in
the study took AREDS formula (vitamin C, E, zinc with/ without beta-carotene)
* * The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and
its 95% CI). The assumed risk in the comparison group is est imated using data f rom AREDS: low risk = AREDS category 2; high risk = AREDS category 4.
CI: Conf idence interval; RR: Risk rat io
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GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate-certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for indirectness, as everyone in trial took AREDS formula, which may have af fected the est imate of
ef fect
2 Downgraded one level for imprecision, as conf idence intervals crossed line of m inimum important dif f erence.
3 Downgraded for one level for imprecision (as included studies were underpowered to look at adverse ef fects), one level for
risk of bias (adverse ef fects were inconsistent ly reported) and one level for inconsistency (inconsistent results reported).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Vitamin E versus placebo
Patient or population: people with AMD
Setting: community
Intervention: vitamin E*
Comparison: placebo
Outcomes Anticipated absolute effects∗∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with M ultivitamin
antioxidant vitamin or
mineral supplement
Progression to
late AMD (neovascular
AMD, geographic atro-
phy or both)
Low RR 1.36 (0.31 to 6.05; 998
(1 RCT)
⊕⊕©©
VERY LOW1,2
Average follow-up 4
years
15 per 1000 20 per 1000
(5 to 91)
High
430 per 1000 585 per 1000
(133 to 1000)
Progression to neovas-
cular AMD
Not reported
Progression to geo-
graphic atrophy
Not reported
Progression to visual
loss (loss of 3 or more
lines on logMAR chart)
Low RR 1.04
(0.74 to 1.47)
998
(1 RCT)
⊕⊕©©
LOW1,2
Average follow-up 4
years
15 per 1000 16 per 1000
(11 to 22)
High
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430 per 1000 447 per 1000
(318 to 632)
Quality of lif e Not reported
Adverse ef fects No serious adverse ef fects were seen. Sim ilar numbers of people in the vitamin E and placebo
groups withdrew due to adverse ef fects (four versus seven), reported any adverse ef fect (91 versus
83), or ocular adverse ef fect (105 versus 90)
⊕©©©
VERY LOW 3
-
Resource use and costs - - - - - Not reported
* Vitamin E 500 IU per day: natural vitamin E in soybean oil medium
* * The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and
its 95% CI). The assumed risk in the comparison group is est imated using data f rom AREDS: low risk = AREDS category 2; high risk = AREDS category 4
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate-certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded two levels for imprecision as only 7 events.
2 Downgraded one level for indirectness as over 80% of the part icipants in this trial had no signs of AMD at baseline.
3 Downgraded three levels for imprecision as study was underpowered to look at rare adverse ef fects.
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Zinc versus placebo
Patient or population: people with AMD
Setting: community
Intervention: zinc*
Comparison: placebo
Outcomes Anticipated absolute effects∗∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with Zinc
Progression to
late AMD (neovascular
AMD, geographic atro-
phy or both)
Low OR 0.83
(0.70 to 0.98)
3790
(3 RCTs)
⊕⊕©©
LOW 1,2
Average follow-up in
study contribut ing most
of the events was 6
years
15 per 1000 12 per 1000
(11 to 15)
High
430 per 1000 385 per 1000
(346 to 425)
Progression to neovas-
cular AMD
Low OR 0.76
(0.62 to 0.93)
2442
(1 RCT)
⊕⊕⊕©
MODERATE2
Average follow-up 6
years
10 per 1000 8 per 1000
(6 to 9)
High
300 per 1000 246 per 1000
(210 to 285)
Progression to geo-
graphic atrophy
Low OR 0.84
(0.64 to 1.10)
2442
(1 RCT)
⊕⊕⊕©
MODERATE2
Average follow-up 6
years
10 per 1000 8 per 1000
(6 to 11)
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High
300 per 1000 265 per 1000
(215 to 320)
Progression to visual
loss (loss of 3 or more
lines on logMAR chart)
Low OR 0.87
(0.75 to 1.00)
3791
(2 RCTs)
⊕⊕⊕©
MODERATE2
Average follow-up in
study contribut ing most
of the events was 6
years
15 per 1000 13 per 1000
(11 to 15)
High
430 per 1000 396 per 1000
(361 to 430)
Quality of lif e Not reported
Adverse ef fects In some studies, gastrointest inal symptoms was reported as a reason for withdrawal. Of 286
people randomised into trials of zinc sulfate supplementat ion compared with placebo (not including
AREDS), 5/ 146 zinc-treated people withdrew due to gastrointest inal symptoms compared with 2/
140 controls. No-one developed copper-def iciency anaemia (high zinc intakes can inhibit copper
absorpt ion). In AREDS part icipants in the zinc arms reported more anaemia (13.2% versus 10.2%,
P = 0.004), however, serum haematocrit levels were the same. In AREDS zinc was associated with
higher risk of genitourinary problems in men, but no dif ference seen between high- and low-dose
zinc groups in AREDS2
⊕©©©
VERY LOW 3
-
Resource use and costs - - - - - Not reported
* Most of the evidence in this table is drawn f rom the AREDS study which studied a daily dose of zinc 80 mg as zinc oxide, copper 2 mg as cupric oxide
* * The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and
its 95% CI). The assumed risk in the comparison group is est imated using data f rom AREDS: low risk = AREDS category 2; high risk = AREDS category 4.
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
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GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate-certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for inconsistency because study ef fects ranged f rom 0.50 to 2.31, although I² = 14%
2 Downgraded one level for imprecision because conf idence interval crossed line of m inimum important dif f erence.
3 Downgraded for one level for imprecision (as included studies were underpowered to look at adverse ef fects), one level for
risk of bias (adverse ef fects were inconsistent ly reported) and one level for inconsistency (inconsistent results reported).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
The trials contributing to this review fall into two categories. There
are three large trials with reasonably long treatment duration and
follow-up of four to six years (AREDS 2001; AREDS2 2013;
VECAT 2002). The other 16 trials are smaller (ranging from 20
to 400 participants) and have shorter duration of treatment and
follow-up (six to 24 months).
The large trials provided reasonably clear answers to different ques-
tions. The AREDS 2001 trial provided evidence that long-term
supplementation with vitamins C, E, beta-carotene, and zinc, in
people with AMD, reduced the risk of progression of the disease
and loss of visual acuity. The overall benefit was modest, with a
risk reduction in the order of 20% to 25%. However, given that
treatment options for AMD are limited, and vision loss is rarely
recovered, this may be of interest to people with AMD. In people
with very early signs of AMD, who are at low risk of progression,
this would mean that there would be approximately 4 fewer cases
of progression to late AMD for every 1000 people taking vitamins
(1 fewer to 6 fewer cases). In people at high risk of progression (i.e.
people with moderate AMD) this would correspond to approxi-
mately 8 fewer cases of progression for every 100 people taking
vitamins (3 fewer to 13 fewer).
AREDS22013 compared lutein or zeaxanthinwith placebo.There
was a modest or no risk reduction in AMD progression that was
not statistically significant, but as all participants took the AREDS
formula, there was no proper control group. Secondary analyses
from the trial suggested that theremay be some benefit in replacing
beta-carotene with lutein, but these analyses were only exploratory
(AREDS 2014). Other trials of lutein or zeaxanthin were small,
of short duration, and did not report relevant outcomes. Limited
data on mean visual acuity and quality of life did not suggest any
important effects of these supplements on outcomes important to
patients.
The VECAT 2002 study suggested that the general population
should not take vitamin E with a view to preventing the incidence
or progression of AMD (Evans 2017). However, the study was
underpowered to answer the question about whether people with
signs of AMD, such as those participating in the AREDS 2001
study, should take vitamin E. Currently, VECAT 2002 is the only
published trial on vitamin E supplementation and AMD.
The other trials of multivitamin preparations, Ocuguard (
AMDSG1996),Ocupower (Veterans LAST study 2004), Visaline
(Kaiser 1995), and lutein or antioxidant (Bartlett 2007), were ei-
ther too small to provide evidence either way, or the data were not
available in a format suitable to include in this review (CARMIS
2011; LISA 2011). Pooling results, where possible, did not pro-
vide evidence of any benefit of supplementation. However, these
trials were of relatively short duration.
A total of four published trials investigated zinc supplementation
(AREDS 2001; Holz 1993; Newsome 1988; Stur 1996), and one
trial examined a novel zinc-monocysteine formulation (Newsome
2008). The AREDS 2001 study indicated that the beneficial ef-
fect of zinc supplementation was of a similar order to that of vita-
min supplementation. The other trials provided more conflicting
evidence. Newsome 1988 found a reduction in the risk of visual
acuity loss with supplementation over 12 to 24 months. However,
Stur 1996 found no effect of treatment. Stur 1996, which was
planned to recruit 500 participants, was terminated early because
the results of the first 40 participants at 24 months indicated no
benefit of treatment. The other two trials of zinc supplementation
are as yet unpublished, although limited results from Holz 1993
were published in abstract form and were included here.Newsome
2008 found that zinc-monocysteine had beneficial effects on vi-
sual acuity and contrast sensitivity.
Overall completeness and applicability of
evidence
The main evidence that antioxidant vitamin and mineral supple-
mentation was of benefit came from the AREDS 2001 trial. As
AREDS 2001 was a large, well-conducted randomised study, po-
tential biases would have been minimised. The only area where
bias may have been introduced was if there were different systemic
effects of the antioxidant and zinc supplementation (for example,
yellowing of skin or difficulty swallowing tablets), which led the
participants to guess which group they were in or alternatively, the
retinal fundus photographsmight have been different in someway,
such that the graders’ response was affected by treatment group.
However, this is unlikely, and there was little evidence that this
was a problem in the study.
It is worth comment that pooling data from trials other than
AREDS 2001 revealed little evidence for effectiveness of antioxi-
dant vitamin and mineral supplements on preventing visual loss
or progression of the disease. However, the other studies encom-
passed many different formulations and in general, were rather
small and of short duration, which may explain the lack of effect.
AREDS 2001 was the only study to examine in detail the ques-
tion of safety. They found little evidence of harm, but there was
an increased risk of hospital admission due to genitourinary com-
plications in people taking the zinc supplements. The safety of
some of the components of the AREDS formulation have been
questioned in other studies. Two large randomised controlled tri-
als have indicated that smokers who take beta-carotene may be at
increased risk of developing lung cancer (ATBC; Omenn 1996).
TheHeartOutcomes PreventionEvaluation (HOPE) study found
that among people with vascular disease or diabetes, vitamin E
supplementation was associated with a higher risk of heart failure
(Lonn 2005). A systematic search of the literature for systematic
reviews addressing harms of vitamin supplements did not identify
any further relevant evidence. Huang 2006 did not identify any
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consistent adverse effects of mineral and vitamin supplements, but
only included nine RCTs in their review. A subsequent Cochrane
Review that investigated antioxidant supplements for preventing
all cause mortality, included 78 trials with 296,707 participants,
and concluded “We found no evidence to support antioxidant
supplements for primary or secondary prevention. Beta-carotene
and vitamin E seem to increase mortality, and so may higher doses
of vitamin A” (Bjelakovic 2012).
Quality of the evidence
As the majority of the trials were placebo-controlled, we mostly
assessed them as being at low risk of bias. In particular, the two
trials that contributed most of the data to this review were judged
at low risk of bias (AREDS 2001; AREDS2 2013). There was
some variable reporting of the smaller trials; the extent to which
attrition bias may have played a role was not always clear. There
was some evidence of selective outcome reporting with respect to
data on visual acuity. We identified three trials that did not report
non-significant data. Another problem with visual acuity was the
variety of ways in which it could be reported dichotomous with
a variety of potential cut-points, as a continuous variable reporting
change or final value. It was possible that investigators had done
analyses of visual acuity in a variety of ways and reported the
most significant finding. However, in these trials, we did not find
evidence of improved visual acuity associated with treatment.
The main reasons for downgrading the evidence were imprecision
and indirectness. In particular, as all participants inAREDS2 2013
took multivitamin supplements, the results may not have repre-
sented a true reflection of the effect of lutein supplementation.
Potential biases in the review process
This review follows the guidance for the preparation of Cochrane
reviews. We have made various changes to the protocol over the
years (see Differences between protocol and review) but these have
been guided by improvements in Cochrane methods, the structure
of the data, or collaboration with NICE, rather than being data
driven.
Agreements and disagreements with other
studies or reviews
There have been a number of reviews published on this topic in
the last 3 years (Andreatta 2014; Angelo 2015; Broadhead 2015;
Buschini 2015;Carneiro 2017;Chew2014;Downie 2014;Grover
2014; Hanus 2016; Liu 2015; Manikandan 2016; Prasad 2014;
Sacconi 2017; Schmidl 2015; Zampatti 2014). In general, these
reviews have been a narrative assessment of observational stud-
ies and RCT evidence, focusing mainly on the results of AREDS
and AREDS2. On the basis of AREDS, these reviews generally
conclude that supplementation may benefit people with AMD.
This is the same conclusion as the current review. In general, more
emphasis has been placed by these other studies on the secondary
analyses of the AREDS2 study of lutein and zeaxanthin as a re-
placement for beta-carotene in the AREDS formula.
There has been one systematic review of lutein and zeaxanthin sup-
plementation published (Liu 2015) which pooled data for 8 stud-
ies. All of these studies were identified by the current review but
one has been excluded because lutein/zeaxanthin were combined
with omega-3 fatty acids (LUTEGA 2013). In the current review,
we only included studies that were lutein/zeaxanthin alone i.e.
not combined with other antioxidant vitamins (CARMA 2013;
CARMIS 2011). The data for the remaining studies were similar,
but not identical, comparing Liu 2015 and the current review.
The overall estimates of effect for visual acuity were similar with
a pooled mean difference of -0.04 logMAR (95% CI -0.06 to -
0.03) in Liu 2015 and -0.00 logMAR (95% CI -0.05 to 0.05) in
the current review. Liu 2015 used the Jadad scale to assess quality
of the included studies but this assessment was ignored in the con-
clusions. Similarly, no attempt was made to assess the overall cer-
tainty of the evidence. Although Liu 2015 concluded that lutein/
zeaxanthin improve visual performance, we would probably have
concluded, with the same data, that there was low-certainty evi-
dence that lutein/zeaxanthin make little important difference to
visual acuity as a mean difference of 2 letters (0.04 logMAR) is
probably not clinically significant. Liu 2015 also included contrast
sensitivity as an outcome and concluded that lutein/zeaxanthin
showed “remarkable benefit”. We did not consider contrast sensi-
tivity.
The authors of AREDS2 2013 concluded in the main trial report
that “Addition of lutein + zeaxanthin [...] to the AREDS formula-
tion in primary analyses did not further reduce risk of progression
to advanced AMD.” This is similar to the findings of this review,
where we conclude that supplements containing lutein and zeax-
anthin may have little or no effect on the progression of AMD.
The authors of AREDS2 2013 go onto suggest that “...because of
potential increased incidence of lung cancer in former smokers,
lutein + zeaxanthin could be an appropriate carotenoid substitute
in the AREDS formulation.” Subsequent exploratory analyses of
trial data fromAREDS22013 suggested a benefit of lutein/zeaxan-
thin versus beta-carotene in this trial population, all of whomwere
taking supplements. For this reason, the authors of AREDS2 2013
recommend replacing beta-carotene with lutein. See for example
https://nei.nih.gov/areds2/PatientFAQ. We have not considered
these secondary analyses of AREDS2 2013 in this review. They
were exploratory analyses and the subgroups considered were not
pre-planned in this review.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
People with AMD may experience modest delay in progression
of the disease with antioxidant vitamin and mineral supplemen-
tation. This finding was drawn from one large trial conducted in
a relatively well-nourished American population. Until it is repli-
cated by other large-scale trials in other populations, we will not
know whether these findings can be applied more generally. Our
review shows little effect, if any, of supplements containing lutein
and zeaxanthin on the progression of AMD but the evidence was
low-certainty.
Antioxidant vitamin andmineral supplements are readily available
for purchase without prescription inmany countries. The decision
to take these supplements is at the discretion of the person with
AMD. The following benefits and harms need to be considered.
People with AMD may delay the progression of their condition if
they take antioxidant vitamins and zinc at the levels described in
this review. Given that there are few other interventions that offer
much in the way of disease prevention or cure, this is an important
consideration. However, harmful effects associated with long-term
vitamin supplementation, particularly in smokers and people with
vascular disease, cannot be ruled out. A healthy diet with a variety
of fresh fruit and vegetables will havemany benefits and is unlikely
to be harmful. However, it may be difficult to consume, as part of
a normal diet, the levels of antioxidants and zinc described in the
trials included in this review.
Implications for research
Trials in other populations, preferably with a variety of nutritional
status, are required. These trials should have a large enough sam-
ple size, and long enough duration, to demonstrate effects that are
meaningful for people, and should also include outcomes relevant
to people affected by AMD, including quality of life assessment. It
is likely that AMD develops over many years. Three categories of
people may be identified: healthy people at risk because of age or
genetic factors; people with early stages of the disease; and people
with intermediate or late-stage disease. If antioxidant supplemen-
tation is protective, there may be differences in the effect, depend-
ing on the stage of the disease.
Trial reporting should include enough information to assess the
role of selective outcome reporting bias (ideally by providing online
access to the protocol for the study), and clearer information about
follow-up of participants in the study, in particular reasons for
exclusion.
As antioxidant vitamin and mineral supplements have systemic
effects, the literature on this topic would be much improved by a
systematic review of the potential harms of such products, includ-
ing broader sources of evidence than just randomised controlled
trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
AMDSG 1996
Methods Parallel group RCT
Method of allocation: sponsor prepared coded tablets
Masking: participant - not clear; provider - yes; outcome - yes
Losses to follow-up: 4 died (2 treatment, 2 control); 1 adverse effect withdrawn (treat-
ment); 7 lost to follow-up (1 treatment, 6 control)
Participants Country: USA
Number of people randomised: 71 (eyes unknown)
Number (%) of people followed up: 59 (83%) (eyes unknown)
Average age (range): 72 years (unknown)
Percentage women: 7%
Ethnic group: unknown
Baseline visual acuity: unknown
Comorbidities affecting the eye: unknown
Percentage current smokers: unknown
Inclusion criteria:
• people with a monocular 1 line drop in Snellen visual acuity not attributable to
cataract, amblyopia, systemic, or ophthalmic disease AND clinically observable drusen,
RPE disruption and loss of macular reflex
Exclusion criteria:
• longer than 1 year use of vitamins
• ex-prisoners of war
• chronic alcoholics with tobacco or nutritional amblyopia
• gastrointestinal absorption disorders
Interventions Intervention:
• Ocuguard (Twin Lab Inc, Ronkonkoma, NY) broad-spectrum antioxidant: beta-
carotene 20,000 IU, vitamin E 200 IU, vitamin C 750 mg, citrus bioflavonoid
complex 125 mg, quercitin (bioflavonoid) 50 mg, bilberry extract (bioflavonoid) 5 mg,
rutin (bioflavonoid) 50 mg, zinc picolinate 12.5 mg, selenium 50 µg, taurine 100 mg,
n-acetyl cysteine 100 mg, l-glutathione 5 mg, vitamin B2 25 mg, chromium 100 µg
(daily)
◦ unknown number people randomised (eyes unknown )
◦ 39 (unknown %) people followed up (eyes unknown )
Comparator:
• placebo, starch
◦ unknown number people randomised (eyes unknown)
◦ 32 (unknown %) people followed up (eyes unknown)
Duration: 18 months
Similarity between intervention and comparator: treatment and placebo may not have
been identical
Outcomes Primary: not specified
Secondary: not specified
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AMDSG 1996 (Continued)
Outcomes reported in the paper:
• Snellen acuity with best refraction converted to logMAR units for analysis
• near vision M units with dual sided Bailey-Lovie chart
• contrast sensitivity
• retinal grading score (adapted from Chesapeake Bay Study)
• subjective perception of vision; adverse gastrointestinal reactions
Follow-up: 18 months
Eyes: Reported right and left eyes separately
Notes Source of funding: Twin Laboratories Inc, Ronkokoma NY; StereoOptical Inc, Chicago,
IL; Eye Communications Inc, Upland, CA; Illinois College of Optometry, Chicago, IL;
Pacific University College of Optometry, Forest Grove, OR; Ezell Foundation, American
Academy of Optometry, Rockville, MD
Declaration of interest: unknown
Date study conducted: unknown
Trial registration number: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Both the capsule for the placebo
group (starch) and the capsule for
the antioxidant group (Ocuguard) were
formulated by Twin Laboratores Inc.,
Ronkonkoma, NY. An intermediary com-
pany, Eye Communications, Inc., Upland,
CA. was responsible for assigning and
maintaining the identity of codes, labelling
and distribution of masked bottles of cap-
sules to each DVA Medical Centre phar-
macy service”
Quote: “Group one and group two patients
were randomised between capsule number
1601 (starch placebo) and capsule number
1602 (Ocuguard) at each center by the op-
tometrist co-investigator. Neither the op-
tometrist nor the registered dietitian co-in-
vestigators nor the veteran subject knew the
identify of the capsules.”
Allocation concealment (selection bias) Unclear risk Quote: “Both the capsule for the placebo
group (starch) and the capsule for
the antioxidant group (Ocuguard) were
formulated by Twin Laboratores Inc.,
Ronkonkoma, NY. An intermediary com-
pany, Eye Communications, Inc., Upland,
CA. was responsible for assigning and
maintaining the identity of codes, labelling
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AMDSG 1996 (Continued)
and distribution of masked bottles of cap-
sules to each DVA Medical Centre phar-
macy service”
Quote: “Group one and group two patients
were randomised between capsule number
1601 (starch placebo) and capsule number
1602 (Ocuguard) at each center by the op-
tometrist co-investigator. Neither the op-
tometrist nor the registered dietitian co-in-
vestigators nor the veteran subject knew the
identify of the capsules.”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Quote: “Both the capsule for the placebo
group (starch) and the capsule for
the antioxidant group (Ocuguard) were
formulated by Twin Laboratores Inc.,
Ronkonkoma, NY. An intermediary com-
pany, Eye Communications, Inc., Upland,
CA. was responsible for assigning and
maintaining the identity of codes, labelling
and distribution of masked bottles of cap-
sules to each DVA Medical Centre phar-
macy service”
Quote: “Group one and group two patients
were randomised between capsule number
1601 (starch placebo) and capsule number
1602 (Ocuguard) at each center by the op-
tometrist co-investigator. Neither the op-
tometrist nor the registered dietitian co-in-
vestigators nor the veteran subject knew the
identify of the capsules.”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Quote: “Both the capsule for the placebo
group (starch) and the capsule for
the antioxidant group (Ocuguard) were
formulated by Twin Laboratores Inc.,
Ronkonkoma, NY. An intermediary com-
pany, Eye Communications, Inc., Upland,
CA. was responsible for assigning and
maintaining the identity of codes, labelling
and distribution of masked bottles of cap-
sules to each DVA Medical Centre phar-
macy service”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Quote: “Both the capsule for the placebo
group (starch) and the capsule for
the antioxidant group (Ocuguard) were
formulated by Twin Laboratores Inc.,
Ronkonkoma, NY. An intermediary com-
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AMDSG 1996 (Continued)
pany, Eye Communications, Inc., Upland,
CA. was responsible for assigning and
maintaining the identity of codes, labelling
and distribution of masked bottles of cap-
sules to each DVA Medical Centre phar-
macy service”
Quote: “Group one and group two patients
were randomised between capsule number
1601 (starch placebo) and capsule number
1602 (Ocuguard) at each center by the op-
tometrist co-investigator. Neither the op-
tometrist nor the registered dietitian co-in-
vestigators nor the veteran subject knew the
identify of the capsules.”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Quote: “Both the capsule for the placebo
group (starch) and the capsule for
the antioxidant group (Ocuguard) were
formulated by Twin Laboratores Inc.,
Ronkonkoma, NY. An intermediary com-
pany, Eye Communications, Inc., Upland,
CA. was responsible for assigning and
maintaining the identity of codes, labelling
and distribution of masked bottles of cap-
sules to each DVA Medical Centre phar-
macy service”
Quote: “Group one and group two patients
were randomised between capsule number
1601 (starch placebo) and capsule number
1602 (Ocuguard) at each center by the op-
tometrist co-investigator. Neither the op-
tometrist nor the registered dietitian co-in-
vestigators nor the veteran subject knew the
identify of the capsules.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 17 participants withdrew from the study
over 18 months. 4 participants died. 1 par-
ticipant experienced an idiosyncratic reac-
tion and was dropped. Attrition data were
as follows: “71 patients at baseline, 67 pa-
tients at 6 m, 59 patients at 12 m, 59 pa-
tients at 18 m.” Similar numbers of drop-
outs from groups 1 and 2 but the numbers
were not clearly described
Selective reporting (reporting bias) Unclear risk Difficult to assess with the information
given - no access to study protocol and trial
was not registered
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Methods Parallel group RCT
2 x 2 factorial design. 67% participants took additional supplements to RDA levels
(Centrum). In 1996 current smokers offered option of discontinuing supplementation;
2% of participants and 18% of smokers did so. A further 2.3% reassigned to no beta-
carotene group. Intention-to-treat analysis maintained
Method of allocation: coded bottles
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 2.4% balanced across study groups
Participants Country: USA
Number of people randomised: 3640 (eyes unknown)
Number (%) of people followed up: 2.4% lost to follow up
Average age (range): 69 years (55 to 80)
Percentage women: 56%
Ethnic group: 96% white
Baseline visual acuity: unknown
Comorbidities affecting the eye: unknown
Percentage current smokers: 8%
Inclusion criteria:
• 20/32 or better in at least 1 eye
• ocular media clear and therefore able to obtain adequate stereoscopic fundus
photographs
• at least 1 eye free from eye disease that could complicate assessment of AMD
Exclusion criteria:
• illness or disorders that would make long-term follow-up or compliance with
study protocol unlikely or difficult
Interventions Intervention:
• antioxidants vitamin C 500 mg, vitamin E 400 IU, beta-carotene 15 mg (daily)
• zinc 80 mg as zinc oxide, copper 2 mg as cupric oxide (daily)
◦ 2737 people randomised (eyes unknown) (945 antioxidants only, 904 zinc
only, 888 antioxidants plus zinc)
◦ 2.4% lost to follow-up but numbers by group not reported. Quote:
“Participants without photographic or visual acuity follow-up were evenly distributed
across treatment groups.”
Comparator:
• placebo
◦ 903 people randomised (eyes unknown)
◦ 2.4% lost to follow-up but numbers by group not reported. Quote:
“Participants without photographic or visual acuity follow-up were evenly distributed
across treatment groups.”
Duration: average follow-up 6.3 years
Similarity between intervention and comparator: Quote: “Study medication tablets for
the 4 treatment groups were identical in external appearance and similar in internal
appearance and taste.”
Outcomes Primary:
• progression to advanced AMD (assessed using stereoscopic fundus colour
photograph)
• 15 letter or more decrease in visual acuity score (EDTRS logMAR chart)
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Secondary:
• safety outcomes included: reported adverse events; serum levels of haemoglobin;
hospitalisations and mortality.
Follow-up: annual follow-up for at least 5 years
Eyes: outcome was “in at least one eye” i.e. reported by person
Notes Source of funding: Quote: “Supported by contracts from the National Eye Institute,
National Institutes of Health, with additional support from Bausch and Lomb Pharma-
ceuticals.”
Declaration of interest: Quote: “The AREDS investigators have no commercial or pro-
prietary interest in the supplements used in this study.”
Date study conducted: 1992 to 2001
Trial registration number: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Simple randomization, stratified
by clinical center and AMD category, was
used to assign treatment. Participants in
Categories 2, 3, and 4 were assigned with
probability one quarter to each treatment
group”
Quote: “Multiple unique bottle codes were
randomly assigned to each of the 4 treat-
ments for Categories 2, 3, and 4, and also
to each of the 2 treatments for participants
in Category 1. A bottle code corresponding
to the assigned treatment was randomly se-
lected for each participant”
Allocation concealment (selection bias) Low risk Quote: “Multiple unique bottle codes were
randomly assigned to each of the 4 treat-
ments for Categories 2, 3, and 4, and also
to each of the 2 treatments for participants
in Category 1. A bottle code corresponding
to the assigned treatment was randomly se-
lected for each participant”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Quote: “The 4 treatment interventions
were double-masked...”
“Study medication tablets for the 4 treat-
ment groups were identical in external ap-
pearance and similar in internal appearance
and taste. The coordinating center was cus-
todian of the treatment code”
Quote: “Four participants (0.1%) were re-
ported to have been unmasked during the
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trial”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Quote: “The 4 treatment interventions
were double-masked...”
Quote: “Study medication tablets for the 4
treatment groups were identical in external
appearance and similar in internal appear-
ance and taste. The coordinating centerwas
custodian of the treatment code”
Quote: “Four participants (0.1%) were re-
ported to have been unmasked during the
trial”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Quote: “Visual acuity was assessed by cer-
tified examiners using the ETDRS log-
MAR chart and a standardized refraction
and visual acuity protocol (AREDS Man-
ual of Operations; The EMMES Corpora-
tion, Rockville, Md)”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Quote: “Stereoscopic fundus photographs
of themaculawere taken at baseline and an-
nually, beginning 2 years after randomiza-
tion, and graded centrally using standard-
ized grading procedures.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Participants without pho-
tographic or visual acuity follow-up were
evenly distributed across treatment groups.
”
Quote: “Only 2.4% of AREDS partici-
pants were lost to follow-up (missed at least
their last 2 consecutive visits). Losses to
follow-up were balanced across treatment
groups”
Quote: “Of almost 50,000 possible fol-
low-up visits, 10% were missed. The fre-
quency of missed visits and mean follow-
up time (6.3 years) did not differ by treat-
ment group. Most participants (90%) had
at least 5 years of follow-up.”
Selective reporting (reporting bias) Low risk Quote: “At the start of the study, 2 primary
outcomes were defined for study eyes in
the AMD trial: (1) progression to advanced
AMD and (2) at least a 15-letter decrease
in visual acuity score.”
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AREDS2 2013
Methods Parallel group RCT
Method of allocation: coded tablets
Masking: participant - yes; provider - yes; outcome - yes
Loss to follow-up: Quote: “Of the 4203 randomised participants, 141 (3%) were lost to
follow-up and 368 (9%) died during the course of the study. Distributions were similar
across the 4 treatment groups.” Quote: “Participants lost to follow-up or who died during
the course of the study were censored at the time of last contact.” See follow-up data
below - 99% of participants were included in the analysis
Participants Country: USA
Number of people randomised: 4203 (6916 eyes)
Number (%) of people followed up: 4176 (99%) using LOCF (6891 eyes)
Average age (range): 74 years (68 to 79)
Percentage women: 56%
Ethnic group: 97% white
Baseline visual acuity: average 78 letters on EDTRS chart
Comorbidities affecting the eye: 25% bilateral pseudophakic, 13% with diabetes
Percentage current smokers: 7%
Inclusion criteria:
• high risk of progression to advanced AMD with either bilateral large drusen or
non-foveal geographic atrophy (no advanced AMD) or large drusen or non-foveal
geographic atrophy in one eye and advanced AMD in the fellow eye (AREDS Simple
Scale Score of 2, 3 or 4)
• age 50 to 85 years
• took at least 75% of study medication during the run-in phase
• able and willing to consent to both the qualification and the randomisation/
follow-up phases of the study
• likely, willing, and able to undergo yearly examinations for at least five years
• agreed to stop current use of supplements containing lutein, zeaxanthin, omega-3
LCPUFAs (specifically DHA+EPA), vitamin C, vitamin E, beta-carotene, zinc or
copper, other than those supplied by AREDS2
• fundus photographs of adequate quality as assessed with a standardized protocol
by the Reading Center (University of Wisconsin Fundus Photograph Reading Center)
• randomised within three months following the qualification visit
Exclusion criteria:
• the presence of ocular disease in either eye that may have confounded evaluation
of the retina
• previous retinal or other ocular surgical procedures (other than cataract
extraction) that may have complicated assessment of the progression of AMD
• a chronic requirement for any systemic or ocular medication administered for
other diseases and known to be toxic to the retina or optic nerve
• previous daily supplementation with 2 mg or more of lutein, or 500 mg or more
of omega-3 LCPUFAs, or both, for a period of 1 year or more prior to the date of
randomization. (A participant was eligible for the study if he or she agreed to stop
taking these supplements during the study run-in period)
• intraocular pressure of 26 mm Hg or higher, or some reason to believe that the
participant might have glaucoma
• cataract surgery within 3 months or capsulotomy within 6 weeks prior to the
qualification visit
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• history of lung cancer
• any systemic disease with a poor five-year survival prognosis
• haemochromatosis
• Wilson’s disease
• recent diagnosis of oxalate kidney stones
• any condition that would make adherence or follow-up difficult or unlikely
• current participation in other studies that might affect adherence to the AREDS2
follow-up schedule
• use of systemic anti-angiogenic therapy for treatment of choroidal
neovascularization or cancer
Interventions Intervention:
• lutein 10 mg and zeaxanthin 2 mg (1 tablet/day)
◦ 2123 people randomised (3468 eyes)
◦ 2107 (99%) people followed up (3451 eyes)
Comparator:
• placebo (1 tablet/day)
◦ 2080 people randomised (3448 eyes)
◦ 2069 (99%) people followed up (3440 eyes)
Almost all participants in both intervention and comparator groups took AREDS sup-
plement and multivitamin with the study medication
Duration: 5 years (median)
Similarity between intervention and comparator: The placebo was composed from free
flowing corn starch-coated matrix of beadlets formed into a tablet of identical shape,
size, and coating/internal colour (using the same quantity of colorings agents) as that
containing lutein + zeaxanthin
Other study arm: There was another study arm looking at docosahexaenoic acid (DHA)
350 mg and eicosapentaenoic acid (EPA) 650 mg (2 soft-gel capsules/day); it was not
included in this review
Outcomes Primary:
• progression to advanced AMD in people at moderate to high risk for progression
Secondary:
• progression to moderate vision loss
• adverse events
• progression of lens opacity or incidence of cataract surgery
• effect of study supplements on cognitive function
• effect of DHA/EPA on cardiovascular morbidity and mortality
Follow-up: annual follow-up for 5 years
Eyes: Quote: “The unit of analysis for ophthalmic outcomes was by eye. The primary
efficacy outcome, time to progression to advanced AMD, was assessed using a Cox
proportional hazards model incorporating the method of Wei et al for obtaining robust
variance estimates that allows for dependence among multiple event times (1 or 2 study
eyes).”
Notes Source of funding: Quote: “This study is supported by the intramural program funds
and contracts from the National Eye Institute/National Institutes of Health (NEI/NIH)
, Department of Health and Human Services, Bethesda, MD. Contract No. HHS-N-
260-2005-00007-C. ADB Contract No. N01-EY-5-0007. Funds were generously con-
tributed to these contracts by the following NIH institutes: Office of Dietary Supple-
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ments (ODS), National Center for Complementary and Alternative Medicine (NC-
CAM), National Institute on Aging (NIA), National Heart, Lung and Blood Institute
(NHLBI), and National Institute of Neurological Disorders and Stroke (NINDS)”
Declaration of interest: Quote: “A complete list of all AREDS2 investigator financial
disclosures, which were collected for regulatory purposes, pursuant to US FDA regu-
lations in 21 CFR Part 54, can be found at www.areds2.org. The member(s) of the
writing committee have made the following disclosure(s): Frederick L. Ferris III; Bausch
& Lomb (P) and the remainder had no conflicts of interest.”
Date study conducted: September 2006 to October 2012 (from clinicaltrials.gov entry)
Trial registration number: NCT00345176
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A random block design was im-
plemented using the AREDS2 Advantage
Electronic Data Capture system (Advan-
tageEDC SM ) by the AREDS2 Co-ordi-
nating Center (The EMMESCorporation,
Rockville,Maryland) and stratified by clin-
ical center and AMD status (large drusen
both eyes or large drusen in one eye and ad-
vancedAMDin the fellow eye) to assure ap-
proximate balance across centers over time.
”
Allocation concealment (selection bias) Low risk Judgement comment: Central co-ordinat-
ing centre organised the random allocation
and placebo controlled study
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Judgement comment: Placebo controlled
trial. Personnel measuring visual acuity un-
aware of allocation
Quote: “All 4 formulations are balanced
on excipients and packaged in capsules of
identical size, shape and color.”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Judgement comment: Placebo controlled
trial. Fundus images graded by masked
graders
Quote: “All 4 formulations are balanced
on excipients and packaged in capsules of
identical size, shape and color.”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Judgement comment: Placebo controlled
trial. Personnel measuring visual acuity un-
aware of allocation
Quote: “All 4 formulations are balanced
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on excipients and packaged in capsules of
identical size, shape and color.”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Judgement comment: Placebo controlled
trial. Fundus images graded by masked
graders
Quote: “All 4 formulations are balanced
on excipients and packaged in capsules of
identical size, shape and color.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Of the 4203 randomised partici-
pants, 141 (3%) were lost to follow-up and
368 (9%) died during the course of the
study. Distributions were similar across the
4 treatment groups.”
Selective reporting (reporting bias) Low risk Judgement comment: AMDoutcomes pre-
specified in clinical trials registry and in
published protocol paper were reported
Bartlett 2007
Methods Parallel group RCT
Method of allocation: sponsor prepared coded tablets
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 5 (2 treatment, 3 control)
Participants Country: UK
Number of people randomised: 30 (30 eyes)
Number (%) of people followed up: 25 (83%) (25 eyes)
Average age (range): 69 years (55 to 82)
Percentage women: 53%
Ethnic group: 100% white
Baseline visual acuity: average visual acuity in intervention group was 0.20 logMAR and
in control group was 0.08 logMAR
Comorbidities affecting the eye: unknown
Percentage current smokers: unknown
Inclusion criteria:
• provide written informed consent
• be available to attend one of the research centres
• present with no ocular pathology in at least 1 eye, or no ocular pathology other
than soft or hard drusen, and areas of increased or decreased pigment associated with
drusen. Fundus examination was used to determine the presence of AMD.
Exclusion criteria:
• type I and II diabetes
• prescribed antiplatelet or anticoagulant medication
• concurrent use of nutritional supplements
• advanced AMD in 1 or both eyes
48Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bartlett 2007 (Continued)
Interventions Intervention:
• lutein esters 6 mg, retinol 750 mg, vitamin C 250 mg, vitamin E 34 mg, zinc 10
mg, copper 0.5 mg (daily)
◦ 17 people randomised (17 eyes)
◦ 15 (88%) people followed up (15 eyes)
Comparator:
• placebo tablets containing cellulose (daily)
◦ 13 people randomised (13 eyes)
◦ 10 (77%) people followed up (10 eyes)
Duration: 9 months
Similarity between intervention and comparator: Quote: “The study formulation and
placebo tablets were produced by Quest Vitamins Ltd, and were identical in external
and internal appearance, and taste.”
Outcomes Primary: unknown
Secondary: unknown
Outcome measures specified on trial registration entry:
• Distance and near visual acuity (VA) measured using Bailey-Lovie logMAR charts
• Contrast sensitivity (CS) measured using a Pelli-Robson chart (Clement Clarke
International, Harlow Essex, UK)
• Colour vision measured using the PV-16 quantitative colour vision test
• Macular Mapping (MM) test
• Eger Macular Stressometer (EMS) used to assess glare recovery
• Fundus photographs of the macular will be assessed using colour and edge
analysis software
Trial publication provided data on contrast sensitivity at 9-month follow-up
Protocol listed more outcomes (see below under selective reporting) and specified 9 and
18 months follow-up
Follow-up: 9 months (reported) and 18 months (not reported)
Eyes: Trial eye selected (initial visit only). If both eyes were eligible for inclusion, the
right eye was used
Notes Sample size calculations reported in trial report: “A group size of nine was calculated to
be sufficient to provide 80% power at the 5% significance level for CS based on an effect
size of 0.3 log units, and mean and standard deviation (SD) values taken from a sample
of 50 ARM and atrophic AMD patients of the University optometry clinic (1.3970.22
log CS).”
Sample size calculations reported in protocol paper: “From initial data collection we have
calculated the treatment group sizes required in order to have 80% power at the 5%
significance level for VA, CS, MM test, and the EMS. These values suggest that a total
of 63 normal, and 96 age-related macular disease participants are required.”
Source of funding: Quote: “The project was sponsored by the UK College of Op-
tometrists. Intervention and placebo tablets were provided by Quest Vitamins Ltd UK.
”
Declaration of interest: unknown
Date study conducted: March 2003 and December 2004
Trial registration number: ISRCTN78467674 (registered retrospectively)
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The random number generator function
in Microsoft Excel is being used to allocate
participants to µ and λ groups. Odd num-
bers allocate to the µ group.”
“Only one investigator (HB) was involved
in the randomization process, which em-
ployed the random number generator in
Microsoft Excel for Windows XP. Odd and
even numbers were used to identify group.
”
Allocation concealment (selection bias) Low risk “Enrolment was carried out by HB, who,
alongwith FE, wasmasked to group assign-
ment.”
“Only one investigator (HB) was involved
in the randomization process, which em-
ployed the random number generator in
Microsoft Excel for Windows XP. Odd and
even numbers were used to identify group.
”
“Investigators and participants do not
know which symbol represents the placebo
tablets, and which represents the active for-
mulation.”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “The study formulation andplacebo tablets
have been produced by Quest Vitamins
Ltd, Aston Science Park, Birmingham, B7
4AP, and are identical in external and in-
ternal appearance, and taste. The manu-
facturer has allocated distinguishing sym-
bols, µ and λ. The tablets are packaged
in identical, sealed, white containers; the
only difference being the symbol on the la-
bel. Investigators and participants do not
know which symbol represents the placebo
tablets, and which represents the active for-
mulation.”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Not reported
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Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk “The study formulation andplacebo tablets
have been produced by Quest Vitamins
Ltd, Aston Science Park, Birmingham, B7
4AP, and are identical in external and in-
ternal appearance, and taste. The manu-
facturer has allocated distinguishing sym-
bols, µ and λ. The tablets are packaged
in identical, sealed, white containers; the
only difference being the symbol on the la-
bel. Investigators and participants do not
know which symbol represents the placebo
tablets, and which represents the active for-
mulation.”
“End of trial assessment using question-
naires indicated‘masking success. Out of
those participants taking the placebo tablet,
10% correctly guessed which tablet they
were taking, and 10% incorrectly guessed.
Out of those taking nutritional supple-
ment, 13% guessed correctly which tablet
they were taking, and 7% incorrectly
guessed. The remaining participants did
not know which group they were ran-
domised to.”
Blinding of outcome assessment (detection
bias)
Progression AMD
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Statistical analysis was carried out on a per
protocol basis.”
Selective reporting (reporting bias) High risk Protocol report: following outcomes listed:
visual acuity, contrast sensitivity, colour vi-
sion, macular mapping test, glare recovery,
fundus photographs analysed by colour and
edge analysis software
Trial report only reported contrast sensi-
tivity (CS): Quote: “Outcome measure CS
was measured using a Pelli-Robson chart
(Clement Clarke International, Edinburgh
Way, Harlow, Essex, CM20 2TT, UK) and
scored per letter.”
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Methods Parallel group RCT
Method of allocation: unclear
Masking: participant - no; provider - no; outcome - yes
Loss to follow-up: unclear, either no loss to follow-up or 2/16 (12.5%) loss to follow-up
Participants Country: UK
Number of people randomised: 14 (14 eyes)
Number (%) of people followed up: 14 (100%) (14 eyes)
Average age (range): 68 years (56 to 83)
Percentage women: unknown
Ethnic group: Caucasian
Baseline visual acuity: unknown
Comorbidities affecting the eye: unknown
Percentage current smokers: unknown but average 7 pack-years in antioxidant group
and 13.5 pack-years in the placebo group
Inclusion criteria:
• best-corrected distance VA of 0.2 LogMAR or better (for good mfERG central
fixation)
• clear optical media, as determined by a clear view of the fundus
• no signs of other retinal or optic nerve disease other than ARM (as determined by
fundal photography and questionnaire) in the study eye
• good general health (as determined by health questionnaire)
• no prescribed medication that could affect the retina (as determined by health
questionnaire)
Exclusion criteria:
• moderate-to-dense lens opacities
• intraocular lens
• corneal opacities
• glaucoma or ocular hypertension
• previous history of intraocular inflammation
• previous history of retinal detachment
• retinal disease (other than ARM)
• previous retinal laser
• diabetes
• systemic hypertension
• history of ocular trauma
• neurological disease
• age-related macular degeneration (AMD) in the study eye
• drugs causing retinal toxicity
• previous ocular surgery
• epilepsy
Interventions Intervention:
• Ocuvite Duo (Bausch and Lomb) vitamin C 150 mg, cupric oxide 400 µg,
vitamin E 15 mg, zinc oxide 20 mg, lutein 12 mg, zeaxanthin 0.6 mg, EPA 240 mg,
DHA 840 mg
◦ 8 people randomised (8 eyes)
◦ 8 (100%) people followed up (8 eyes)
Comparator:
• no treatment
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◦ 6 people randomised (6 eyes)
◦ 6 (100%) people followed up (6 eyes)
Duration: 40 weeks
Similarity between intervention and comparator: different because no placebo group
Outcomes from clinical trial registry entry
Primary:
• multifocal electroretinogram amplitudes and latencies, assessed every 20 weeks for
a period of 80 weeks
Secondary:
• macular pigment optical density, assessed every 20 weeks for a period of 80 weeks
No numeric data on outcomes reported. Quote: “All participants undertook VA and CS
assessment at all three visits. There were no significant changes between the treated and
non-treated groups over 40 weeks for these measures.”
Follow-up: 40 weeks and 60 weeks
Eyes: Quote: “Only one eye from each participant was studied.[...] The eye with the
best-corrected distance VA was determined at the participant’s first visit and this eye
was assessed for subsequent visits. If one eye had ARM, this eye was used. If both eyes
had ARM, the eye with the best-corrected distance VA was used to ensure good mfERG
fixation.”
Notes Source of funding: Quote: “The authors would like to thank Bausch and Lomb,
Kingston-Upon-Thames, Surrey, UK for funding the research position and supplying
the Ocuvite Duo nutritional supplement.”
Declaration of interest: Quote: “The authors declare no competing financial interests”
Date study conducted: January 2009 to December 2011
Trial registration number: ISRCTN17842302 (retrospectively registered)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A total of fourteen participants
with ARM were randomly allocated, using
Microsoft Excel random number genera-
tor, to either receive a lutein-based oral sup-
plement (treated group) or no supplement
(non-treated group) at visit one.”
Allocation concealment (selection bias) Unclear risk Judgement comment:Not clearly reported.
Blinding of participants and personnel
(performance bias)
Visual acuity
High risk Judgement comment: No placebo - control
group did not receive any intervention
Blinding of participants and personnel
(performance bias)
Progression AMD
High risk Judgement comment: No placebo - control
group did not receive any intervention
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Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk Judgement comment: No placebo - control
group did not receive any intervention but
study was described as “single masked”, so
outcome assessors were not aware of group
assignment up to 40 weeks, when unmask-
ing occurred. However, measurement of vi-
sual acuity may be influenced by partici-
pants knowledge of intervention
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Judgement comment: No placebo - control
group did not receive any intervention but
study was described as “single masked”, so
outcome assessors were not aware of group
assignment up to 40 weeks, when unmask-
ing occurred
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “A total of fourteen participants
with ARM were randomly allocated, using
Microsoft Excel random number genera-
tor, to either receive a lutein-based oral sup-
plement (treated group) or no supplement
(non-treated group) at visit one. Thesewere
from an original cohort of sixteen partici-
pants, two of which withdrew without giv-
ing reason. Only one eye from each”
Judgement comment: Unclear to which
group the 2 participants whowithdrew had
been randomly allocated
Selective reporting (reporting bias) High risk Judgement comment: Trial was registered
retrospectively, so not possible to check
this. Follow-up at 80 weeks was not re-
ported
CARMA 2013
Methods Parallel group RCT
Method of allocation: labelled containers
Masking: participant - yes; provider - yes; outcome - yes
Loss to follow-up: high attrition after 12 months - 9% follow-up at 3 years
Participants Country: Ireland
Number of people randomised: 433 (614 eyes)
Number (%) of people followed up: at 12 months, 493 eyes (80%); at 24 months, 260
eyes (42%); and at 36 months, 58 eyes (9%)
Average age (range): 74 years (unknown)
Percentage women: 57%
Ethnic group: unknown
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Baseline visual acuity: average 80 letters on logMAR chart
Comorbidities affecting the eye: unknown
Percentage current smokers: 14%
Inclusion criteria:
• 50 years and older
• any severity of early AMD in one eye and late AMD (neovascular AMD or central
geographic atrophy) in the fellow eye. The study eye was the eye free of late-stage AMD.
• features of early AMD in at least 1 eye when both eyes were free of late-stage
AMD.The minimum severity level was 20 soft distinct or indistinct drusen in the
central macular field; if there were fewer than 20 drusen, focal hyperpigmentation was
required to be present. Both eyes could be study eyes.
• visual acuity of 0.3 logMAR units or better (70 letters or better on the ETDRS
chart equivalent to Snellen 20/40) in the eye selected to be study eye
Exclusion criteria:
• not explicitly stated
Interventions Intervention:
• Ocuvite (Bausch and Lomb, Berlin, Germany) lutein 12 mg, zeaxanthin 0.6 mg,
vitamin E 15 mg, vitamin C 150 mg, zinc oxide 20 mg, copper 0.4 mg (daily dose) one
tablet twice daily
◦ 216 people randomised (304 eyes)
◦ unknown number (unknown %) people followed up (243 eyes) at 12 months
Comparator:
• Placebo (cellulose microcrystalline, lactose and magnesium stearate) (twice daily)
◦ 217 people randomised (310 eyes)
◦ unknown number (unknown %) people followed up (250 eyes) at 12 months
Duration: Total study duration 3 years but high attrition after 12 months
Similarity between intervention and comparator: Quote: “The placebo consisted of
cellulose, lactose, and magnesium stearate and was manufactured to be indistinguishable
from the active preparation in size, color, smell, and taste.”
Outcomes Primary:
• distance visual acuity
Secondary:
• retinal visual acuity
• morphological progression of AMD (grading of stereoscopic colour fundus
photographs)
• macular pigment levels and serum levels of antioxidants
Follow-up: every 6 months for 3 years, but high attrition after 12 months
Eyes: mixture of one or two eyes per person (see above for details). Quote “Data will be
aggregated to one result per participant-the sole result will stand for group 1 participants,
and the mean of the two results will be applied to group 2 participants. ” Analysis were
then weighted by number of eyes
Notes Source of funding: Quote: “Supported by a grant from Bausch and Lomb, Dr. Mann
Pharma, Berlin, Germany. The data set was managed and analyzed by the independent
statistician (MRS) and his team. The senior corresponding author (UC) had full access
to the data outputs. The funders had no access to the data, were not involved in the data
analysis, and had no role in the construction of the manuscript, except in the approval
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CARMA 2013 (Continued)
of the final draft.”
Declarationof interest:Quote: “The author(s) have noproprietary or commercial interest
in any materials discussed in this article.”
Date study conducted: June 2004 to April 2008
Trial registration number: ISRCTN94557601 (retrospectively registered)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Each participant enrolled in the
CARMA Study is allocated a unique num-
ber, which determines treatment allocation
according to the computerized randomiza-
tion database.”
Quote: “A block randomization design
was used with stratification by center and
by group status, and separate block ran-
domised lists were provided to each site.”
Allocation concealment (selection bias) Low risk Quote: “Each participant enrolled in the
CARMA Study is allocated a unique num-
ber, which determines treatment allocation
according to the computerized randomiza-
tion database.” and “This unique number
exists on the identification label of each
study preparation box. The masked study-
preparation boxes are kept in the hospi-
tal pharmacy, and released in a sequential
manner by the pharmacist on randomiza-
tion of each participant, beginningwith the
first in the numerical series assigned to each
clinical center. The participants are advised
to take 1 tablet twice daily with a meal.The
CARMA Study is strictly a double-masked
clinical trial in that neither the CARMA
participants nor the study staff, including
the study investigator, are aware of the na-
ture of study preparation allocated to the
participants. To ensure masking, the study-
preparation boxes are labelled with pre-as-
signed numbers at the site of manufactur-
ing, and then shipped to both clinical cen-
ters for distribution. A single pharmacist
involved with manufacturing of the study
preparation holds the key to randomization
of the CARMA supplements.”
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CARMA 2013 (Continued)
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Quote: “The study preparations (active and
placebo) were packaged in identical con-
tainers that bore only the participant infor-
mation and study label and were indistin-
guishable in all respects from each other.
” and “Participants and study staff were
masked to treatment assignments”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Quote: “The study preparations (active and
placebo) were packaged in identical con-
tainers that bore only the participant infor-
mation and study label and were indistin-
guishable in all respects from each other.
” and “Participants and study staff were
masked to treatment assignments”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Quote: “The study preparations (active and
placebo) were packaged in identical con-
tainers that bore only the participant infor-
mation and study label and were indistin-
guishable in all respects from each other.
” and “Participants and study staff were
masked to treatment assignments”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Judgement comment: Fundus images
graded bymasked graders and all study per-
sonnel masked to intervention allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Judgement comment: High attrition and
people with CNV and geographic atrophy
excluded from analyses of visual acuity
Selective reporting (reporting bias) Low risk Judgement comment: Negative primary
outcome eventually published (in Oph-
thalmology) as letter, separately from the
publication of the positive results in the sec-
ondary analysis, which appeared as a full
paper in the same journal
CARMIS 2011
Methods Parallel group RCT
Method of allocation: random list, unclear how delivered
Masking: participant - no; provider - no; outcome - unclear
Losses to follow-up: 18% in supplement group, 38% in no supplement group
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CARMIS 2011 (Continued)
Participants Country: Italy
Number of people randomised: 145 (145 eyes)
Number (%) of people followed up: 84 (58%) (84 eyes)
Average age (range): 73 years (unknown)
Percentage women: 59%
Ethnic group: unknown
Baseline visual acuity: average 82 letters (ETDRS chart)
Comorbidities affecting the eye: 30% of intervention group had had cataract surgery
but none of the control group
Percentage current smokers: 17%
Inclusion criteria:
• age 55 to 80
• diagnosis of nonexudative (dry) age-related macular degeneration (AMD) in at
least one eye having extensive (as measured by drusen area) intermediate (≥ 63 mm,
<125 mm) drusen; and at least one large (≥125 mm) drusen or geographic atrophy not
involving the center of the macula
• best-corrected visual acuity in the trial eye ≥ 20/32 (0.2 logarithm of the
minimum angle of resolution [logMAR]), 74 letters of Early Treatment Diabetic
Retinopathy Study [ETDRS] chart)
• able to understand and comply with the requirements of the trial
• no condition limiting view of the fundus (e.g. vitreous haemorrhage, cataracts,
epiretinal membrane)
• available for a minimum trial duration of approximately 6 months
• agree to take only the nutritional supplement that is provided during this study
Exclusion criteria:
• ocular disease that causes irreversible reduction of visual acuity (amblyopia,
uncontrolled glaucoma, anterior ischaemic optic neuropathy, clinically significant
macular edema)
• lens opacity and score 4+ (Lens Opacity Classification System II)
• insufficient pupil dilation
• previous laser treatment of the posterior pole for any other reason
• macular changes not attributable to AMD
• carotenoids intolerance
• major chronic disease
• life expectation lower than 6 months
• withdrawal of informed consent
• enrolment in another clinical study with experimental product within the last 4
weeks or during the current study
Interventions Intervention:
• vitamin C 180 mg, vitamin E 30 mg, zinc 22.5 mg, copper 1 mg, lutein 10 mg,
zeaxanthin 1 mg and astaxanthin 4 mg (AZYR SIFI, Catania, Italy) (daily)
◦ 103 people randomised (103 eyes)
◦ 84 (82%) people followed up (84 eyes)
Comparator:
• no dietary supplementation
◦ 42 people randomised (42 eyes)
◦ 26 (62%) people followed up (26 eyes)
Duration: 24 months
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CARMIS 2011 (Continued)
Similarity between intervention and comparator: different, no placebo group
Outcomes Reported in methods section of paper:
Primary:
• change in BCVA (the number of letters read on the logMAR chart)
Secondary:
• changes in macular function by CS using a Pelli-Robson chart (Clement Clarke
International, Harlow Essex, UK) scored per lines
• changes in visual function via the Italian-validated version of the 25-item NEI
VFQ
Reported in results section:
• multi-focal electroretinograms (ERG) at 6 and 12 months
Follow-up: 6, 12, and 24 months
Eyes: One eye per person. Quote: “When patients fulfilled the inclusion criteria (Tab. I)
, the eye with the best VA was selected. When both eyes had the same VA, the right eye
was chosen for final analysis.”
Notes Source of funding: unknown
Declaration of interest: Quote: “The authors report no proprietary interest or financial
support.”
Date study conducted: December 2003 to September 2006
Trial registration number: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A permuted blocks allocation
scheme was used to perform this random
allocation”
Allocation concealment (selection bias) Unclear risk Quote: “A 24-month prospective open-la-
bel randomised study... ”
Quote: “The study coordinator allocated
study numbers sequentially, as participants
were enrolled. Participants were then ran-
domly allocated to the treatment or no
treatment group. A permuted blocks allo-
cation scheme was used to perform this
random allocation. The allocation list was
stored at a remote site.”
Quote: “Study drug was administered by
an unmasked physician who had no other
role in the study.”
No mention was made of allocation ratios,
but 103 people were recruited to treatment
group and 42 to no treatment group
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CARMIS 2011 (Continued)
Blinding of participants and personnel
(performance bias)
Visual acuity
High risk Quote: “A 24-month prospective open-la-
bel randomised study... ”
Blinding of participants and personnel
(performance bias)
Progression AMD
High risk Quote: “A 24-month prospective open-la-
bel randomised study... ”
Blinding of outcome assessment (detection
bias)
Visual acuity
High risk Quote: “A 24-month prospective open-la-
bel randomised study... ”
Quote: “In order to allow for an unbiased
assessment of VA and ancillary study mea-
sures, an independent physician was as-
signed the role of masked evaluator.”
However, as participants were not masked,
this could have affected the measurement
of visual acuity
Blinding of outcome assessment (detection
bias)
Progression AMD
Unclear risk Quote: “A 24-month prospective open-la-
bel randomised study... ”
Quote: “In order to allow for an unbiased
assessment of VA and ancillary study mea-
sures, an independent physician was as-
signed the role of masked evaluator.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Nineteen people in the group T-
AMD, and 16 subjects from the groupNT-
AMD, were excluded from final data analy-
sis.”This exclusionwas unevenbetween the
2 groups: 19/103 (18.4%) and 16/42 (38.
1%), and also inconsistent with the data
in table III, page 6. In table III, 14 people
withdrew from the carotenoids group and 3
from the control group; 20 people discon-
tinued the intervention in the carotenoids
group and 17 in the control group
Selective reporting (reporting bias) Unclear risk Unclear. Fundus examination but progres-
sion of AMD was not reported
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CLEAR 2013
Methods Parallel group RCT
Method of allocation: coded tablets prepared by manufacturer
Masking: participant - yes; provider - yes; outcome - yes
Loss to follow-up: 13%
Participants Country: The Netherlands and the UK
Number of people randomised: 84 (84 eyes)
Number (%) of people followed up: 73 (87%) (73 eyes)
Average age (range): 71 years (unknown)
Percentage women: 61% (56% in intervention group, 67% in control group)
Ethnic group: unknown
Baseline visual acuity: average 0.1 logMAR in intervention group, and 0.05 logMAR in
control group
Comorbidities affecting the eye: unknown
Percentage current smokers: unknown
Inclusion criteria:
• 50 to 80 years
• AMD grade 0 to 4 in one eye (Rotterdam grading)
• best corrected visual acuity (BCVA) of logMAR 0.5 or better
• minimal cataract
Exclusion criteria:
• any ophthalmic disorder, such as diabetic retinopathy; optic atrophy; pigmentary
abnormalities considered by the investigating ophthalmologist to be less typical of
AMD than of some other condition (e.g. myopia)
• history of glaucoma
• any dietary supplements containing lutein, zeaxanthin, or meso-zeaxanthin
within 3 months of the start of the study
• unable to understand the study procedures or unable to give informed consent
Interventions Intervention:
• lutein 10 mg (daily)
◦ 42 people randomised (42 eyes)
◦ 36 (86%) people followed up (36 eyes)
Comparator:
• placebo soya bean oil (daily)
◦ 42 people randomised (42 eyes)
◦ 37 (88%) people followed up (37 eyes)
Duration: 12 months
Similarity between intervention and comparator: Quote: “The [..] capsules and their
packaging were completely indistinguishable”
Outcomes Primary:
• not described in paper but main aim was to investigate effects on MPOD and VA
Secondary:
• not described in paper
Quote: “Othermeasurements conducted as part of the studywere scanning laser ophthal-
moscope (SLO)-based MPOD, retinal reflectometry-based MPOD, dark adaptometry,
optical coherence tomography (OCT), and ocular scatter. These data will be described
in separate reports.”
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CLEAR 2013 (Continued)
From clinical trials registry entry (but not prospectively registered):
Primary Outcome Measures: Macular Pigment Optical Density (time frame: baseline, 4
months, 8 months, 12 months; designated as safety issue: No)
Secondary OutcomeMeasures: Visual Acuity (time frame: baseline, 4months, 8months,
12 months; designated as safety issue: No)
Follow-up: 3, 8, and 12 months
Eyes: one eye per person, unclear how selected. Quote: “According to the inclusion
criteria, a ‘test eye’ was allocated to each patient and data fromonly this eye were analyzed”
Notes Source of funding: Quote: “Supported partly by BASF, the UKMedical Research Coun-
cil, the Manchester Biomedical Research Centre, and the Greater Manchester Compre-
hensive Local Research Network.”
Declaration of interest: All authors reported no declaration of interest
Date study conducted August 2007 to August 2009 (from clinical trials registry entry)
Trial registration number: NCT01042860 (registered retrospectively)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A randomization code was gen-
erated by the sample manufacturer. Treat-
ment numbers were allocated in ascending
order using the next available consecutive
number and capsules distributed accord-
ingly.”
Judgement comment: Unclear how code
was generated, but we have assumed it was
unpredictable
Allocation concealment (selection bias) Low risk Quote: “The P and L capsules and their
packaging were completely indistinguish-
able. The code remainedwith themanufac-
turer until the end of the intervention trial.
The experimenters were unaware of which
patients were assigned to which groups.”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Quote: “The P and L capsules and their
packaging were completely indistinguish-
able. The code remainedwith themanufac-
turer until the end of the intervention trial.
The experimenters were unaware of which
patients were assigned to which groups”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Quote: “The P and L capsules and their
packaging were completely indistinguish-
able. The code remainedwith themanufac-
turer until the end of the intervention trial.
The experimenters were unaware of which
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CLEAR 2013 (Continued)
patients were assigned to which groups”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Quote: “The P and L capsules and their
packaging were completely indistinguish-
able. The code remainedwith themanufac-
turer until the end of the intervention trial.
The experimenters were unaware of which
patients were assigned to which groups”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Quote: “The P and L capsules and their
packaging were completely indistinguish-
able. The code remainedwith themanufac-
turer until the end of the intervention trial.
The experimenters were unaware of which
patients were assigned to which groups”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: Follow-up high and
similar between lutein (86%) and placebo
groups (88%)
Selective reporting (reporting bias) Low risk Judgement comment: Outcomes in trials
registry entry were reported
France 1998
Methods Parallel group RCT
Method of allocation: unknown
Masking: participant - unknown; provider - unknown; outcome - unknown
Loss to follow-up: unknown
Participants Country: France
Number of people randomised: 170 (170 eyes)
Number (%) of people followed up: unknown
Average age (range): unknown
Percengage female: unknown
Ethnic group: unknown
Baseline visual acuity: unknown
Comorbidities affecting the eye: unknown
Percentage current smokers: unknown
Inclusion criteria:
• neovascular AMD in one eye and drusen in the other
Interventions Intervention:
• zinc supplementation (30 mg/day)
◦ unknown number people randomised (eyes unknown)
◦ unknown number people followed up (eyes unknown)
Comparator:
• not known, but study described as “double blind”
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France 1998 (Continued)
◦ unknown number people randomised (eyes unknown)
◦ unknown number people followed up (eyes unknown)
Duration: unknown
Similarity between intervention and comparator: unknown
Outcomes Primary: unknown
Secondary: unknown
Follow-up: unknown
Eyes: one eye per person
Notes Trial is unpublished.
“Following an initial analysis, the study was terminated due to lack of effect, combined
with high rate of intolerance to study medication.” [Personal communication from in-
vestigator.]
Source of funding: unknown
Declaration of interest: unknown
Date study conducted: unknown
Trial registration number: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information available
Allocation concealment (selection bias) Unclear risk No information available
Blinding of participants and personnel
(performance bias)
Visual acuity
Unclear risk No information available
Blinding of participants and personnel
(performance bias)
Progression AMD
Unclear risk No information available
Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk No information available
Blinding of outcome assessment (detection
bias)
Progression AMD
Unclear risk No information available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information available
Selective reporting (reporting bias) Unclear risk No information available
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Holz 1993
Methods Parallel group RCT
Method of allocation: not known
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: not known
Participants Country: UK
Number of people randomised: 58 (eyes not known)
Number (%) of people followed up: not known
Average age (range): 68 years (55 to 82)
Percentage women: not known
Ethnic group: not known
Baseline visual acuity: not known
Comorbidities affecting the eye: not known
Percentage current smokers: not known
Interventions Intervention:
• zinc sulfate 200 mg (daily) 2 x 100 mg tablet
◦ 28 people randomised (eyes not known)
◦ unknown number people followed up (eyes not known)
Comparator:
• placebo (lactose capsule) 2 x 1 tablet daily
◦ 30 people randomised (eyes not known)
◦ unknown number people followed up (eyes not known)
Duration: 12 to 24 months
Similarity between intervention and comparator: not known
Outcomes Primary: not known
Secondary: not known
Quote: “Parameters tested included visual acuity, peripheral andmacular colour-contrast-
sensitivity; pattern ERG and dark adaptation. Stereo fundus photographs and fluorescein
angiograms were analyzed by investigators in a masked fashion using a standardized
grading scheme”
Follow-up: 12 to 24 months
Eyes: unclear
Notes Data available from abstract only:
Source of funding: Gertrud-Kusen-Stiftung, Hamburg, grant # Ho92/93-01-2
Declaration of interest: not known
Date study conducted: not known
Trial registration number: not known
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised double-blind study”
Allocation concealment (selection bias) Unclear risk Not reported
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Holz 1993 (Continued)
Blinding of participants and personnel
(performance bias)
Visual acuity
Unclear risk “randomised double-blind study”
Blinding of participants and personnel
(performance bias)
Progression AMD
Unclear risk “randomised double-blind study”
Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk “randomised double-blind study”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk “randomised double-blind study”
“Stereo fundus photographs and fluores-
cein angiograms were analyzed by investi-
gators in a masked fashion using a stan-
dardized grading scheme”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) High risk For visual acuity, trial report states that
outcome was analysed but only reports that
result was not significant
Kaiser 1995
Methods Parallel group RCT
Method of allocation: sponsor prepared coded tablets
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: none
Participants Country: Switzerland
Number of people randomised: 20 (20 eyes)
Number (%) of people followed up: 20 (20 eyes)
Average age (range): 73 years (50 to unknown)
Percentage women: 74%
Ethnic group: not known
Baseline visual acuity: not known
Comorbidities affecting the eye: not known
Percentage current smokers: not known
Inclusion criteria:
• people with non serous AMD. All participants had regional atrophy of the
pigment epithelium. Corrected visual acuity was between 20/100 and 20/25 with
distance correction of less than 4 dioptres.
Exclusion criteria:
• people with diabetes mellitus, endocrine problems, cardiac dysrhythmia, cardial
infarction or hypotension, other ocular disorders
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Kaiser 1995 (Continued)
Interventions Intervention:
• Visaline (Novopharma Cham, Switzerland). Each tablet contains 1.5 mg
buphenine HCl, 10 mg beta-carotene, 10 mg tocopherol acetate and 50 mg ascorbic
acid. Participants took 2 tablets in the morning and at night, daily, except for Saturdays
and Sundays.
◦ 9 people randomised (9 eyes)
◦ 9 (100%) people followed up (9 eyes)
Comparator:
• placebo resembling active treatment prepared by sponsor
◦ 11 people randomised (11 eyes)
◦ 11 (100%) people followed up (11 eyes)
Duration: 6 months
Similarity between intervention and comparator: not known
Outcomes Primary: not specified
Secondary: not specified
Outcomes reported:
• distance and near visual acuity
• intraocular pressure
• visual fields
• lens opacity
• retinal visual acuity
• colour vision
• contrast sensitivity
Follow-up: 3 and 6 months
Eyes: Only 1 eye per person was evaluated. In cases of bilateral AMD, the eye with better
visual acuity was selected
Notes Source of funding:not known
Declaration of interest: not known
Date study conducted: not known
Trial registration number: not known
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence generation not described in the
report but through contact with investiga-
tor
Quote: “The allocation schedulewas gener-
ated by the company and treatment sched-
ulewas concealed frompeople enrolling pa-
tients.”
Allocation concealment (selection bias) Low risk Allocation concealment not described in
the report but through contact with inves-
tigator
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Kaiser 1995 (Continued)
Quote: “The allocation schedulewas gener-
ated by the company and treatment sched-
ulewas concealed frompeople enrolling pa-
tients.”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Study was placebo-controlled. Placebo not
described in the report but investigator re-
ported that: “The placebowas also prepared
by the company and tablets resembled the
active treatment.”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Study was placebo-controlled. Placebo not
described in the report but investigator re-
ported that: “The placebowas also prepared
by the company and tablets resembled the
active treatment.”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Study was placebo-controlled. Placebo not
described in the report but investigator re-
ported that: “The placebowas also prepared
by the company and tablets resembled the
active treatment.”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Study was placebo-controlled. Placebo not
described in the report but investigator re-
ported that: “The placebowas also prepared
by the company and tablets resembled the
active treatment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 20 participants enrolled and 20 followed
up
Selective reporting (reporting bias) Unclear risk Difficult to assess with the information
available
LISA 2011
Methods Parallel group RCT
Method of allocation: 2:1 intervention:control
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: unclear
Participants Country: Austria
Number of people randomised: 126 (126 eyes)
Number (%) of people followed up: 116 (92%) using LOCF (116 eyes)
Average age (range): 72 years (50 to 90)
Percentage women: 57%
Ethnic group: not known
Baseline visual acuity: 83.9% (visual acuity reported as a percentage)
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LISA 2011 (Continued)
Comorbidities affecting the eye: not known
Percentage current smokers: not known
Inclusion criteria:
• people in categories 2, 3, or 4, according to the AREDS grading scheme
• aged 50 to 90 years
• clear nonlenticular ocular media
• visual acuity > 0.4
Exclusion criteria:
• primary retinal pigment epithelium atrophy >125 µm
• moderate or severe nonproliferative diabetic retinopathy, proliferative diabetic
retinopathy
• participation in a clinical trial in the 3 weeks preceding the study
• ocular surgery within the last 6 months
• history of treatment with photosensitising drugs
Interventions Intervention:
• lutein (Lutamax DUO; Pharmaselect, Vienna, Austria). The dosage in months 1
to 3 was 20 mg once daily, and in months 4 to 6 was 10 mg once daily
◦ 84 people randomised (84 eyes)
◦ unknown number people followed up (eyes unknown)
Comparator:
• placebo
◦ 42 people randomised (42 eyes)
◦ unknown number people followed up (eyes unknown)
Duration: 6 months
Similarity between intervention and comparator: unclear
Outcomes Primary: not known
Secondary: not known
Outcomes reported in paper:
• macular pigment optical density
• mean differential light threshold
• distance visual acuity (ETDRS chart)
• mean arterial pressure
• pulse rate
• intraocular pressure
From clinical trials.gov, but retrospectively registered
Primary Outcome Measures: Macular pigment optical density (MPOD) as measured
with optical reflectometry (time frame: 5 minutes; designated as safety issue: No)
Secondary Outcome Measures: visual acuity using ETDRS charts (time frame: 15 min-
utes; designated as safety issue: No)
Central visual field defects assessed with scanning laser scotometry (time frame: 30
minutes; designated as safety issue: No)
Changes in fundus appearance as documented with fundus photos (time Frame: 5 min-
utes; designated as safety issue: No)
Determination of an increased systemic antioxidative state in plasma and low density
lipoprotein and Ppasma lutein concentrations (time frame: 5 minutes; designated as
safety issue: No)
Follow-up: 1 month, 3 months, and 6 months
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LISA 2011 (Continued)
Eyes: Quote: “In each subject only one eye was chosen for inclusion. If both eyes were
eligible, one eye was selected randomly.”
Notes Source of funding: Quote: “Supported by Pharmaselect, Vienna, Austria”
Declaration of interest: All authors reported none
Date study conducted: November 2006 to May 2011 (from clinicaltrials.gov)
Trial registration number: NCT00879671 (registered retrospectively)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The randomization of lutein (Lutamax
DUO; Pharmaselect, Vienna, Austria) ver-
sus placebo was 2:1, resulting in a total of
84 patients in the lutein group and 42 pa-
tients in the placebo group.”
Allocation sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk No description of allocation concealment.
However, states ‘double masked’
Blinding of participants and personnel
(performance bias)
Visual acuity
Unclear risk “All subjects were asked to bring their study
medication to all visits, to allow compliance
testing by tablet counting.”
Nodescription of placebo. Potential for un-
masking as to intervention received
No specific information provided as to the
blinding of outcome assessors (grading of
fundus images, assessment of MPOD or
visual function)
Blinding of participants and personnel
(performance bias)
Progression AMD
Unclear risk “All subjects were asked to bring their study
medication to all visits, to allow compliance
testing by tablet counting.”
Nodescription of placebo. Potential for un-
masking as to intervention received
No specific information provided as to the
blinding of outcome assessors (grading of
fundus images, assessment of MPOD or
visual function)
Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk “All subjects were asked to bring their study
medication to all visits, to allow compliance
testing by tablet counting.”
Nodescription of placebo. Potential for un-
masking as to intervention received
No specific information provided as to the
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LISA 2011 (Continued)
blinding of outcome assessors (grading of
fundus images, assessment of MPOD or
visual function)
Blinding of outcome assessment (detection
bias)
Progression AMD
Unclear risk “All subjects were asked to bring their study
medication to all visits, to allow compliance
testing by tablet counting.”
Nodescription of placebo. Potential for un-
masking as to intervention received
No specific information provided as to the
blinding of outcome assessors (grading of
fundus images, assessment of MPOD or
visual function)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 10 people were not included in the analysis,
but not clear to which group these people
were randomised
In addition, 10/84 (11.9%) people in the
lutein group were lost to follow-up. In two
people, the withdrawal was due to serious
adverse events. One participant had a my-
ocardial infarction, and the other partici-
pant developed CNV in the study eye. 6/
42 (14.3%) people in the placebo group
were lost to follow-up. One person devel-
oped CNV, which was again classified as a
serious adverse event. In participants who
were lost to follow-up, the last observation
was carried forward
Selective reporting (reporting bias) Unclear risk Difficult to assess with the information
available.
Ma 2012
Methods Parallel group RCT
Method of allocation: not described
Masking: participant - yes; provider - yes; outcome - yes
Loss to follow-up: unclearly reported but could be 1/108
Participants Country: China
Number of people randomised: 108 (eyes unknown)
Number (%) of people followed up: 107 (99%) (eyes unknown)
Average age (range): 69 (unknown)
Percentage women: 58%
Ethnic group: unknown
Baseline visual acuity: 0.30 logMAR
Comorbidities affecting the eye: 23% early cataracts
Percentage current smokers: 6%
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Inclusion criteria:
• early AMD defined as the presence of soft drusen, presence of any retinal
pigmentary abnormalities in the absence of signs of late AMD, or both), according to
the AREDS classification system
Exclusion criteria
• late AMD or other macular or choroidal disorders (e.g. macular edema, macular
holes, central serous chorioretinopathy, or macular epiretinal membrane)
• demonstrated the presence of significant central lens opacities precluding fundus
autofluorescence
• had an implanted intraocular lens
• glaucoma
• unstable chronic illness
• history of intraocular inflammation
• ocular trauma
• laser treatment for retinal diseases
• retina-vitreous surgery
• photodynamic therapy
• currently taking medications affecting macular function (e.g., chloroquine or
oxazepam)
• consumed dietary supplements containing vitamins or carotenoids within the 6
months before enrolment
Interventions Intervention:
• lutein 10 mg or lutein 20 mg or lutein 10 mg and zeaxanthin 10 mg (3 groups)
(daily)
◦ 80 people randomised (eyes unknown)
◦ 79 (99%) people followed up (eyes unknown)
Comparator:
• placebo (daily)
◦ 27 people randomised (eyes unknown)
◦ 27 (100%) people followed up (eyes unknown)
Duration: 12 months
Similarity between intervention and comparator: unclear, placebo was not described
Outcomes From the published paper:
Primary:
• macular pigment optical density
Secondary:
• best-corrected visual acuity
• contrast sensitivity
• photorecovery time
• Amsler grid testing
From clinical trials.gov (registered retrospectively):
Primary Outcome Measures: MPOD and multifocal electroretinograms (time frame: 1
year)
Secondary Outcome Measures: risk of advanced AMD. (time frame: 1 year)
Follow-up: 24 weeks and 48 weeks
Eyes: unclear how many eyes included in study
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Notes Source of funding: Quote: “Supported by the National Natural Science Foundation of
China (grant no.: NSFC-30872113), Beijing, China.”
Declarationof interest:Quote: “The author(s) have noproprietary or commercial interest
in any materials discussed in this article.”
Date study conducted: September 2009 to April 2012
Trial registration number: NCT01048476 (registered retrospectively) and
NCT10528605 (registered retrospectively)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization sequence with
stratification by baseline macular pigment
optical density (MPOD) was computer
generated, using a permuted block design
with block size of 8.”
Allocation concealment (selection bias) Low risk Quote: “All participants, the study inves-
tigators, and data analysts were masked to
treatment assignment.”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Quote: “All participants, the study inves-
tigators, and data analysts were masked to
treatment assignment.”
Quote: “To protect the blinding, the differ-
ent capsules were indistinguishable by size,
weight, or color.”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Quote: “All participants, the study inves-
tigators, and data analysts were masked to
treatment assignment.”
Quote: “To protect the blinding, the differ-
ent capsules were indistinguishable by size,
weight, or color.”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Quote: “All participants, the study inves-
tigators, and data analysts were masked to
treatment assignment.”
Quote: “To protect the blinding, the differ-
ent capsules were indistinguishable by size,
weight, or color.”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Quote: “All participants, the study inves-
tigators, and data analysts were masked to
treatment assignment.”
Quote: “To protect the blinding, the differ-
ent capsules were indistinguishable by size,
73Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ma 2012 (Continued)
weight, or color.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: Only 1/108 partic-
ipants apparently discontinued treatment
and was excluded from the analysis. All
other participants were followed up
Selective reporting (reporting bias) High risk Judgement comment: Trial registered mid-
way through recruitment. Outcome “late
AMD” on trials register but not reported
because: “... the present study was not pow-
ered adequately to detect a reduction in late
AMD incidence”. Other differences noted
between publication and trials register en-
try - see above
Newsome 1988
Methods Parallel group RCT
Method of allocation: computer-generated table of random numbers
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 23 (10 treatment, 13 placebo)
Participants Country: USA
Number of people randomised: 174 (eyes unknown)
Number (%) of people followed up: 151 (87%) (258 eyes)
Average age (range): unknown (42 to 89 years)
Percentage women: 65%
Ethnic group: unknown
Baseline visual acuity: unknown
Comorbidities affecting the eye: unknown
Percentage current smokers: unknown
Inclusion criteria:
• macular degeneration: clinically visible drusen with varying degrees of pigmentary
change with visual acuity in 1 eye of 20/80 or better
Exclusion criteria:
• cataract reducing vision more than 1 line
• other known serious eye disease; diabetes mellitus
• other known systemic or metabolic disease or congenital condition, which might
interfere with results
Interventions Intervention:
• zinc sulfate 200 mg (daily) 1 x 100 mg twice daily
◦ 90 people randomised (eyes unknown)
◦ 80 (89%) people followed up (134 eyes)
Comparator:
• placebo
◦ 84 people randomised (eyes unknown)
◦ 71 (85%) people followed up (124 eyes)
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Newsome 1988 (Continued)
Duration: 1 to 2 years
Similarity between intervention and comparator: Quote: “Identical appearing tablets
containing lactose and fructose served as the placebo.” Analyses were also stratified
according to number of eyes per person
Outcomes Primary: not specified
Secondary: not specified
Outcomes reported in paper:
• Pinhole corrected visual acuity using ETDRS charts
• changes in visible pigment, drusen or atrophy from grading of macular
photographs
• adverse effects of zinc including copper deficiency anaemia
Follow-up: 6, 12, 18, and 24 months
Eyes: Some people had one eye enrolled in the study and some had two eyes: “To analyze
the results of two eyes of the same participant, the individual eye data were averaged and
that value was used.”
Notes Source of funding: Research Fund, Department of Veterinary Science, Utah State Uni-
versity, Logan; James L Shupe, DVM; Mary Katherine Peterson Foundation, Houston
Declaration of interest: unknown
Date study conducted: unknown
Trial registration number: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subjectswere randomly assigned [.
..] using a computer-generated table of ran-
dom numbers.”
Allocation concealment (selection bias) Low risk Quote: “Subjects were randomly assigned
to receive either zinc or placebo [...]. The
individual who recorded the zinc-treated
or placebo group assignment maintained
personal control over the randomization
sheet and participated in no other phases of
the study. This individual also handed the
study tablets to subjects. All other person-
nel were masked to the study.”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Quote: “All other personnel were masked
to the study.”
Quote: “Zinc sulfate was prepared as white
tablets containing 100 mg of United States
Pharmacopeia-graded material. Identical-
appearing tablets containing lactose and
fructose served as the placebo. All tablets
were bottled in identical containers.”
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Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Quote: “All other personnel were masked
to the study.”
Quote: “Zinc sulfate was prepared as white
tablets containing 100 mg of United States
Pharmacopeia-graded material. Identical-
appearing tablets containing lactose and
fructose served as the placebo. All tablets
were bottled in identical containers.”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Quote: “All visual acuities were determined
by one of twomasked observers throughout
the study”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Quote: “Two independent observers
masked as to patient identity,...”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “A total of 90 subjects [...] were randomised
to zinc and 84 subjects [...] to placebo. [.
.....]. A total of ten subjects were lost to
follow-up from the zinc-treated group and
13 subjects from the placebo group. [...]
This figure represents dropout rates of 11.
1% and 15.4% from the zinc-treated and
placebo groups, respectively.”
Reasons for loss to follow-up zinc/placebo
• Stopped taking pills 5/6
• Started taking zinc 1/2
• Gastrointestinal symptoms 1/0
• Died 2/1
• Poor compliance 0/1
• Developed diabetes mellitus 0/1
• Unavailable 1/2
Selective reporting (reporting bias) High risk “Other ocular functions assessed included
ocular vision and photostress recover tests
(These observations are being analysed and
will be reported later)”
Newsome 2008
Methods Parallel group RCT
Method of allocation: random allocation using a 50% likelihood scheme
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: total of 6; 3 in each group of 40 participants
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Newsome 2008 (Continued)
Participants Country: USA
Number of people randomised: 80 (eyes unknown)
Number (%) of people followed up: 74 (93%) (74 right and 72 left eyes)
Average age (range): 74 years (unknown)
Percentage women: 80%
Ethnic group: 81% white
Baseline visual acuity: unknown
Comorbidities affecting the eye: unknown
Percentage current smokers: unknown
Inclusion criteria:
• Presence of macular drusen with or without pigment changes
Exclusion criteria:
• Choroidal neovascular activity
• Any condition preventing view of the fundus
• Other conditions affecting eye: diabetes, eye surgery (except cataract). Chronic
open angle glaucoma with stable intraocular pressures and visual fields was allowed.
Both ZMCand placebo groups enrolled 40 participants, with best-corrected visual acuity
20/25 to 20/70, macular drusen, and pigment changes
Interventions Intervention:
• zinc-monocysteine 50 mg (daily 1 x 25 mg twice daily
◦ 40 people randomised (eyes unknown)
◦ 37 (100%) people followed up (37 right and 25 left eyes)
Comparator:
• placebo
◦ 40 people randomised (eyes unknown)
◦ 37 (100%) people followed up (37 right and 37 left eyes)
Duration: 6 months
Similarity between intervention and comparator: unknown
Outcomes Primary:
• change in acuity
• change in contrast sensitivity
• change in photorecovery time
Secondary: not specified
Follow-up: 6 months
Eyes: analysed right and left eyes separately
Notes Source of funding: “This study was supported in part by the Retinal Disease Research
Foundation, Inc. DN co-owns the U.S. patents on ZMC, licensed to Pipex Pharmaceu-
ticals.”
Declaration of interest: unknown
Date study conducted: unknown
Trial registration number: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
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Newsome 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “A total of 80 subjects (40 per
group) volunteered for the study and
were randomised using a 50% likelihood
scheme.”
Allocation concealment (selection bias) Low risk Quote: “An unmasked co-ordinator gave
subjects, upon enrolment, study materials
in numbered containers using the random-
ization scheme. This individual performed
no data collection.”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Quote: “Study materials were in tinted
pharmaceutical capsules that provided
an indistinguishable appearance between
ZMC and the plant cellulose placebo.”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Quote: “Study materials were in tinted
pharmaceutical capsules that provided
an indistinguishable appearance between
ZMC and the plant cellulose placebo.”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Quote: “Functional assessment....by
masked trained examiners...”
Quote: “Masked examiners determined
contrast sensitivity....”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Quote: “Functional assessment....by
masked trained examiners...”
Quote: “Masked examiners determined
contrast sensitivity....”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Thirty-seven [out of 40] in each
group competed all visits...”
Reasons for drop-out: 2 of placebo group
died from pre-existing medical conditions;
the rest of the dropouts (N = 4) were due
to gastrointestinal-related complaints
Selective reporting (reporting bias) Unclear risk Judgement comment: Difficult to assess
with the information available
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Stur 1996
Methods Parallel group RCT
Method of allocation: sponsor-prepared coded bottles
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 6 withdrawn due to adverse gastrointestinal effects (4 treatment, 2
control); 14 withdrawn when developed neovascularisation (9 treatment, 5 control); 14
lost to follow-up (6 treatment, 8 control)
Participants Country: Austria
Number of people randomised: 112 (112 eyes)
Number (%) of people followed up: 92 (82%) (92 eyes); 78 (70%) (78 eyes) included
the analyses because eyes that developed CNV were excluded
Average age (range): 71 years (50 to unknown)
Percentage women: 57%
Ethnic group: unknown
Baseline visual acuity: average 0.075 logMAR
Comorbidities affecting the eye: unknown
Percentage current smokers: 21%
Inclusion criteria:
• exudative AMD in 1 eye (defined as angiographic evidence of classic or occult
choroidal neovascularisation or RPE detachment) and early ARM with visual acuity
20/40 or better in other eye (early ARM: macular drusen with no angiographic
evidence of exudative lesion)
Exclusion criteria:
• dense senile cataract
• any other eye disease that could produce significant and permanent loss of visual
acuity during follow-up
• physical status that could prevent follow-up; history of serious systemic or
metabolic disease
Interventions Intervention:
• zinc sulfate 200 mg (daily) 1 tablet
◦ 56 people randomised (56 eyes)
◦ unknown number (%) people followed up but 37 (37 eyes) included in the
analyses, excluding eyes that developed CNV
Comparator:
• placebo 1 tablet
◦ people randomised (eyes unknown)
◦ unknown number (%) people followed up but 41 (41 eyes) included in the
analyses, excluding eyes that developed CNV
Duration: 24 months
Similarity between intervention and comparator: Intervention was lemon flavoured ef-
fervescent tablet made of citric acid containing saccharine and sorbitol and placebo was
as treatment, but without the zinc sulfate
Outcomes Primary: not specified
Secondary: not specified
Outcomes reported in paper:
• Best-corrected logMAR visual acuity measured using Bailey-Lovie chart
• contrast sensitivity
• incidence of choroidal neovascularisation
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Stur 1996 (Continued)
• progression of disease (Wisconsin Age-related Maculopathy Grading System)
• copper deficiency anaemia
Follow-up: 6, 12, 18, and 24 months
Eyes: one eye per person, CNV in one eye and not in the fellow eye. The fellow eye was
the “study eye.”
Notes A priori sample size estimate was 500 participants, but trial stopped early because interim
analysis showed no detectable trend
Funders: Astra, Linz, Austria; Austrian Foundation for the Propagation of Scientific
Research
Source of funding: “Supported in part by the Austrian Foundation for the Propagation
of Scientific Research (Ostetreichischer Fonds zur Forderung der xuissenschaftlichen
Forschung), Project 7215-MED.” and “The authors thank the staff at Astra GmbH,
Linz, Austria, for providing the coded doses of zinc sulfate and placebo.”
Declaration of interest: “Proprietary interest category: No”
Date study conducted: March 1990 to June 1992
Trial registration number: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “This was a double-masked, ran-
domised, placebo-controlled study con-
ducted at a single center. The randomiza-
tion between zinc and placebo was per-
formed in a ratio 1:1”
Judgement comment: No details provided
of method of sequence generation, how-
ever, since coding provided by sponsor, this
is unlikely to be a source of bias
Allocation concealment (selection bias) Low risk Quote: “Coded doses of zinc sulfate and
placebo were prepared by the sponsor (As-
tra, Linz, Austria). All doses were lemon-
flavored effervescent tablets made of cit-
ric acid that provided improved gastroin-
testinal absorption and contained saccha-
rine and sorbitol. Treatment group doses
contained an additional 200mg of zinc sul-
fate. (This preparation is identical to a zinc
sulfate preparation registered inAustria and
other European countries under the name
Solvezink; Astra,Wedel, Germany.) Tablets
were bottled in identical containers.”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Quote: “Coded doses of zinc sulfate and
placebo were prepared by the sponsor (As-
tra, Linz, Austria). All doses were lemon-
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Stur 1996 (Continued)
flavored effervescent tablets made of cit-
ric acid that provided improved gastroin-
testinal absorption and contained saccha-
rine and sorbitol. Treatment group doses
contained an additional 200mg of zinc sul-
fate. (This preparation is identical to a zinc
sulfate preparation registered inAustria and
other European countries under the name
Solvezink; Astra,Wedel, Germany.) Tablets
were bottled in identical containers.”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Quote: “Coded doses of zinc sulfate and
placebo were prepared by the sponsor (As-
tra, Linz, Austria). All doses were lemon-
flavored effervescent tablets made of cit-
ric acid that provided improved gastroin-
testinal absorption and contained saccha-
rine and sorbitol. Treatment group doses
contained an additional 200mg of zinc sul-
fate. (This preparation is identical to a zinc
sulfate preparation registered inAustria and
other European countries under the name
Solvezink; Astra,Wedel, Germany.) Tablets
were bottled in identical containers.”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Quote: “Coded doses of zinc sulfate and
placebo were prepared by the sponsor (As-
tra, Linz, Austria). All doses were lemon-
flavored effervescent tablets made of cit-
ric acid that provided improved gastroin-
testinal absorption and contained saccha-
rine and sorbitol. Treatment group doses
contained an additional 200mg of zinc sul-
fate. (This preparation is identical to a zinc
sulfate preparation registered inAustria and
other European countries under the name
Solvezink; Astra,Wedel, Germany.) Tablets
were bottled in identical containers.”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Quote: “Coded doses of zinc sulfate and
placebo were prepared by the sponsor (As-
tra, Linz, Austria). All doses were lemon-
flavored effervescent tablets made of cit-
ric acid that provided improved gastroin-
testinal absorption and contained saccha-
rine and sorbitol. Treatment group doses
contained an additional 200mg of zinc sul-
fate. (This preparation is identical to a zinc
sulfate preparation registered inAustria and
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other European countries under the name
Solvezink; Astra,Wedel, Germany.) Tablets
were bottled in identical containers.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “One hundred twelve patients were
enrolled between March 1, 1990 and June
30, 1992. Six patients (four in the treat-
ment group, two in the placebo group)
could not tolerate the medication because
of gastrointestinal side effects and had to
be withdrawn from the study. Fourteen pa-
tients did not return for the scheduled fol-
low-up visits or decided to withdraw from
the study because of personal reasons. The
withdrawal of these 14 patients was not
connected to any side effects of the study
medication. The rest of the recruited pa-
tients (92 patients) returned for all required
visits.”
Quote: “During the treatment period, a
CNV developed in the study eye in 14 pa-
tients (nine in the treatment group, five in
the placebo group). Ten of these patients
underwent laser treatment and were with-
drawn from the study.”
Selective reporting (reporting bias) Unclear risk Difficult to assess with the information
available
VECAT 2002
Methods Parallel group RCT
Method of allocation: coded bottles
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 11 participants excluded after randomisation
Participants Country: Australia
Number of people randomised: 1204 (eyes unknown) randomised, but 11 participants
excluded after randomisation, and reported 1193 (eyes unknown) randomised by group
Number of people followed up: 1179 (98%)
Average age (range): 66 years (55 to 80)
Percentage women: 56%
Ethnic group: unknown
Baseline visual acuity: 99% ≥ 40 letters on logMAR chart
Comorbidities affecting the eye: only 19% with AMD; 4%with diabetes; approximately
20% with lens opacity
Percentage current smokers: 2%
Inclusion criteria:
• lens and retina of at least 1 eye available for documentation
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VECAT 2002 (Continued)
Exclusion criteria:
• previous cataract surgery or advanced cataract in both eyes
• steroid or anticoagulation use
• serious disease
• regular use or sensitivity to vitamin E
Interventions Intervention:
• vitamin E 500 IU per day: natural vitamin E in soybean oil medium
◦ 595 people randomised (eyes unknown)
◦ 587 (99%) people followed up (eyes unknown)
Comparator:
• placebo of soybean oil medium
◦ 598 people randomised (eyes unknown)
◦ 592 (99%) people followed up (eyes unknown)
Duration: 4 years
Similarity between intervention and comparator: Quote: “Vitamin E and placebo cap-
sules were of identical appearance and taste.”
Outcomes Primary:
• development of early AMD
Secondary:
• progression of early AMD
• development of late AMD
• changes in visual acuity (the number of letters read on the logMAR chart)
• changes in visual function (VF14 score).
Follow-up: annual follow-up for 4 years
Eyes: Quote: “Participants were categorised by their worse eye.”
Notes Source of funding: “The VECAT study was funded in part by grants from the National
Health and Medical Research Council, Jack Brockhoff Foundation, the Eirene Lucas
Foundation, the Stoicesco Foundation, the Carleton Family Charitable Trust, Je Hope
Knell Trust Fund, Smith and Nephew, Australia, and Henkel Australia.”
Declaration of interest: no competing interests declared
Date study conducted: January 1995 to January 2000
Trial registration number: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants were then randomly
allocated to treatment group. This random
allocation was performed by using a “per-
muted blocks” allocation scheme.”
Allocation concealment (selection bias) Low risk Quote: “Study numbers were allocated se-
quentially by the study coordinator as par-
ticipants were enrolled in the study.”
Quote: “Bulk medications were dispensed
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VECAT 2002 (Continued)
into labelled jars by a person not involved
in the study. Vitamin E and placebo were
dispensed on different days to avoid con-
fusion. Identical containers were used. The
jars were packed in numerical order and
then dispensed by study personnel.”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Quote: “Vitamin E and placebo capsules
were of identical appearance and taste. Nei-
ther study staff nor examiners or partici-
pants were aware of the treatment alloca-
tion, although all knew that participants
would be randomly assigned to receive ei-
ther vitamin E or placebo.”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Quote: “Vitamin E and placebo capsules
were of identical appearance and taste. Nei-
ther study staff nor examiners or partici-
pants were aware of the treatment alloca-
tion, although all knew that participants
would be randomly assigned to receive ei-
ther vitamin E or placebo.”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Quote: “Vitamin E and placebo capsules
were of identical appearance and taste. Nei-
ther study staff nor examiners or partici-
pants were aware of the treatment alloca-
tion, although all knew that participants
would be randomly assigned to receive ei-
ther vitamin E or placebo.”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Quote: “Vitamin E and placebo capsules
were of identical appearance and taste. Nei-
ther study staff nor examiners or partici-
pants were aware of the treatment alloca-
tion, although all knew that participants
would be randomly assigned to receive ei-
ther vitamin E or placebo.”
Quote: “At the end of the study we re-
assessed the initial and final photographs
for any change with a “side by side” com-
parison in a masked and randomised fash-
ion.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: 78/595 (13%) par-
ticipants in vitamin E group and 72/598
(12%) of placebo group withdrew over the
course of the study. Reasons for withdrawal
reported in table form
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Selective reporting (reporting bias) High risk Judgement comment: For visual acuity,
trial report states that outcome was anal-
ysed but only reports that result was not
significant
Veterans LAST study 2004
Methods Parallel group RCT
Method of allocation: coded bottles
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 7 withdrew, 4 lost to follow-up, 3 died. Slightly lower % follow-
up in group 2 (lutein or antioxidant), 80% compared with other 2 groups (lutein alone
86%, placebo 87%)
Participants Country: USA
Number of people randomised: 90 (eyes unknown)
Number of people followed up: 76 (84%) (eyes unknown)
Average age (range): approximate 75 years
Percentage women: 4%
Ethnic group: unknown
Baseline visual acuity: average ranged from0.279 to 0.445 logMAR by eye and treatment
group
Comorbidities affecting the eye: unknown
Percentage current smokers: unknown
Inclusion criteria:
• atrophic AMD diagnosed by ophthalmoscopy
• at least one visual abnormality reduced contrast sensitivity, photo-stress glare
recovery deficit or deficit on Amsler grid
• clear ocular media
• free of any other ocular/systemic disease that could affect central or parafoveal
macular visual function.
Exclusion criteria:
• cataract or retinal surgery within 6 months
• photosensitising drugs
• taken lutein supplements within the previous 6 months
Interventions Intervention:
• lutein 10 mg non-esterified lutein (FloraGlo from Kemin Foods International,
Des Moines, Iowa)
◦ 29 people randomised (eyes unknown)
◦ 25 (86%) people followed up (eyes unknown)
• lutein plus additional antioxidants and nutrients (OcuPower, Nutraceutical
Sciences Institute (NSI), Boynton Beach, Florida)
◦ 30 people randomised (eyes unknown)
◦ 24 (80%) people followed up (eyes unknown)
Comparator:
• placebo, maltodextrin
◦ 31 people randomised (eyes unknown)
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Veterans LAST study 2004 (Continued)
◦ 27 (87%) people followed up (eyes unknown)
Duration: 12 months
Ocupower had a range of nutrients including lutein, vitamin A, beta-carotene, vitamins
C, D3, E, B1, B2, B3, B5, B6, B12, folic acid, biotin, calcium, magnesium, iodine,
zinc copper, manganese, selenium, chromium, molybdenum, lycopene, bilberry extract,
alpha lipoic acid, N-acetyl cysteine, quercetin, rutin, citrus bioflavonoids, plant enzymes,
black pepper extract, malic acid, taurine, L-glycine, L-glutathione, boron
Similarity between intervention and comparator: “Subjects were provided with opaque
capsules of identical appearance in numbered containers taken as three capsules twice
per day with food”
Outcomes Primary:
• macular pigment optical density
Secondary:
• not specified
The following clinical measurements were made:
• lens opacity
• retinal images
• Macular Pigment Optical Density (MPOD)
• visual acuity (Snellen) distance and near
• glare testing
• glare recovery
• contrast sensitivity
• VFQ-14 (activities of daily living, night driving, glare recovery symptoms)
• Amsler grid
• self reported vision
It was difficult to extract data on outcomes of relevance to this review: i.e. visual acuity
and progression of AMD
Follow-up: 12 month
Eyes: reported right and left eyes separately
Notes Source of funding: “This material is based on work supported by the DVA Medical
Center, North Chicago, Illinois and the Department of Veteran’s Affairs, Hines, Illinois.
” and “Grant sponsors are Kemin Foods, Inc. (Des Moines, Iowa); L/itacost.com, with
its subsidiary Nutraceutical Sciences Institute (NSI: Boynton Beach, Florida); and Great
Smokies Diagnostic Laboratory (Asheville, North Carolina). FloraGloB non-esterified
lutein is a product of Kemin Foods. The FloraGloB lutein antioxidant supplement
evaluated is known as OcuPower@, U.S. Patent #6,103,756-Wayne Gorsek, inventor;
L/itacost.com assignee.”
Declaration of interest: unknown
Date study conducted: August 1999 to May 2001
Trial registration number: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
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Veterans LAST study 2004 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “... were randomly assigned to one
of three capsule groups by consecutive ran-
dom card-3-choice, allocation sequence”
Allocation concealment (selection bias) Low risk Quote: “Nutraceutical Sciences Institute
prepared the lutein capsules, the L/A cap-
sules, and the P capsules and also main-
tained and concealed the blinding and
four-digit allocation codes.”
“All personnel at the DVA Medical Cen-
ter were unaware of the masked allocation
codes during the 12-month clinical study.”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Quote: “All personnel at the DVAMedical
Center were unaware of the masked allo-
cation codes during the 12-month clinical
study.”
“Subjects were provided with opaque cap-
sules of identical appearance in numbered
containers taken as three capsules twice per
day with food.”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Quote: “All personnel at the DVAMedical
Center were unaware of the masked allo-
cation codes during the 12-month clinical
study.”
Quote: “Subjects were provided with
opaque capsules of identical appearance in
numbered containers taken as three cap-
sules twice per day with food.”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Quote: “All personnel at the DVAMedical
Center were unaware of the masked allo-
cation codes during the 12-month clinical
study.”
Quote: “Subjects were provided with
opaque capsules of identical appearance in
numbered containers taken as three cap-
sules twice per day with food.”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Quote: “All personnel at the DVAMedical
Cetnter were unaware of the masked allo-
cation codes during the 12-month clinical
study.”
Quote: “Subjects were provided with
opaque capsules of identical appearance in
numbered containers taken as three cap-
sules twice per day with food.”
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Veterans LAST study 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Judgement comment: Loss to follow-up
14/90:
Lutein 10 mg group N = 29
• 1 person lost to follow-up
• 1 person died
• 2 other withdrawals
Lutein 10 mg and antioxidant group N =
30
• 2 persons lost to follow-up
• 4 other withdrawals
Placebo group N = 31
• 1 persons lost to follow-up
• 1 person died
• 1 other withdrawals
Members of placebo group removed from
analysis due to the fact that they had taken
lutein
Selective reporting (reporting bias) Unclear risk Judgement comment: Difficult to assess
with the information available
Wang 2004
Methods Parallel group RCT
Method of allocation: unknown
Masking: participant - unknown; provider - unknown; outcome - unknown
Losses to follow-up: unknown
Participants Country: China
Number of people randomised: 400 (400 eyes)
Number of people followed up: unknown
Average age (range): 65 years (52 to 76)
Percentage women: 53%
Ethnic group: unknown
Baseline visual acuity: unknown
Comorbidities affecting the eye: unknown
Percentage current smokers: unknown
Interventions Intervention:
• zinc oxide 80 mg daily, vitamin C, vitamin E
◦ unknown number people randomised (eyes unknown)
◦ unknown number (%) people followed up (eyes unknown)
Comparator:
• placebo
◦ unknown number people randomised (eyes unknown)
◦ unknown number (%) people followed up (eyes unknown)
Duration: 24 to 32 months
Similarity between intervention and comparator: unknown
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Wang 2004 (Continued)
Outcomes Primary:
• not specified
Secondary:
• not specified
Outcomes:
• visual acuity
• early and late AMD
Follow-up: every 6 months for 24 to 32 months
Eyes: one eye per person, worse eye was selected
Notes Limited information available on this trial. AMD participants were stratified into early
and late-stage disease
Source of funding: unknown
Declaration of interest: unknown
Date study conducted: unknown
Trial registration number: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
Visual acuity
Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
Progression AMD
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
Progression AMD
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear
Selective reporting (reporting bias) Unclear risk Visual acuity was measured but not re-
ported, possibly because of non-significant
results
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AMD: age-related macular degeneration
AREDS: Age-Related Eye Disease Study
ARM: Age-related maculopathy
CNV: Choroidal neovascularisation
ERG: electroretinogram
ETDRS: Early Treatment Diabetic Retinopathy Study
GA: Geographic atrophy
LOCF: last observation carried forward
logMAR: logarithm of the minimal angle of resolution
mfERG: multifocal electroretinogram
MPOD: macular pigment optical density
NEI: National Eye Institute
RCT: randomised controlled trial
RDA: recommended dietary allowance
RPE: retinal pigment epithelium
SD: standard deviation
VFQ: Visual function questionnaire
ZMC: zinc-monocysteine
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akuffo 2015 No placebo or untreated group in the study
Anonymous 2015 Review
Bahrami 2006 Not AMD
Barakat 2006 Not antioxidant vitamin
Benzie 2006 Bioavailability study
Bone 2007 Bioavailability study
Cangemi 2007 No control group
Christen 2007 RCT in healthy population group. Included in Cochrane review on prevention of AMDwith antioxidant
supplements
Connolly 2011 No AMD outcomes
CREST 2014 Lutein and zeaxanthin compared to placebo with the aim of enhancing vision in healthy people. Some
of the participants had AMD but they were all given supplementation i.e. no control group
Cumurcu 2006 Not an RCT
Falsini 2010 Trial of saffron
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(Continued)
Franciose 2006 Bioavailability study
Goodrow 2006 Bioavailability study
ISRCTN35481392 Participants had no ocular pathology
www.controlled-trials.com/ISRCTN35481392/ISRCTN35481392
ISRCTN57556290 No comparator group
www.biomedcentral.com/1471-2415/7/3
ISRCTN81595685 Comparison of two active formulations
Kamburoglu 2006 Not an RCT, not antioxidant
Khachik 2006 Bioavailability study
Kolber 2013 Review
Kopsell 2006 Bioavailability study
Landrum 2012 Pilot study of effects of lutein supplementation on serum and macular pigment
Lim 2006 Not antioxidant
LUNA 2007 Bioavailability study
LUTEGA 2013 Antioxidants combined with omega-3 fatty acids
LUXEA 2006 only MPOD measured; no clinical outcomes
Meagher 2013 Conference abstract reporting MPOD only
Moeller 2006 Not an RCT
NCT00006202 Dose ranging study for lutein supplementation. No control group
NCT00121589 Phase I study only. Looking at changes in plasma levels and macular pigment density only
NCT00563979 Active comparator (omega-3)
NCT00564902 Active comparator (lutein)
NCT00718653 Effect on macular pigments only, not on AMD
NCT00800995 Not antioxidant vitamin or mineral (superoxide dismutase)
NCT00893724 Antioxidants combined with inosine
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(Continued)
NCT02264938 No control group
Nolan 2006 Not a RCT
Nolan 2007 Not a RCT
Nolan 2012 Effect on macular pigments in healthy people only, not on AMD
Nussenblatt 2006 Not AMD
Owsley 2006 Not antioxidant
PHS II 2012 RCT in healthy population group. Will be included in Cochrane Review on prevention of AMD with
antioxidant supplements
Rosenthal 2006 Small dose ranging study. Data on vision only collected for nine months and not possible to extract from
report
Sabour-Pickett 2014 No control group
Sasamoto 2011 Not an RCT
Scalinci 2002 Antioxidants combined with omega-3
Scorolli 2002 Antioxidants combined with PDT
Souied 2013 Not an antioxidant supplement (omega-3)
Told 2014 Small study of physiological effects in healthy volunteers
Told 2015 Small study of physiological effects in healthy volunteers
Vannas 1958 Allocation concealment inadequate
Vidal 2011 RCT in healthy population group. Will be included in Cochrane review on prevention of AMD with
antioxidant supplements
Wang 2007 Bioavailability study
Wenzel 2006 Bioavailability study
Wolf-Schnurrbusch 2015 Antioxidant compared to antioxidant plus omega-3
Wong 2010 Phase II open-label study in 10 participants only
Zhao 2006 Bioavailability study
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AMD: age-related macular degeneration
MPOD: macular pigment optical density
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT01694680
Trial name or title Intervention trial in early age-related macular degeneration
Methods Parallel group RCT
Participants N = 120
Interventions Dietary Supplement: Lutein-enriched-egg beverage (NWT-02)
Dietary Supplement: Placebo
Outcomes from clinicaltrials.gov
“Primary Outcome Measures: Visual function (time frame: 12 months; designated as safety issue: No)
Secondary Outcome Measures: Carotenoid levels (time frame: 12 months; designated as safety issue: No);
Levels of lutein and Zeaxanthin”
Starting date October 2012 to April 2016
Contact information EJ Johnson PhD Jean Mayer USDA Human Nutrition research Centyer on Aging (HNRCA), Boston
Notes
NCT02625376
Trial name or title Resveratrol for exudative age-related macular degeneration
Methods Parallel group RCT
Participants N = 489
Interventions Dietary Supplement: Resvega
Dietary Supplement: Trans-Resveratrol
Dietary Supplement: placebo
Outcomes from clinical trials.gov
“Primary Outcome Measures: Comparaison of incidence of choroidal neovascularization between resveratrol
group and placebo group at 24 months (time frame: 24 months; designated as safety issue: Yes) What is the
influence of the daily intake of 500 mg of resveratrol on the incidence of neovascularization of the second
eye?
Secondary Outcome Measures: Comparaison of incidence of choroidal neovascularization between Resvega
group and placebo group at 24 months (time frame: 24 months; designated as safety issue: Yes) What is the
influence of the daily intake resvega on the incidence of neovascularization of the second eye?”
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NCT02625376 (Continued)
Starting date August 2015 to August 2019
Contact information Nicolas LEVEZIEL, MD, Ph Dpt of Ophthalmology, University Hospital of Poitiers, France
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Antioxidant multivitamin and mineral supplement versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Progression to late AMD
(neovascular AMD or
geographic atrophy)
3 2445 Odds Ratio (Fixed, 95% CI) 0.72 [0.58, 0.90]
2 Progression to neovascular AMD 1 Odds Ratio (Fixed, 95% CI) Totals not selected
3 Progression to geographic
atrophy
1 Odds Ratio (Fixed, 95% CI) Totals not selected
4 Progression to visual loss (loss of
3 or more lines on logMAR
chart)
1 Odds Ratio (Fixed, 95% CI) Totals not selected
5 Mean visual acuity 5 595 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.03, 0.07]
5.1 Mean visual acuity at end
of study
1 59 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.13, 0.21]
5.2 Change in visual acuity 4 536 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.03, 0.07]
6 Quality of life 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Lutein and/or zeaxanthin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Progression to late AMD
(neovascular AMD and/or
geographic atrophy
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Progression to neovascular AMD 1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
3 Progression to geographic
atrophy
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
4 Progression to visual loss (loss of
3 or more lines on logMAR
chart)
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Distance visual acuity: mean 3 231 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.05, 0.05]
5.1 Mean visual acuity at end
of study
1 72 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.06, 0.06]
5.2 Change in visual acuity 2 159 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.09, 0.08]
6 Visual Function Quality (VFQ) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Comparison 3. Vitamin E versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Progression to late AMD
(neovascular AMD and/or
geographic atrophy
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Progression to visual loss (loss of
3 or more lines on logMAR
chart)
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 4. Zinc versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Progression to late AMD
(neovascular AMD or
geographic atrophy)
3 3790 Odds Ratio (Fixed, 95% CI) 0.83 [0.70, 0.98]
2 Progression to neovascular AMD 1 Odds Ratio (Fixed, 95% CI) Totals not selected
3 Progression to geographic
atrophy
1 Odds Ratio (Fixed, 95% CI) Totals not selected
4 Progression to visual loss (loss of
3 or more lines on logMAR
chart)
2 3791 Odds Ratio (Fixed, 95% CI) 0.87 [0.75, 1.00]
5 Distance visual acuity: mean 2 155 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.05, 0.04]
5.1 Mean visual acuity at end
of study
1 78 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.04, 0.08]
5.2 Change in visual acuity 1 77 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.14, 0.02]
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Analysis 1.1. Comparison 1 Antioxidant multivitamin and mineral supplement versus placebo, Outcome 1
Progression to late AMD (neovascular AMD or geographic atrophy).
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 1 Antioxidant multivitamin and mineral supplement versus placebo
Outcome: 1 Progression to late AMD (neovascular AMD or geographic atrophy)
Study or subgroup Multivitamin Placebo log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS 2001 (1) 888 903 -0.3857 (0.124423) 78.2 % 0.68 [ 0.53, 0.87 ]
CARMA 2013 (2) 252 257 -0.17435 (0.255778) 18.5 % 0.84 [ 0.51, 1.39 ]
CARMIS 2011 (3) 103 42 0.3164 (0.603858) 3.3 % 1.37 [ 0.42, 4.48 ]
Total (95% CI) 1243 1202 100.0 % 0.72 [ 0.58, 0.90 ]
Heterogeneity: Chi2 = 1.71, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours multivitamin Favours placebo
(1) By person (event in at least one eye): progression to advanced AMD over average 6.3 years follow-up
(2) Follow-up: 12 months
(3) Follow-up: 24 months
Analysis 1.2. Comparison 1 Antioxidant multivitamin and mineral supplement versus placebo, Outcome 2
Progression to neovascular AMD.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 1 Antioxidant multivitamin and mineral supplement versus placebo
Outcome: 2 Progression to neovascular AMD
Study or subgroup Multivitamin Placebo log [Odds Ratio] Odds Ratio Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS 2001 610 596 -0.478 (0.143419) 0.62 [ 0.47, 0.82 ]
0.5 0.7 1 1.5 2
Favours multivitamin Favours placebo
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Analysis 1.3. Comparison 1 Antioxidant multivitamin and mineral supplement versus placebo, Outcome 3
Progression to geographic atrophy.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 1 Antioxidant multivitamin and mineral supplement versus placebo
Outcome: 3 Progression to geographic atrophy
Study or subgroup Multivitamin Placebo log [Odds Ratio] Odds Ratio Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS 2001 610 596 -0.2877 (0.196819) 0.75 [ 0.51, 1.10 ]
0.5 0.7 1 1.5 2
Favours multivitamin Favours placebo
Analysis 1.4. Comparison 1 Antioxidant multivitamin and mineral supplement versus placebo, Outcome 4
Progression to visual loss (loss of 3 or more lines on logMAR chart).
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 1 Antioxidant multivitamin and mineral supplement versus placebo
Outcome: 4 Progression to visual loss (loss of 3 or more lines on logMAR chart)
Study or subgroup Multivitamin Placebo log [Odds Ratio] Odds Ratio Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS 2001 (1) 888 903 -0.2614 (0.111512) 0.77 [ 0.62, 0.96 ]
0.5 0.7 1 1.5 2
Favours multivitamin Favours placebo
(1) By person (event in at least one eye): progression to advanced AMD over average 6.3 years follow-up
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Analysis 1.5. Comparison 1 Antioxidant multivitamin and mineral supplement versus placebo, Outcome 5
Mean visual acuity.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 1 Antioxidant multivitamin and mineral supplement versus placebo
Outcome: 5 Mean visual acuity
Study or subgroup Multivitamin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[logMAR]N Mean(SD)[logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean visual acuity at end of study
AMDSG 1996 (1) 35 0.33 (0.41) 24 0.29 (0.24) 7.7 % 0.04 [ -0.13, 0.21 ]
Subtotal (95% CI) 35 24 7.7 % 0.04 [ -0.13, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
2 Change in visual acuity
Bartlett 2007 (2) 20 0.01 (0.07) 10 -0.02 (0.07) 75.8 % 0.03 [ -0.02, 0.08 ]
CARMA 2013 172 -0.1 (7) 173 -0.3 (7.7) 0.1 % 0.20 [ -1.35, 1.75 ]
CARMIS 2011 (3) 84 -0.121 (0.4562) 26 0.04 (0.302) 9.3 % -0.16 [ -0.31, -0.01 ]
Veterans LAST study 2004 (4) 24 -0.03 (0.2131) 27 -0.14 (0.4045) 7.0 % 0.11 [ -0.06, 0.28 ]
Subtotal (95% CI) 300 236 92.3 % 0.02 [ -0.03, 0.07 ]
Heterogeneity: Chi2 = 6.43, df = 3 (P = 0.09); I2 =53%
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 335 260 100.0 % 0.02 [ -0.03, 0.07 ]
Heterogeneity: Chi2 = 6.49, df = 4 (P = 0.17); I2 =38%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.80), I2 =0.0%
-1 -0.5 0 0.5 1
Favours placebo Favours multivitamin
(1) Right eye: LogMAR score (converted from Snellen decimal acuity) at 18 months
(2) Study eye: Change in logMAR score (EDTRS chart) over 9 months
(3) Study eye: 12 months
(4) Right eye: Change in logMAR score (converted from Snellen decimal acuity) over 12 months
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Analysis 1.6. Comparison 1 Antioxidant multivitamin and mineral supplement versus placebo, Outcome 6
Quality of life.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 1 Antioxidant multivitamin and mineral supplement versus placebo
Outcome: 6 Quality of life
Study or subgroup Multivitamin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
CARMIS 2011 (1) 84 3.6 (14.2848) 26 -8.7 (19.4103) 12.30 [ 4.24, 20.36 ]
-50 -25 0 25 50
Favours placebo Favours multivitamin
(1) NEI-VFQ at 24 months
Analysis 2.1. Comparison 2 Lutein and/or zeaxanthin versus placebo, Outcome 1 Progression to late AMD
(neovascular AMD and/or geographic atrophy.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Lutein and/or zeaxanthin versus placebo
Outcome: 1 Progression to late AMD (neovascular AMD and/or geographic atrophy
Study or subgroup Lutein/zeaxanthin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
AREDS2 2013 (1) 940/3451 1000/3440 0.94 [ 0.87, 1.01 ]
0.5 0.7 1 1.5 2
Favours lutein/zeaxanthin Favours placebo
(1) Everyone took AREDS formula
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Analysis 2.2. Comparison 2 Lutein and/or zeaxanthin versus placebo, Outcome 2 Progression to
neovascular AMD.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Lutein and/or zeaxanthin versus placebo
Outcome: 2 Progression to neovascular AMD
Study or subgroup Lutein/zeaxanthin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
AREDS2 2013 607/3451 655/3440 0.92 [ 0.84, 1.02 ]
0.5 0.7 1 1.5 2
Favours lutein/zeaxanthin Favours placebo
Analysis 2.3. Comparison 2 Lutein and/or zeaxanthin versus placebo, Outcome 3 Progression to geographic
atrophy.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Lutein and/or zeaxanthin versus placebo
Outcome: 3 Progression to geographic atrophy
Study or subgroup Lutein/zeaxanthin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
AREDS2 2013 367/3451 398/3440 0.92 [ 0.80, 1.05 ]
0.5 0.7 1 1.5 2
Favours lutein/zeaxanthin Favours placebo
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Analysis 2.4. Comparison 2 Lutein and/or zeaxanthin versus placebo, Outcome 4 Progression to visual loss
(loss of 3 or more lines on logMAR chart).
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Lutein and/or zeaxanthin versus placebo
Outcome: 4 Progression to visual loss (loss of 3 or more lines on logMAR chart)
Study or subgroup Lutein/zeaxanthin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
AREDS2 2013 (1) 1015/3332 1034/3324 0.98 [ 0.91, 1.05 ]
0.5 0.7 1 1.5 2
Favours lutein/zeaxanthin Favours placebo
(1) Everyone took AREDS formula
Analysis 2.5. Comparison 2 Lutein and/or zeaxanthin versus placebo, Outcome 5 Distance visual acuity:
mean.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Lutein and/or zeaxanthin versus placebo
Outcome: 5 Distance visual acuity: mean
Study or subgroup Lutein/zeaxanthin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[logMAR]N Mean(SD)[logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean visual acuity at end of study
CLEAR 2013 (1) 36 0.09 (0.14) 36 0.09 (0.13) 64.0 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 36 36 64.0 % 0.0 [ -0.06, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Change in visual acuity
Ma 2012 (2) 80 -0.02 (0.1817) 27 0 (0.2275) 27.9 % -0.02 [ -0.11, 0.07 ]
Veterans LAST study 2004 (3) 25 -0.1 (0.218) 27 -0.14 (0.4045) 8.2 % 0.04 [ -0.13, 0.21 ]
Subtotal (95% CI) 105 54 36.0 % -0.01 [ -0.09, 0.08 ]
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
-0.2 -0.1 0 0.1 0.2
Favours lutein/zeaxanthin Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Lutein/zeaxanthin Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD)[logMAR]N Mean(SD)[logMAR] IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 141 90 100.0 % 0.00 [ -0.05, 0.05 ]
Heterogeneity: Chi2 = 0.36, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.90), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours lutein/zeaxanthin Favours placebo
(1) Study eye: 12 months
(2) Unclear eyes/people: 12 months
(3) Right eye: 12 months
Analysis 2.6. Comparison 2 Lutein and/or zeaxanthin versus placebo, Outcome 6 Visual Function Quality
(VFQ).
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Lutein and/or zeaxanthin versus placebo
Outcome: 6 Visual Function Quality (VFQ)
Study or subgroup Lutein/zeaxanthin Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[score] N Mean(SD)[score] IV,Fixed,95% CI IV,Fixed,95% CI
Ma 2012 (1) 80 78.79 (13.899) 28 77.31 (17.05) 1.48 [ -5.53, 8.49 ]
-50 -25 0 25 50
Favours placebo Favours lutein/zeaxanthin
(1) 24 months
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Analysis 3.1. Comparison 3 Vitamin E versus placebo, Outcome 1 Progression to late AMD (neovascular
AMD and/or geographic atrophy.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 3 Vitamin E versus placebo
Outcome: 1 Progression to late AMD (neovascular AMD and/or geographic atrophy
Study or subgroup Vitamin E Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
VECAT 2002 4/494 3/504 1.36 [ 0.31, 6.05 ]
0.5 0.7 1 1.5 2
Favours vitamin E Favours placebo
Analysis 3.2. Comparison 3 Vitamin E versus placebo, Outcome 2 Progression to visual loss (loss of 3 or
more lines on logMAR chart).
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 3 Vitamin E versus placebo
Outcome: 2 Progression to visual loss (loss of 3 or more lines on logMAR chart)
Study or subgroup Vitamin E Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
VECAT 2002 (1) 59/587 57/592 1.04 [ 0.74, 1.47 ]
0.5 0.7 1 1.5 2
Favours vitamin E Favours placebo
(1) Loss of 2 lines (9 letters).
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Analysis 4.1. Comparison 4 Zinc versus placebo, Outcome 1 Progression to late AMD (neovascular AMD or
geographic atrophy).
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 4 Zinc versus placebo
Outcome: 1 Progression to late AMD (neovascular AMD or geographic atrophy)
Study or subgroup Zinc Placebo log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS 2001 (1) 1792 1848 -0.1985 (0.086422) 97.2 % 0.82 [ 0.69, 0.97 ]
Holz 1993 (2) 28 30 -0.6931 (0.922) 0.9 % 0.50 [ 0.08, 3.05 ]
Stur 1996 (3) 46 46 0.688135 (0.603204) 2.0 % 1.99 [ 0.61, 6.49 ]
Total (95% CI) 1866 1924 100.0 % 0.83 [ 0.70, 0.98 ]
Heterogeneity: Chi2 = 2.42, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours zinc Favours placebo
(1) By person (event in at least one eye): progression to advanced AMD over average 6.3 years follow-up
(2) By person: ’new exudative or dry macular lesions’ over 12 to 24 months
(3) Study eye: incidence of exudative AMD over 24 months
Analysis 4.2. Comparison 4 Zinc versus placebo, Outcome 2 Progression to neovascular AMD.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 4 Zinc versus placebo
Outcome: 2 Progression to neovascular AMD
Study or subgroup Zinc Placebo log [Odds Ratio] Odds Ratio Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS 2001 (1) 1209 1233 -0.2744 (0.101849) 0.76 [ 0.62, 0.93 ]
0.5 0.7 1 1.5 2
Favours zinc Favours placebo
(1) By person (event in at least one eye): progression to advanced AMD over average 6.3 years follow-up
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Analysis 4.3. Comparison 4 Zinc versus placebo, Outcome 3 Progression to geographic atrophy.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 4 Zinc versus placebo
Outcome: 3 Progression to geographic atrophy
Study or subgroup Zinc Placebo log [Odds Ratio] Odds Ratio Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS 2001 (1) 1209 1233 -0.1744 (0.139467) 0.84 [ 0.64, 1.10 ]
0.5 0.7 1 1.5 2
Favours zinc Favours placebo
(1) By person (event in at least one eye): progression to advanced AMD over average 6.3 years follow-up
Analysis 4.4. Comparison 4 Zinc versus placebo, Outcome 4 Progression to visual loss (loss of 3 or more
lines on logMAR chart).
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 4 Zinc versus placebo
Outcome: 4 Progression to visual loss (loss of 3 or more lines on logMAR chart)
Study or subgroup Zinc Placebo log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS 2001 (1) 1792 1848 -0.1278 (0.074246) 98.2 % 0.88 [ 0.76, 1.02 ]
Newsome 1988 (2) 80 71 -0.82098 (0.544933) 1.8 % 0.44 [ 0.15, 1.28 ]
Total (95% CI) 1872 1919 100.0 % 0.87 [ 0.75, 1.00 ]
Heterogeneity: Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours zinc Favours placebo
(1) By person (event in at least one eye): ETDRS chart over an average of 6.3 years
(2) Study eye: ETDRS chart over 24 months
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Analysis 4.5. Comparison 4 Zinc versus placebo, Outcome 5 Distance visual acuity: mean.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 4 Zinc versus placebo
Outcome: 5 Distance visual acuity: mean
Study or subgroup Zinc Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean visual acuity at end of study
Stur 1996 (1) 37 0.046 (0.12) 41 0.03 (0.14) 66.0 % 0.02 [ -0.04, 0.08 ]
Subtotal (95% CI) 37 41 66.0 % 0.02 [ -0.04, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
2 Change in visual acuity
Newsome 1988 (2) 40 0.082 (0.124) 37 0.14 (0.219) 34.0 % -0.06 [ -0.14, 0.02 ]
Subtotal (95% CI) 40 37 34.0 % -0.06 [ -0.14, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
Total (95% CI) 77 78 100.0 % -0.01 [ -0.05, 0.04 ]
Heterogeneity: Chi2 = 2.45, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 2.45, df = 1 (P = 0.12), I2 =59%
-100 -50 0 50 100
Favours placebo Favours zinc
(1) Study eye: LogMAR score (Bailey-Lovie chart) at 24 months
(2) Study eye: logMAR score calculated from change in no. of letters (EDTRS) 19 to 24 months
A D D I T I O N A L T A B L E S
Table 1. Multivitamin supplements
Study AMDSG
1996
AREDS
2001
Berrow
2013
Bartlett
2007
CARMA
2013
CARMIS
2011
Kaiser
1995
Veterans
LAST
study
2004
Wang
2004
Brand
name
of supple-
ment if re-
ported
Ocu-
Guard
(Twin
Lab Inc,
Ronkonkoma,
NY)
- Ocu-
vite Duo
(Bausch
and
Lomb,
Berlin)
- Ocuvite
(Bausch
and
Lomb,
Berlin)
- Visaline
(Novopharma
Cham,
Switzer-
land).
OcuPower
(Nu-
traceutical
Sciences
Insti-
tute (NSI)
-
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Table 1. Multivitamin supplements (Continued)
, Boyn-
tonBeach,
Florida
FloraGlo
(Kemin
Foods In-
terna-
tional,
Des
Moines,
Iowa)
Vitamin A - - - retinol 750
mg
- - - 2500 IU -
Vitamin C 750 mg 500 mg 150 mg 250 mg 150 mg 180 mg 100 mg 1500 mg
vitamin C
(as calcium
ascorbate)
dose not
specified
Vitamin E 200 IU 400 IU 15 mg 34 mg 15 mg 30 mg 10 mg 500
IU natural
vitamin
E (d-
alpha toco-
pherol suc-
cinate)
dose not
specified
Beta-
carotene
20,000 IU 15 mg - - - - 10 mg 15,000 IU
natural
beta
carotene
(Be-
tatenem)
-
Lutein - - 12 mg 6 mg 12 mg 10 mg - 10 mg -
Zeaxan-
thin
- - 0.6 mg - 0.6 mg 1 mg plus
astaxan-
thin 4 mg
- - -
Zinc 12.5 mg as
zinc picoli-
nate
80 mg as
zinc oxide
with
cupric ox-
ide 2 mg
25
mg as zinc
oxide with
cupric ox-
ide 0.4 mg
10mgwith
copper 0.5
mg
20 mg as
zinc oxide
with cop-
per glu-
conate 0.4
mg
zinc 22.5
mg
copper 1
mg
- 25 mg as
zinc L-me-
thionine-
L-OptiZ-
incB
1 mg cop-
per
-
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Table 1. Multivitamin supplements (Continued)
Selenium 50 µg - - - - - - 200 µg -
Other in-
gredients
citrus
bioflavonoid
complex
125 mg
quercitin
(bioflavonoid)
50 mg
bilberry
extract
(bioflavonoid)
5 mg
rutin
(bioflavonoid)
50 mg
taurine
100 mg
N-
acetyl cys-
teine 100
mg
L-glu-
tathione 5
mg
vitamin B2
25 mg
chromium
100 µg
- omega-3
fatty acids:
EPA 240
mg and
DHA 840
mg
- - - 1.5
mg buphe-
nine HCl
400 IU vi-
tamin D3
50mg vita-
min B1
10mg vita-
min B2
70mg vita-
min B3
50mg vita-
min B
550 mg vi-
tamin B6
500 µg vi-
tamin B12
800 µg
folic acid
300 µg bi-
otin
500 mg
calcium
300
mgmagne-
sium
75 µg io-
dine
2 mg man-
ganese
200 µg
chromium
75
µg molyb-
denum
600 µg ly-
copene
160 mg
bilberry
ex-
tract (stan-
dardized to
25% an-
thocyano-
sides)
-
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Table 1. Multivitamin supplements (Continued)
150 mg al-
pha lipoic
acid
200 mg N-
acetyl cys-
teine
100 mg
quercetin
100 mg
rutin
250 mg
citrus
bioflavonoids
50 mg
plant
enzymes
5 mg black
pep-
per extract
(Bioper-
ineB)
325 mg
malic acid
900 mg
taurine
100 mg L-
glycine
10 mg L-
glu-
tathione
2 mg
boron
Table 2. Characteristics of included trials
Study Type of
AMD
Treatment
(dose/day)
Treatment
duration
Follow-up Data on
eyes or peo-
ple
Visual acu-
ity
Progression
AMD
Notes
AMDSG
1996
Early AMD Ocuguard:
Beta-
carotene 20,
000 IU
Vitamin E
200 IU
Vitamin C
750 mg
18 months 18 months Right and
left eyes re-
ported sepa-
rately
Mea-
sured using
Snellen
chart
but reported
in logMAR
units
Based on
Chesapeake
Bay grading
but using in-
direct oph-
thal-
moscopy:
expressed
-
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Table 2. Characteristics of included trials (Continued)
Citrus
bioflavonoid
complex
125 mg
Quercitin
(bioflavonoid)
50 mg
Bilberry
extract
(bioflavonoid)
5 mg
Rutin
(bioflavonoid)
50 mg
Zinc picoli-
nate 12.5
mg
Selenium 50
µg
Taurine 100
mg
N-acetyl
cysteine 100
mg
l-
glutathione
5 mg
Vitamin B2
25 mg
Chromium
100 µg
as an average
grade
AREDS
2001
AMD
and VA 20/
32 or better
in 1 eye
956/3640
had AMD
Antioxi-
dants:
Vitamin C
500 mg
Vitamin E
400 IU
Beta-
carotene 15
mg
Zinc
(zinc oxide)
80 mg
Cupric ox-
ide 2 mg
Factorial de-
sign
Antioxi-
Average
duration 6.3
years
Average fol-
low-up 6.3
years; 2.4%
lost to fol-
low-up
Person; out-
come ’in at
least one eye’
Loss of 3
ormore lines
VA (equiva-
lent to dou-
bling visual
angle) mea-
sured us-
ing ETDRS
chart
Progression
to advanced
AMD: pho-
tocoagula-
tion or other
treatment
for CNV;
GA involv-
ing centre of
the macula,
RPE detach-
ment, haem-
orrhage un-
der the
retina, sub-
retinal fibro-
-
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Table 2. Characteristics of included trials (Continued)
dants x zinc sis
Colour fun-
dus photog-
raphy
AREDS2
2013
bilateral
large drusen
or non-
foveal ge-
ographic at-
rophy (no
advanced
AMD) or
large drusen
or non-
foveal ge-
ographic at-
rophy in one
eye and ad-
vanced
AMD
in the fellow
eye (AREDS
Simple Scale
Score of 2, 3
or 4)
lutein 10 mg
and zeaxan-
thin 2 mg (1
tablet/day)
Al-
most all par-
ticipants in
both inter-
vention and
comparator
groups took
AREDS
sup-
plement and
multivita-
minwith the
study medi-
cation
Other study
arm: There
was another
study
arm looking
at docosa-
hexaenoic
acid (DHA)
350 mg and
eicosapen-
taenoic acid
(EPA) 650
mg (2 soft-
gel capsules/
day); it was
not included
in this re-
view
5 years (me-
dian)
5 years (me-
dian)
Eyes
adjusted for
within per-
son correla-
tion
Progression
to
moderate vi-
sion loss us-
ing ETDRS
charts.
Progression
to advanced
AMD
-
Bartlett
2007
Soft or
hard drusen,
and areas of
increased
or decreased
pigment
asso-
Lutein esters
6 mg
Retinol 750
mg
Vitamin C
250 mg
Vitamin E
9 months 9 months Trial eye se-
lected (ini-
tial
visit only); If
both
eyes were el-
igible for in-
Change
in logMAR
acuity mea-
sured us-
ing ETDRS
chart
Fundus
photographs
graded using
AREDS
classi-
fication sys-
tem (4 cate-
-
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Table 2. Characteristics of included trials (Continued)
ciated with
these drusen
34 mg
Zinc 10 mg
Copper 0.5
mg
clusion, the
right eye was
used
gories)
. Mean (SD)
grade was re-
ported
Berrow
2013
ARM Ocuvite
Duo
(Bausch and
Lomb) vita-
min C 150
mg,
cupric oxide
400 µg, vi-
tamin E 15
mg, zinc ox-
ide 20 mg,
lutein 12
mg, zeaxan-
thin 0.6 mg,
EPA 240
mg, DHA
840 mg
40 weeks 40 weeks
and 60
weeks
One eye per
participant
NA NA -
CARMA
2013
any severity
of early
AMD in one
eye and late
AMD (neo-
vascu-
lar AMD or
central geo-
graphic
atrophy) in
the fel-
low eye. The
study eye
was the eye
free of late-
stage AMD
Ocu-
vite (Bausch
and Lomb,
Berlin, Ger-
many)
lutein 12
mg, zeaxan-
thin 0.6 mg,
vitaminE15
mg, vitamin
C 150 mg,
zinc oxide
20 mg, cop-
per 0.4 mg
(daily dose)
one tablet
twice daily
3 years every 6
months for 3
years
Mixture of
one and two
eyes
ET-
DRS charts
(logMAR)
Grad-
ing of colour
fundus pho-
tographs
-
CARMIS
2011
AMD in at
least
1 eye having
extensive (as
measured by
drusen area)
interme-
diate (≥ 63
Vitamin C
180 mg
Vitamin E
30 mg
Zinc 22.5
mg
Copper 1
mg
24 months 24 months The eye with
the best VA
was selected;
when both
eyes had the
same
VA, the right
eye was cho-
Letters
and lines re-
ported
as continu-
ous variable
(ETDRS
chart)
Not
reported
-
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Table 2. Characteristics of included trials (Continued)
mm,
< 125 mm)
drusen; and
at least one
large (≥ 125
mm) drusen
or ge-
ographic at-
ro-
phy not in-
volving the
centre of the
macula
Lutein 10
mg
Zeaxanthin
1 mg
Astaxanthin
4 mg
sen for final
analysis
CLEAR
2013
AMD grade
0 to 4 in one
eye (Rotter-
dam
grading) and
visual acuity
0.5 or better
Lutein 10
mg
12 months 12 months One eye per
participant
Early Treat-
ment
Diabetic
Retinopathy
Study (ET-
DRS) log-
MAR chart
at 4 m
Not
reported
-
Holz 1993 People with
drusen
Zinc sulfate
200 mg
Not stated
but assume
same as fol-
low-up du-
ration
12 to 24
months
Unclear but
assumed to
be people
Not
reported
’Incidence
of new ex-
udative
or dry mac-
ula lesions’
-
Kaiser 1995 Nonserous
AMD
Visaline:
Buphe-
nineHCL 1.
5 mg
Beta-
carotene 10
mg
To-
copherol ac-
etate 10 mg
Vitamin C
50 mg
6 months 6 months Study eye
identified
Decimal
acuity mea-
sured us-
ing a Snellen
chart
Not
reported
-
LISA 2011 AREDS cat-
egories 2, 3,
or 4
Lutein
20 mg a day
for 3months
and then
lutein 10 mg
a day for 3
months
6 months 6 months Study eye
identified; if
both
eyes were el-
igible,
one eye was
selected ran-
Reported in
graph form,
not possi-
ble to extract
data. Mea-
sured us-
ing ETDRS
Not
reported
-
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Table 2. Characteristics of included trials (Continued)
domly chart
Ma 2012 Early AMD
(drusen,
pig-
mentary ab-
normalities)
Lutein
10mg
Lutein
20mg
Lutein
10mg
and zeaxan-
thin 10mg
12 months 12 months Unclear how
many eyes
included
Unclear how
measured
but reported
in logMAR
Not
reported
-
Newsome
1988
Drusen
or pigmen-
tary change
(or both),
VA 20/80 or
better
Zinc sulfate
200 mg
12 to 24
months
12 to 24
months
Reported by
eye; also data
from 2 eyes
averaged
Number
of letters lost
on EDTRS
chart
Difficult to
extract data
on this. Re-
ported num-
ber with in-
creased pig-
ment,
drusen and
atrophy for
2 observers.
In general,
found re-
sults favour-
ing the zinc-
treated
group
-
Newsome
2008
Pres-
ence of mac-
ular drusen
with or
without pig-
ment
changes
Zinc-mono-
cysteine 25
mg
6 months 6 months Right and
left eyes re-
ported sepa-
rately
Number of
letters read
on EDTRS
chart
Not
reported
-
Stur 1996 Neovascular
AMD in 1
eye, VA bet-
ter than 20/
40 in other
eye
Zinc sulfate
200 mg
24 months 24 months Study eye,
which was
fellow eye;
other eye
had neovas-
cular AMD
Mean log-
MAR score
mea-
sured using
Bailey-Lovie
chart
Note:
participants
with neovas-
cu-
lar event ex-
cluded from
Incidence
of neovascu-
lar lesion in
study eye
Orig-
inal trial of
N = 500 ter-
minated by
sponsor (As-
tra) because
statis-
tical evalua-
tion of first
40 partic-
ipants at 24
months fol-
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Table 2. Characteristics of included trials (Continued)
this
outcome
low-up “did
not show
any treat-
ment bene-
fit”
VECAT
2002
Early AMD
(18%)
Late AMD
(0.5%)
Rest pre-
sumably had
no signs of
AMD
Vitamin E
500 IU
48 months 48 months Worse eye Loss of more
than 9 let-
ters (2 or
more lines)
on (Bailey-
Lovie chart
Investiga-
tors defined
6 stages of
AMD pro-
gression and
defined pro-
gression as
move-
ment from a
lower stage
to a higher
stage in their
worst eye
-
Veterans
LAST study
2004
Atrophic
AMD
and reduced
vision
Lutein 10
mg
Ocupower:
Natural
beta-
carotene
(Betatenem)
15,000 IU
Vita-
min C 1500
mg (as cal-
cium ascor-
bate-Ester
CB)
Vitamin D3
400 IU
Vitamin
E 500 IU (d-
alpha toco-
pherol succi-
nate)
Vitamin B1
50 mg
Vitamin B2
10 mg
Vitamin B3
70 mg
Vitamin B5
12 months 12 months Right and
left eyes re-
ported sepa-
rately
Change
in logMAR
score. Mea-
sured using
Snellen
chart
but reported
in logMAR:
units
Data not re-
ported
-
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Table 2. Characteristics of included trials (Continued)
50 mg
Vitamin B6
50 mg
Vitamin
B12 500 µg
Folic acid
800 µg
Biotin 300
µg
Calcium
500 mg
Magnesium
300 mg
Iodine 75 µg
Zinc 25 mg
(as zinc L-
methionine-
L-
OptiZincB)
Copper 1
mg
Manganese
2 mg
Selenium
200 µg
Chromium
200 µg
Molybde-
num 75 µg
Lycopene
600 µg
Bilberry ex-
tract 160 mg
(stan-
dardised to
25% antho-
cyanosides)
Alpha lipoic
acid 150 mg
N-acetyl
cysteine 200
mg
Quercetin
100 mg
Rutin 100
mg
Citrus
bioflavonoids
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Table 2. Characteristics of included trials (Continued)
250 mg
Plant en-
zymes 50mg
Black pep-
per extract 5
mg (Bioper-
ineB)
Malic acid
325 mg
Taurine 900
mg
L-glycine
100 mg
L-glu-
tathione 10
mg
Boron 2 mg
AMD: age-related macular degeneration
CNV: choroidal neovascularisation
ETDRS: Early Treatment Diabetic Retinopathy Study
GA: geographic atrophy
RPE: retinal pigment epithelium
VA: visual acuity
Table 3. Adverse effects in the included studies.
Study number Study name Intervention Adverse effects
1 AMDSG 1996 Multivitamin (Ocuguard) One person developed an “allergic reac-
tion”, although it was not clear whether
or not this was related to the treatment
2 AREDS 2001 Multivitamin and zinc Over 100 comparisons of zinc versus
no zinc and antioxidants versus no an-
tioxidants. Participants in the antioxi-
dant arms more frequently reported yel-
low skin (8.3% versus 6.0%, P = 0.008).
No important effect on mortality associ-
ated with multivitamin use (hazard ratio
for mortality 0.87, 95% CI 0.60 to 1.25)
Participants in the zinc arms reported
more anaemia (13.2% versus 10.2%, P =
0.004), however, serum haematocrit lev-
els were the same. They found that par-
ticipants taking zinc had a lower mor-
tality. Later follow-up of the cohort of
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Table 3. Adverse effects in the included studies. (Continued)
people taking part in the AREDS study
found that there was a significant increase
in hospital admissions due to genitouri-
nary diseases in people taking zinc supple-
ments (11.1% versus 7.6%, P = 0.0003)
3 AREDS2 2013 Lutein and zeaxanthin Quote “No clinically or statistically sig-
nificant differences in reported serious
adverse events, including rates of devel-
opment of neoplasms, were noted across
the treatment groups in the primary
randomization. However, secondary ran-
domization excluding participants who
were smokers showed more lung can-
cers in the beta carotene group than in
the no beta carotene group (23 [2.0%]
vs 11 [0.9%]) (nominal P=.04).” and
“Rates of reported gastrointestinal disor-
ders and hospitalizations for genitouri-
nary diseases were similar in the 2 ran-
domly assigned groups (high-dose zinc,
low-dose zinc) inAREDS2” “TheHR for
mortality comparing lutein zeaxanthin vs
no lutein zeaxanthin was 1.06 (95% CI,
0.87-1.31;P=.56) for lutein zeaxanthin vs
no lutein zeaxanthin”
4 Bartlett 2007 Multivitamin “There were no reported adverse effects
from any of the study participants.”
5 Berrow 2013 Multivitamin (Ocuvite) Did not report adverse effects.
6 CARMA 2013 Multivitamin (Ocuvite) Did not report adverse effects.
7 CARMIS 2011 Multivitamin Quote “There were no significant sys-
temic or ocular adverse events related to
the nutritional supplementation.”
8 CLEAR 2013 Lutein 3/42 in the lutein group and 1/42 in the
placebo group “discontinued due tomed-
ical reasons”, but it was unclear if these
were complications, per se
9 France 1998 Zinc Unpublished study, no data available.
10 Holz 1993 Zinc Quote “the zinc therapy was well-toler-
ated”.
11 Kaiser 1995 Multivitamin Did not report adverse effects.
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Table 3. Adverse effects in the included studies. (Continued)
12 LISA 2011 Lutein (Lutamax) Quote “In two subjects, the withdrawal
was due to serious adverse events. One
subject had a myocardial infarction, and
the other subject developed CNV in the
study eye.”
13 Ma 2012 Lutein and zeaxanthin Quote “No adverse events were observed
or reported.” and “No significant ad-
verse events or changes in biochemical
or hematologic profiles were observed or
reported in any subject throughout the
study. No subject developed or reported
occasional skin pigmentation (caroteno-
dermia).”
14 Newsome 1988 Zinc Did not report adverse effects.
15 Newsome 2008 Zinc mono-cysteine Quote “ZMC (zinc mono-cysteine) ap-
peared to be well tolerated”; 1/40 had
gastrointestinal symptoms attributable to
treatment
16 Stur 1996 Zinc 4/56 in the zinc-treated group and 2/56
in the placebo group withdrew because of
gastrointestinal symptoms
17 VECAT 2002 Vitamin E 11 in the vitamin E and 7 in the control
groupdied; 16 in the vitaminE group and
17 in the control group had an adverse
reaction
18 Veterans LAST study 2004 Multivtamin (OcuPower) and lutein
(FloraGlo)
The number of adverse effects were tab-
ulated, but the study was underpowered
to detect any differences
19 Wang 2004 Multivitamin and zinc Did not report adverse effects.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Retinal Neovascularization
#4 MeSH descriptor Choroidal Neovascularization
#5 MeSH descriptor Macula Lutea
#6 macula* near lutea*
#7 ((macul* OR retina* OR choroid*:TI) AND (degener* OR neovasc*:TI))
#8 ((macul* OR retina* OR choroid*:AB) AND (degener* OR neovasc*:AB))
#9 maculopath*
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Vitamins
#12 vitamin*
#13 MeSH descriptor Vitamin A
#14 retinol*
#15 MeSH descriptor beta Carotene
#16 caroten*
#17 MeSH descriptor Ascorbic Acid
#18 ascorbic next acid
#19 MeSH descriptor Vitamin E
#20 MeSH descriptor alpha-Tocopherol
#21 alpha tocopherol*
#22 MeSH descriptor Vitamin B 12
#23 cobalamin*
#24 MeSH descriptor Antioxidants
#25 antioxidant* or anti oxidant*
#26 MeSH descriptor Carotenoids
#27 carotenoid*
#28 MeSH descriptor Zinc
#29 zinc*
#30 MeSH descriptor Riboflavin
#31 riboflavin*
#32 MeSH descriptor Selenium
#33 selenium*
#34 MeSH descriptor Lutein
#35 lutein*
#36 MeSH descriptor Xanthophylls
#37 xanthophyll*
#38 zeaxanthin*
#39 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)
#40 (#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38)
#41 (#39 OR #40)
#42 (#10 AND #41)
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Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp macular degeneration/
14. exp retinal degeneration/
15. exp retinal neovascularization/
16. exp choroidal neovascularization/
17. exp macula lutea/
18. (macula$ adj2 lutea).tw.
19. ((macul$ or retina$ or choroid$) adj4 degener$).tw.
20. ((macul$ or retina$ or choroid$) adj4 neovasc$).tw.
21. (AMD or ARMD or CNV).tw.
22. maculopath$.tw.
23. or/13-22
24. exp vitamins/
25. exp vitamin A/
26. vitamin A.tw.
27. retinol$.tw.
28. exp beta carotene/
29. (caroten$ or betacaroten$).tw.
30. exp ascorbic acid/
31. ascorbic acid$.tw.
32. vitamin C.tw.
33. exp Vitamin E/
34. exp alpha tocopherol/
35. alpha?tocopherol$.tw.
36. alpha tocopherol$.tw.
37. vitamin E.tw.
38. exp Vitamin B12/
39. vitamin B12.tw.
40. cobalamin$.tw.
41. exp antioxidants/
42. ((antioxidant$ or anti) adj1 oxidant$).tw.
43. exp carotenoids/
44. carotenoid$.tw.
45. exp zinc/
46. zinc$.tw.
47. exp riboflavin/
48. riboflavin$.tw.
49. exp selenium/
50. selenium$.tw.
51. exp lutein/
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52. lutein$.tw.
53. exp xanthophylls/
54. xanthophyll.tw.
55. zeaxanthin$.tw.
56. or/24-55
57. 23 and 56
58. 12 and 57
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula degeneration/
34. exp retina degeneration/
35. exp retina neovascularization/
36. exp subretinal neovascularization/
37. (AMD or ARMD or CNV).tw.
38. ((macul$ or retina$ or choroid$) adj4 degener$).tw.
39. ((macul$ or retina$ or choroid$) adj4 neovasc$).tw.
40. exp retina macula lutea/
41. (macula$ adj2 lutea$).tw.
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42. maculopath$.tw.
43. or/33-42
44. exp vitamins/
45. exp Retinol/
46. vitamin A.tw.
47. retinol$.tw.
48. exp beta carotene/
49. (caroten$ or betacaroten$).tw.
50. exp ascorbic acid/
51. ascorbic acid$.tw.
52. vitamin C.tw.
53. exp alpha tocopherol/
54. alpha?tocopherol$.tw.
55. alpha tocopherol$.tw.
56. vitamin E.tw.
57. vitamin B12.tw.
58. exp cyanocobalamin/
59. cobalamin$.tw.
60. exp antioxidants/
61. ((antioxidant$ or anti) adj1 oxidant$).tw.
62. exp carotenoid/
63. exp zinc/
64. zinc$.tw.
65. exp riboflavin/
66. riboflavin$.tw.
67. exp selenium/
68. selenium$.tw.
69. exp zeaxanthin/
70. zeaxanthin$.tw.
71. lutein$.tw.
72. xanthophyll.tw.
73. or/44-72
74. 43 and 73
75. 32 and 74
Appendix 4. AMED Ovid search strategy
1. exp eye disease/
2. exp vision disorders/
3. exp retinal disease/
4. maculopath$.tw.
5. ((macul$ or retina$ or choroid$) adj3 degenerat$).tw.
6. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
7. or/1-6
8. exp vitamins/
9. vitamin A.tw.
10. retinol$.tw.
11. exp carotenoids/
12. caroten$.tw.
13. exp ascorbic acid/
14. ascorbic acid$.tw.
15. vitamin C.tw.
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16. vitamin E.tw.
17. alpha tocopherol$.tw.
18. vitamin B12.tw.
19. cobalamin$.tw.
20. exp antioxidants/
21. ((antioxidant$ or anti) adj1 oxidant$).tw.
22. zinc/
23. zinc$.tw.
24. riboflavin$.tw.
25. selenium/
26. selenium$.tw.
27. lutein$.tw.
28. xanthophylls.tw.
29. zeaxanthin$.tw.
30. or/8-29
31. 7 and 30
Appendix 5. OpenGrey search strategy
(macular degeneration OR AMD) AND (antioxidant OR vitamin OR carotene OR selenium OR tocopherol)
Appendix 6. ISRCTN search strategy
(macular degeneration OR AMD) AND (antioxidant OR vitamin OR carotene OR selenium OR tocopherol)
Appendix 7. ClinicalTrials.gov search strategy
(Macular Degeneration OR AMD) AND (Antioxidant OR Vitamin OR Carotene OR Selenium OR Tocopherol)
Appendix 8. ICTRP search strategy
Macular Degeneration OR AMD = Condition AND Antioxidant OR Vitamin OR Carotene OR Selenium OR Tocopherol = Inter-
vention
Appendix 9. MEDLINE Ovid adverse effects search strategy
1. exp retinal degeneration/
2. retinal neovascularization/
3. choroidal neovascularization/
4. exp macula lutea/
5. (macula$ adj2 lutea).tw.
6. ((macul$ or retina$ or choroid$) adj4 degener$).tw.
7. ((macul$ or retina$ or choroid$) adj4 neovasc$).tw.
8. (AMD or ARMD or CNV).tw.
9. maculopath$.tw.
10. or/1-9
11. exp vitamins/
12. vitamin A.tw.
13. retinol$.tw.
14. (caroten$ or betacaroten$).tw.
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15. ascorbic acid$.tw.
16. vitamin C.tw.
17. alpha?tocopherol$.tw.
18. alpha tocopherol$.tw.
19. vitamin E.tw.
20. ((antioxidant$ or anti) adj1 oxidant$).tw.
21. zinc/
22. zinc$.tw.
23. or/11-22
24. 10 and 23
25. ae.fs.
26. 24 and 25
27. limit 26 to (meta analysis or randomized controlled trial or “review”)
WH A T ’ S N E W
Last assessed as up-to-date: 29 March 2017.
Date Event Description
29 March 2017 New citation required but conclusions have not changed Issue 7, 2017: Six new trials (AREDS2 2013; Berrow
2013; CARMA 2013; CLEAR 2013; France 1998; Ma
2012) were included in this update
29 March 2017 New search has been performed Issue 7, 2017: Electronic searches were updated
H I S T O R Y
Protocol first published: Issue 3, 1997
Review first published: Issue 1, 1998
Date Event Description
11 July 2012 New search has been performed Issue 9, 2012: John Lawrenson assisted with this review
update
11 July 2012 New citation required but conclusions have not changed Issue 9, 2012: Update searches were conducted and 3
new trials have been added to the review
28 August 2008 Amended Converted to new review format.
12 August 2007 New search has been performed Issue 1 2008: Results of trial from China (Wang et al)
added. Report from AREDS study on risk of hospital
admission due to genitourinary complications in people
taking high-dose zinc.
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(Continued)
Graphs with only one trial have been deleted and results
have been reported in the text
19 January 2006 New citation required and conclusions have changed Substantive amendment
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JE wrote the protocol and completed the first published version of this review.
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For the 2012 and 2017 updates, both authors searched for new studies, did ’Risk of bias’ assessment, and extracted data. JE cut and
pasted data into RevMan and updated the text. JGL checked the data and provided comments on the text.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The original protocol was published in 1999. Since that time, there have been methodological improvements within Cochrane, and
the methods have been updated to include assessment of risk of bias, ’Summary of findings’ tables, GRADE assessment, and better
consideration of unit of analysis issues.
Previous versions of this review have included a comparison “Any multivitamin or single component antioxidant supplement versus
placebo”. We have dropped this comparison for the current review because the majority of the data for this review come from AREDS
2001 and AREDS2 2013. Given that all participants in AREDS2 2013 received the supplements trialled in AREDS 2001 it did not
make much sense to pool these data.
For the update in 2017, we modified the outcome measures to ensure they were in line with those being used as part of the macular
degeneration guidelines being prepared by NICE (NICE 2016). We also applied the default minimum important difference interval
for dichotomous outcomes of 0.8 to 1.25 for downgrading for imprecision.
Table: Comparing outcome measures in current review with outcome measures in last published version
Current review (2017)* Last published version (2012)
Progression to late AMD (neovascular AMD, geographic atrophy,
or both)
Progression to neovascular AMD
Progression to geographic atrophy
Progression of the disease (secondary)
• as defined by study investigators
Progression to visual loss
• loss of 3 or more lines
• continuous
Visual acuity (primary)
• loss of 3 or more lines
• continuous
Quality of life Quality of life (secondary)
Resource use and costs
Adverse effects Adverse effects
* In the current review no primary / secondary outcomes are specified.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antioxidants [∗therapeutic use]; Dietary Supplements; Macular Degeneration [∗prevention & control]; Minerals [∗therapeutic use];
Randomized Controlled Trials as Topic; Vitamins [∗therapeutic use]
MeSH check words
Aged; Humans
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